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Abstract
The tumor suppressor TP53 is the most frequently altered gene in human cancers. The growthpromoting complex, mTORC1 plays a significant part of the oncogenic profile that results from altered
p53 function. mTORC1 also sits downstream of AMP-activated kinase (AMPK), and other crucial tumor
suppressors and oncogenes, including PTEN, LKB1, and Akt. This complex has therefore garnered much
interest for the development of targeted cancer therapies. This laboratory was instrumental in
uncovering AMPK as the secondary target of the antifolate drug, pemetrexed (PTX), as well as its
mechanism of activation of AMPK. The work presented in this dissertation examined the mechanism of
mTORC1 activation with p53 loss, as well as the mechanism of mTORC1 inhibition by PTX-induced AMPK
activation. Significantly, mTORC1 activity is substantially upregulated by the loss or mutation of p53, and
the mechanism underlying this activation appears to be the loss of the p53-target and tumor suppressor
TSC2 from lysosomal membranes. The lysosome sets the stage for mTORC1 activation by Rheb-GTP, and
this work shows that when TSC2 is lost from lysosomes, Rheb levels at this site are increased. The
control of mTORC1 signaling was restored by exogenous expression of TSC2, correlating to decreases in
Rheb at lysosome. The lysosomal dynamics of mTORC1 were then explored after AMPK activation by
PTX. PTX was not able to activate TSC2 because of the accumulation of a nonfunctional species of p53,
and the subsequent decrease in TSC2 mRNA. The levels of lysosomal TSC2 went down accordingly, but
surprisingly, PTX was nonetheless able to decrease the levels of lysosomal Rheb. Previous work from this
lab had shown that the robust phosphorylation of the mTORC1 scaffold, Raptor by PTX was necessary
and sufficient to suppress mTORC1 signaling. Future studies would question whether this
phosphorylation of Raptor by PTX is involved in the shift of Rheb away from lysosomes. Another exciting
finding was that AMPK activation by PTX significantly increased the translocation of AMPK to the
nucleus, and future work would look into the function of PTX-activated AMPK in the nucleus. Finally, this

xiii

work presents some preliminary data showing that all the classes of classical antifolates are able to
activate AMPK, and cause a decrease in mTORC1 signaling. This was important because these drugs are
firmly established in cancer therapy regimes, and identifying downstream mediators in the cancers that
respond to these drugs would shed light on key therapeutic targets. Overall these findings present a
mechanism involved in the oncogenic signaling of mTORC1 by loss of p53, and offer insight into how the
antifolate PTX may be reinstating control of hyperactive mTORC1.
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1 Background and significance
1.1

Preamble: From antifolates to mTORC1 localization

Pemetrexed (PTX) is a multi-targeted antifolate that has long been at the center of this lab’s research. It
is FDA-approved for first line therapy in non-small cell lung cancer and mesothelioma. Antifolates
disrupt cell proliferation by blocking folate-dependent, one-carbon biosynthetic and methylation
reactions. PTX primarily inhibits thymidylate synthase (Taylor et al. 1992) but was subsequently found by
our lab to have an intriguing secondary target in de novo purine synthesis, aminoimidazolecarboxamide
ribonucleotide formyltranferase (AICART) (Racanelli et al. 2009). Levels of the substrate for this enzyme,
ZMP increase dramatically behind the block. This in turn allosterically enhances AMP-activated kinase
(AMPK) activity via binding to the AMP site on its γ subunit (Rothbart, Racanelli, Moran 2010). This
ultimately leads to the inhibition of the growth-promoting complex, mammalian target of rapamycin
complex 1 (mTORC1). Recent revelations about mTORC1 clarify that, in response to growth signals, it
can only perform its function once targeted to the surface of lysosomes. The work in this dissertation
therefore sought to uncover the lysosomal dynamics of the mTORC1 complex in the context of cancer
cells with deficient p53 tumor suppressor function, or after pharmacological activation of AMPK.
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1.2

The mammalian target of rapamycin is the hub of nutrient-sensing

pathways in the cell
1.2.1 The mTOR kinase forms the catalytic center of two complexes, mTORC1
and mTORC2
Discovery
Cell growth fundamentally requires that an organism sense environmental nutrient levels. Growth
occurs by coupling this nutrient sensing to growth factor and hormone signaling networks. The
mammalian (or mechanistic) target of rapamycin (mTOR) is the central kinase that regulates cell, organ,
and organism growth (Laplante and Sabatini 2013). It is named for the naturally occurring macrolide
antibiotic, rapamycin. Rapamycin was discovered 40 years ago, isolated from Streptomyces
Hygroscopicus cultures originating in soil samples collected on Rapa Nui (Easter Island) off the coast of
Chile (Vezina, Kudelski, Sehgal 1975). Rapamycin was later rediscovered owing to its immunosuppressive
and antiproliferative properties in patients with autoimmune disorders and in the prevention of graft
rejection (Borel and Gunn 1986),(Kino et al. 1987). Genetic screens in budding yeast identified two
genes, TOR1 and TOR2 as mediators of these effects (Kunz et al. 1993). It was only in 1994 that two
groups, independently, discovered the target in humans. The receptor, FKBP12 (12 kDa FK506-binding
protein), was used as a probe to detect binding proteins in the presence of the structurally related
drugs, FK506 and rapamycin (Brown et al. 1994; Sabatini et al. 1994). The resulting complexes, defined
in this study, were able to inhibit G1 cell cycle progression in yeast, osteosarcoma, liver, and T-cells.
Affinity purification and sequencing identified the 289 kDa binding protein as the mammalian TOR
homolog, or mTOR (Brown et al. 1994; Sabatini et al. 1994).

2

Structure
Mammalian TOR is an atypical serine/threonine protein kinase1 belonging to the phosphoinositide 3kinase (PI3K)-related kinase family (Huang and Houghton 2003). It consists of a catalytic kinase domain,
a FKBP12-rapamycin binding domain, a repressor or auto-inhibitory domain near the C-terminus, and up
to 20 randomly repeated HEAT (Huntington, EF3, PP2A and TOR) motifs near the N-terminus (Huang and
Houghton 2003). These repeated HEAT motifs form sites for protein-protein interaction (Gingras,
Raught, Sonenberg 2001). This, and the fact that mTOR migrated at a large apparent molecular weight
(1.5 – 2.0 mDa), suggested that it was part of a complex (Kim et al. 2002). Indeed, mTOR forms the
catalytic center of two complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
Mammalian TORC1 is composed of six, and mTORC2 of seven known protein components (Laplante and
Sabatini 2012a). Both complexes contain mLST8 (mammalian lethal with sec-13 protein 8), DEPTOR (DEP
domain containing mTOR-interacting protein), and the Tti1/Tel2 complex (Harris and Lawrence 2003;
Jacinto et al. 2004; Kaizuka et al. 2010; Peterson et al. 2009). The scaffolding subunit, Raptor (regulatory
associated protein of mTOR), and the endogenous inhibitor, PRAS40 (proline-rich Akt substrate of 40
kDa) are unique to mTORC1 (Fig. 1.1) (Hara et al. 2002; Kim et al. 2002; Sancak et al. 2007). Rictor
(rapamycin-insensitive companion of mTOR), mSin1 (mammalian stress-activated map kinaseinteracting protein 1), and Protor1/2 (protein observed with Rictor 1 and 2) are solely part of mTORC2
(Frias et al. 2006; Jacinto et al. 2004; Pearce et al. 2007).

1

Atypical protein kinases lack sequence similarity to the eukaryotic protein kinase (ePK) domain, hidden Markov
Model (HMM) profile, but have been shown experimentally to have PK activity, or are clear homologs of PKs with
demonstrated kinase activity (Manning et al. 2002). An HMM is a predictive computational model trained off data
sets, such as one containing all sequenced human ePKs.
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The rapamycin-FKBP12 complex interacts with and inhibits mTORC1 but not mTORC2, by a mechanism
that remains unclear but that may compromise the structural integrity of mTORC1 (Kim et al. 2002),
and/or it may allosterically reduce its kinase activity (Brown et al. 1995; Chen et al. 1995).
Function at a glance
In general, the two mTOR complexes control cell growth, proliferation, and survival but they differ in
terms of function, regulation, and rapamycin sensitivity (Guertin and Sabatini 2005); (Guertin et al.
2009). Mammalian TORC1 controls cell growth, primarily by phosphorylating two known regulators of
protein synthesis, the ribosomal p70-S6 kinase 1 (S6K1), and the eukaryotic translation initiation factor
4E (eIF4E)-binding protein 1 (4EBP1) (Fig. 1.1) (Blommaart et al. 1995; Hara et al. 1998). It also has
targets in lipogenesis, and is able to suppress autophagy (Laplante and Sabatini 2009). mTORC2 is
insensitive to nutrients but it is involved in cell proliferation and survival by phosphorylating and
activating Akt/PKB, a major prosurvival kinase (Sarbassov et al. 2005). Small interfering RNA (siRNA)
knockdown of mTORC2 also suggests that it involved in regulating the actin cytoskeleton (Jacinto et al.
2004). Mammalian TORC1 is the better described of the two complexes, and is the major focus of this
dissertation.

1.2.2 Components of mTORC1
Raptor acts as a regulatory and a scaffold protein
Raptor was the first mTOR-associated protein found in vivo to regulate mTORC1’s response to nutrient
availability (Kim et al. 2002). It was found as a 150 kDa protein that immunoprecipitated with mTOR
under crosslinking conditions (Kim et al. 2002). Sequence information obtained by mass spectrometry
revealed a 1335 amino acid protein that was evolutionarily conserved in eukaryotes including yeast, D.
melanogaster, C. elegans, and humans (Kim et al. 2002). The gene was also expressed in all human
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tissues in a pattern matching that of mTOR, with large amounts in skeletal muscle, brain, kidney, and
placenta (Kim et al. 2002).
Raptor has multiple important structural features: a Raptor N-terminal conserved (RNC) motif, HEAT
repeats in the central region, and WD40 repeats (40 amino acids ending in a tryptophan-aspartic acid) in
the C-terminus (Kim et al. 2002). Importantly, substrate recognition by Raptor involves a five amino acid
sequence named the TOR signaling (TOS) motif that sits within the RNC (Schalm et al. 2003).
Mutagenesis studies revealed that mTOR and Raptor interact at multiple sites, suggesting extensive
contact between the two proteins. This contact was necessary for mTOR kinase activity since siRNA
knockdown of Raptor decreased phospho-S6K1 levels, as well as cell size (Sabatini, 2002). Interestingly,
the amount of Raptor in an mTOR pull-down was inversely correlated to the in vitro kinase activity of
mTOR towards its substrates, S6K1 and 4EBP1 (Kim et al. 2002). In fact, nutrient deprivation stabilized
the mTOR-Raptor association, inhibiting mTORC1 kinase activity (Kim et al. 2003). That is, amino acid
deprivation increased the amount of Raptor recovered with mTOR, and this was rescued by leucine
stimulation (Kim et al. 2003). Rapamycin on the other hand destabilizes the interaction, regardless of
amino acid or nutrient availability (Kim et al. 2002). Thus, even the most well defined aspect of mTORC1
is incompletely understood at a biochemical and biophysical level. This pattern will be seen as a
common facet of the macromolecules involved in this thesis, and highlights the difficulty involved in
interpreting the often surprising and unexpected patterns in the behavior of these central proteins seen
in this work.
The regulatory effect of Raptor on mTOR kinase activity is attributable to Raptor’s ability to function as a
scaffold for substrate binding (Hara et al. 2002). As such, myc-tagged Raptor was recovered with GST4EBP1, and to a lesser extent with GST-S6K1 (Hara et al. 2002). Raptor also bound preferentially to a
mutant form of 4EBP1 that could not be phosphorylated by mTOR, implying it specifically recruits 4EBP1
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for phosphorylation, and releases the phosphorylated form (Hara et al. 2002). In the absence of Raptor,
mTOR exhibited kinase activity to S6K1 but not 4EBP1 (Hara et al. 2002), suggesting that the binding of
Raptor to mTOR enhances phosphorylation of S6K1 but is essential for phosphorylation of 4EBP1 (Hara
et al. 2002). This is probably related to the surprising fact that rapamycin and its analogs are superb
inhibitors of the phosphorylation of S6K1 but, under low concentration conditions, quite a poor inhibitor
of phosphorylation of 4EBP1 (Hsieh et al. 2012). In fact, rapamycin exposure conditions can be found in
which inhibition of S6K1 phosphorylation is complete, while inhibition of 4EBP1 is not even measurable.
More recently, Raptor was also found to interact directly with a Rag GTPase heterodimer in response to
amino acid stimulation, initiating the recruitment of mTORC1 to Rheb-containing membrane
compartments (Sancak et al. 2008).
Raptor is subject to phosphorylation by several kinases, typically in response to energy stress, nutrient
availability, or growth factor signaling. These phosphorylation events directly regulate mTOR kinase
activity. Energy stress-activated AMPK phosphorylates Raptor on Ser722 and Ser792, thus inhibiting
mTORC1, a central observation for this thesis research (Gwinn et al. 2008). P90 ribosomal S6 kinase
(RSK) phosphorylates Raptor on Ser719, Ser721, and Ser722 in response to mitogen stimulation,
activating mTORC1 (Carriere et al. 2008). Furthermore, two-dimensional phosphopeptide mapping
showed mTORC1 can phosphorylate Raptor on Ser863 and Ser859 and this acts as a feed-forward
mechanism to regulate mTORC1 activity (Wang et al. 2009).
PRAS40 and DEPTOR negatively regulate mTORC1
PRAS40 was identified as an mTORC1-associated protein after immunoprecipitation of Raptor under low
salt (150 mM) or less-stringent conditions (Sancak et al. 2007). PRAS40 was then found to be able to
bind and inhibit mTORC1 in insulin-deprived cells, where PI3K-Akt signaling was low (Sancak et al. 2007).
As such, upon growth factor stimulation, PRAS40 dissociates from mTOR and kinase activity increases
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(Vander Haar et al. 2007; Wang et al. 2007). This corresponded with PRAS40 phosphorylation by Akt in
vitro (Sancak et al. 2007). PRAS40 binds Raptor through the same consensus sequence (the TOS motif)
as 4EBP1 (Schalm et al. 2003). It is therefore likely to negatively regulate mTORC1 by competing with
4EBP1 and S6K1 for interaction with Raptor (Wang et al. 2007).
DEPTOR is an mTOR-interacting protein that was identified using the same low salt conditions used to
isolate PRAS40 (Peterson et al. 2009). Under these conditions, mTOR immunoprecipitates with a 48 kDA
protein named DEPTOR for its DEP (dishevelled, egl-10, pleckstrin) domains and mTOR interaction. Using
mass spectrometry, recombinant DEPTOR was found to bind endogenous mTOR, Raptor, as well as the
mTORC2 component Rictor. Functionally, RNAi-mediated knockdown of DEPTOR caused an increase in
mTORC1 and mTORC2 activity in vitro, and an increase in phospho-S6K1 Thr389 and phospho-Akt
Ser473, indicating that it is an inhibitor of both complexes (Peterson et al. 2009).
mLST8
mLST8 is a stable component of both mTORC1 and mTORC2. Despite this, mTORC1 signaling during early
mouse development does not require mLST8 (Guertin et al. 2006). Furthermore, RNAi-mediated
knockdown of mLST8 in NIH3T3 and HEK293T cells diminishes, but does not abolish mTORC1 signaling
(Jacinto et al. 2004). Mammalian TORC1 obtained from mLST8-/- MEFs are still inhibited by rapamycin,
and stimulated by insulin (Guertin et al. 2006). However, it is evident that mLST8 is required to maintain
the Rictor-mTOR interaction of mTORC2, but not the Raptor-mTOR interaction of mTORC1.
Immunoprecipitation of Rictor from mLST8-/- MEFs does not bring down any mTOR, unlike the paired
experiment using an anti-Raptor antibody, and this complex cannot phosphorylate Akt Ser473 in in vitro
kinase assays (Guertin et al. 2006). Interestingly, loss of mLST8, Rictor, or mTORC2 as a whole does not
affect Thr308 phosphorylation in response to insulin stimulation (Guertin et al. 2006). In fact, loss of
mLST8 only affects the Akt substrate, FOXO3 but not its other substrates, TSC2 or GSK3β (Guertin et al.
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2006). Taken together these results suggest that mLST8 is necessary for mTORC2 kinase activity for Akt
at the ser473 site, and that this interaction is essential for FOXO3 activation.

1.3

Downstream targets of mTORC1

1.3.1 Translation initiation is synchronized by mTORC1 via p70-S6K1 and
4EBP1
Protein synthesis is the most well characterized process controlled by mTORC1 and active site inhibitors
of mTORC1 significantly reduce the overall rate of protein synthesis in culture (Thoreen et al. 2009).
Specifically, mTORC1 coordinates the synthesis of ribosomal proteins with the levels of available amino
acids (Kim et al. 2002). This is accomplished by direct phosphorylation of the translational regulators,
4EBP1 (on several sites), and S6K1 on Thr389 (Fig. 1.1) (Ma and Blenis 2009). Translation initiation,
which involves recruitment of the small ribosome subunit to the 5' end of mRNA and its scanning
towards the start codon, is the rate-limiting step in protein synthesis (Fig. 1.2). Recruitment of the small
ribosomal subunit to mRNA requires the assembly of an active eIF4F complex onto the 5', 7-methylguanosine mRNA cap (Holland et al. 2004). This complex contains three initiation factors,
eIF4E, eIF4G, and eIF4A. Initially, eIF4E must bind the 5' cap before recruiting eIF4G and eIF4A (Ma and
Blenis 2009). 4EBP1 normally binds to eIF4E, preventing binding of eIF4G, thereby blocking the
formation of the active translational complex (Gingras et al. 1999; Sonenberg and Pause 2006).
Phosphorylation of 4EBP1 by mTORC1 triggers its release from eIF4E, and its subsequent proteasomal
degradation (Yanagiya et al. 2012).
Further along in the cascade of translation initiation, mTORC1-mediated phosphorylation of S6K1 aids
the assembly of the eIF3 translation pre-initiation complex (PIC) (Holz, 2005). This multisubunit complex
acts as a scaffold for mTORC1 and S6K1 binding. The eIF3 complex consists of at least 12 subunits
9

(Mayeur et al. 2003), and interacts with the 40S ribosomal subunit as part of the 43S translation
preinitiation complex. It thus plays a role in the eIF2/Met-tRNA/GTP ternary-complex association and
mRNA binding (Gingras, Raught, Sonenberg 2001). S6K1 binds the eIF3 complex when inactive. Growth
signals promote mTOR/Raptor binding to the eIF3 complex, and phosphorylation of S6K1 at Thr389 in its
hydrophobic motif. This results in S6K1 dissociation and triggers the phosphorylation of its translational
targets, including eIF4B (Gingras, Raught, Sonenberg 2001). These targets are recruited onto the eIF3
complex in a phosphorylation-dependent manner (Holz et al. 2005). The activation of S6K1 thus
increases mRNA biogenesis, translation initiation, and elongation. S6K1 also modulates the helicase
activity of eIF4A/4B, which associates with the PIC and is important in unwinding complex 5′UTRs that
hinder scanning by the small ribosomal subunit (Methot, Song, Sonenberg 1996). Thus, although we
often assess mTORC1 activity in vivo by simple immunoblotting for the phosphorylation of S6K1 and
4EBP1, the phenomena being disrupted by modifiers of mTORC1 activity are really quite complex.

1.3.2 Other downstream effects that contribute to cell growth
Lipogenesis
De novo lipid biosynthesis is upregulated by mTORC1 through the S6K1-driven expression of sterol
regulatory element-binding protein 1/2 (SREBP1/2) (Porstmann et al. 2008). Inactive SREBPs reside on
the endoplasmic reticulum (ER). Insulin or sterol depletion activates the proteolytic processing of
SREBPs, creating an active form that can travel to the nucleus to activate transcription needed for fatty
acid and cholesterol synthesis. The expression and activity of the master regulator of adipogenesis,
peroxisome proliferator-activated receptor-γ (PPARγ), is also promoted by mTORC1 (Zhang et al. 2009).
Mammalian TORC1 also mediates the nuclear association of PPAR coactivator 1 (PGC1) and the
transcription factor Yin-Yang 1 (YY1), thus inducing the expression of genes involved oxidative
metabolism as well as mitochondrial biogenesis (Cunningham et al. 2007).
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Figure 1.2: Translational control by mTORC1. The recruitment of the 40S ribosomal subunit
to the 5' end of mRNA is a crucial and rate-limiting step during cap-dependent translation.
4EBP1 binds tightly to eIF4E (far left) on the 5’ m7guanosine mRNA cap. This prevents its
interaction with eIF4G and thus inhibiting translation. Phosphorylation of 4EBP1 by growth
factor-activated mTORC1 (middle) releases the 4EBP1 from eIF4E, resulting in the recruitment
of eIF4G to the 5' cap. This allows formation of the initiation complex to proceed far
right). Image adapted from Ma and Blenis, Molecular mechanisms of mTOR-mediated
translational control, May 2009, Nat. Rev. Mol. Cell. Biol. 1-, 307-310, doi:10.1038/nrm2672
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Autophagy
Autophagy involves the recycling of damaged organelles and promotes cell-adaptation to nutrient
starvation. Thus, by promoting cell growth, mTORC1 negatively regulates autophagy by directly
phosphorylating and inactivating ULK1 (unc 51-like kinase also known as ATG13 or FIP200) (Ganley et al.
2009; Hosokawa et al. 2009). In contrast, inhibition of mTORC1 causes an increase in autophagosomes,
the organelles that engulf cytoplasmic proteins and organelles, before fusing with the lysosome (Young,
Narita, Narita 2011).

1.4

Upstream regulation of mTORC1

1.4.1 Regulation of mTORC1 signaling by growth factors and nutrients
The mTOR signaling pathway regulates the anabolic, growth-promoting effects of insulin and insulin-like
growth factor 1 (IGF1). Growth factors activate receptor tyrosine kinases (RTKs) to promote
phosphatidylinositol-(3,4,5)-triphosphate (PIP3) production through PI3K, leading to the activation of
Akt (Manning and Cantley 2007). Akt increases mTORC1 activity by two phosphorylation events:
phosphorylation of PRAS40 reduces the interaction of PRAS40 with mTORC1 (Sancak et al. 2007), and
phosphorylation of tuberous sclerosis complex protein 2 (TSC2 or tuberin) prevents the inhibition of the
mTORC1 activator Rheb by TSC2 GTPase activating protein (GAP) activity (Dibble and Cantley 2015;
Menon et al. 2014). Additionally, RTKs activate Ras, which in turn activates the extracellular-signalregulated kinase 1/2 (ERK1/2) and ribosomal S6 kinase (RSK1), leading to the phosphorylation and
inhibition of TSC2 (Roux et al. 2004; Ma et al. 2005).
Amino acids are required for mTORC1, but not mTORC2, activation (Liu et al. 2015). Amino acids signal
to mTORC1 from inside the lysosomal lumen via the Rag GTPase-Ragulator complex (Bar-Peled et al.
2012; Sancak et al. 2010). This triggers the recruitment of mTORC1 to the lysosomal surface where it can
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interact with its essential activator, Rheb GTPase (Sancak et al. 2008)(Bar-Peled and Sabatini 2012).
These mechanisms of regulation are central to my data in Chapter 2 and will be discussed in more detail
below.

1.4.2 The TSC2/Rheb-GTPase axis controls mTORC1 in response to energy
levels and growth factors
Rheb is an essential activator of mTORC1
Mammalian TORC1 kinase activity is only initiated in the presence of the small GTPase, Rheb (Ras
homolog enriched in brain) (Inoki et al. 2003; Sancak et al. 2007; Saucedo et al. 2003; Stocker et al.
2003), a Ras family member with some distinct characteristics specific for interaction with mTOR and
TSC2. Rheb is required for activation of mTORC1 in response to both growth factors and amino acids
(Bar-Peled and Sabatini 2014). The mechanism of this activation remains elusive but involves, in part,
the direct binding of Rheb to mTOR, which promotes mTOR kinase activity (Long et al. 2005). Rheb is a
184 amino acid, 21 kDa protein that is able to bind and hydrolyze GTP to GDP. Rheb-GTP and Rheb-GDP
interact directly with mTORC1, albeit at low affinity, but only the GTP-bound form stimulates mTOR
kinase activity (Long et al. 2005; Sancak et al. 2007).
Rheb exists as two isoforms encoded by the genes, RHEB1 and RHEB2 (also known as RHEBL1). The gene
products share 54% identity and 74% similarity, and perform similar functions (Heard et al. 2014). Tissue
expression profiles do differ; however, with Rheb1 (referred to as Rheb in this dissertation) being
ubiquitously expressed and Rheb2 showing a more limited expression profile (Saito et al. 2005). Rheb1 is
essential for murine development, with germline deletions or conditional knockout of Rheb1 causing
embryonic death between embryonic day 10.5 (E10.5) and E11.5 (Goorden et al. 2011; Zou et al. 2011).
This is likely because it seemed to be required for the proper development of the cardiovascular system
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(Tamai et al. 2013), as well as myelination processes in brain development (Zou et al. 2011). Germline
deletion of Rheb2, however, had no effect on murine development.
The GTPase domain of Rheb sits within the N-terminal 169 amino acids. The remaining 12 amino acid Cterminal domain is termed the highly variable region (HVR) since the sequence homology with Ras
isoforms is less than 15%, compared to the 90-100% homology of the amino terminal sequences
(Hancock 2003). The C-terminal terminates in a CAAX motif where C = cysteine, A = aliphatic amino acid,
and X = any amino acid. Rheb is synthesized as a cytosolic precursor before undergoing posttranslational processing that will allow membrane association. First, the cytoplasmic enzyme, farnesyl
transferase, attaches a farnesyl group to the cysteine residue of C-terminal CAAX motif (Berger, 2006).
This targets Rheb to the cytoplasmic surface of the ER where the endopeptidase, Rce1 (Ras and a-factor
converting enzyme), removes the –AAX tripeptide (Hanker et al. 2010; Kim et al. 1999). The carboxyterminal farnesylcysteine is then methylated by Icmt (isopenylcysteine carboxyl methyltransferase)
(Hrycyna et al. 1991; Takahashi et al. 2005).
Rheb was first discovered as a small GTPase that could be activated in rat brain by NMDA-dependent
synaptic activity (Yamagata et al. 1994). Mutagenesis studies revealed its importance for cell growth. In
Drosophila mutation of Rheb inhibited cell growth, while overexpression enhanced cell growth via the
mTORC1 effector, S6K1 (Patel et al. 2003; Saucedo et al. 2003). This was ascribed to Rheb being able to
bind and activate mTORC1 directly. Recombinant Rheb is capable of specific binding to the TOR complex
at multiple sites. When overexpressed, Rheb co-immunoprecipitates with an mTOR fragment
encompassing the FKBP12-rapamycin binding domain (Long et al. 2005). GST-Rheb also brings down
endogenous mTOR, as well as Raptor (Long et al. 2005). There is also specific binding of Rheb to mLST8
(Heard et al. 2014). The precise mechanism of mTORC1 activation by Rheb-GTP remains elusive.
Charging with GTP actually diminished the binding of Rheb to mTOR, as compared to nucleotide-free
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Rheb (Long et al. 2005). Nevertheless, addition of recombinant Rheb loaded with GTP enhances
mTORC1 substrate binding and phosphorylation in vitro, and this is abolished when Raptor is absent
from the complex (Sato et al. 2009)(Howell and Manning 2011). Furthermore, FRET-FLIM (Fluorescence
Resonance Energy Transfer and Fluorescence Lifetime Imaging) shows energy transfer from EGFP-mTOR
to DsRed-Rheb, making a compelling case for their direct interaction in living cells (Yadav et al. 2013).
Rheb overexpression also rescues S6K1 inactivation after amino-acid withdrawal (Long et al. 2005), as
well as inhibition by PRAS40 after serum starvation (Sancak et al. 2007).
Numerous other Rheb-binding proteins have been described. Overexpression studies demonstrated the
Rheb-specific regulation of B-Raf kinase activity, as well as the activation and binding of phospholipase
D1 (PLD1) (Karbowniczek et al. 2004; Sun et al. 2008). PLD1 activity produces phosphatidic acid (PA), and
both expression of PLD1 or exogenous application of PA significantly increased mTORC1 activity, at least
in part by stabilizing the Rheb-mTORC1 complex (Hornberger et al. 2006; Sun and Chen 2008). Rheb can
also be phosphorylated at Ser130 by p38 regulated/activated kinase (PRAK) in response to 2deoxyglucose (2-DG) or AICAR, both activators of AMPK (Zheng et al. 2011). This phosphorylation event
was independent of TSC1/2, but nonetheless decreased Rheb nucleotide-binding capability (Zheng et al.
2011).
TSC2 is the only known regulator of Rheb
The Tuberous Sclerosis Complex (TSC) acts as a critical switchboard for extra- and intra-cellular inputs,
including mitogen signaling (Ma et al. 2007), high or low energy levels (Inoki, Zhu, Guan 2003), oxygen
availability (Brugarolas et al. 2004), and genotoxic stress (Budanov and Karin 2008). The complex is
made up of at least three components, TSC1, TSC2 and the recently identified, TBC1D7 (Dibble et al.
2012; Inoki, Zhu, Guan 2003). Co-immunoprecipitation and crystal structure studies showed that the TSC
complex exists as a large oligomeric structure containing up to five copies of each subunit (Hoogeveen-

15

Westerveld et al. 2012). In this study, gel filtration experiments using cell extracts obtained after
hypotonic-lysis showed that TSC1 and TSC2 form complexes up to ~1 MDa in size, and
immunoprecipitation experiments indicated that TSC1-TSC2 complexes contained multiple TSC1 and
TSC2 subunits (Hoogeveen-Westerveld et al. 2012).
Loss or mutation of the TSC1 or TSC2 genes causes the genetic disorder, tuberous sclerosis (TSC),
characterized by benign, growth factor-independent tumors (European Chromosome 16 Tuberous
Sclerosis Consortium 1993). The finding that loss of either TSC1/2 proteins causes the hyper-activation
of mTORC1, even in the absence of upstream positive signals, provided insight into the basis of tumor
formation in TSC. This lead to the discovery that the massive TSC complex is the only known direct
regulator of Rheb, and TSC2 itself appears to have no other substrates (Tee 2003; Inoki 2003; Garami
2003). By any criteria, the evolution of such a large complex, for such a limited function, is an
astonishing situation.
TSC1 acts as a scaffold for both TSC2 and TBC1D7 (Tee 2003; Dibble 2012; Nakashima 2007). TBCD17’s
function remains ambiguous but siRNA-knockdown results in less interaction between TSC1 and TSC2
(Dibble et al. 2012). Rheb has intrinsically low GTPase activity; accordingly, the regulation of Rheb is
crucial to prevent constitutive growth signaling by mTORC1 (Mazhab-Jafari et al. 2012). TSC2 is the
crucial player in this control as it contains a domain that has homology to several GAPs (Fig. 1.3). GAP
activity towards Rheb has since been demonstrated in numerous studies, and recombinant GST-Rheb
was able to pull-down endogenous TSC2 (Li, Inoki, Guan 2004).
The TSC complex is regulated by multiple inputs to inhibit mTORC1. Akt directly phosphorylates TSC2 at
a number of residues including Ser939, Ser981, and Thr1462. Mutation of these sites inhibits mTORC1
kinase activity for its substrates (Inoki et al. 2002). TSC2 is also directly phosphorylated and inactivated
by the effector kinases of the PI3K and Ras pathways: Akt, ERK1/2 (Extracellular signal-related kinase 1
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and 2), and RSK1 (Laplante and Sabatini 2012b). Proimflammatory cytokines such as tumor necrosis
factor-α (TNFα), activate mTORC1 via IκK kinase β (IκKβ) and inhibitory phosphorylation of TSC1 (Lee et
al. 2007). Lastly, glycogen synthase kinase 3β (GSK3β) directly phosphorylates and activates TSC2, and
this is prevented by Wnt signaling, the canonical pathway that regulates proliferation, polarity, and
differentiation (Inoki et al. 2006).

1.4.3 The Gator/Rag-GTPase axis control mTORC1 in response to amino acids
Rag GTPases recruit mTOR to Rheb
Along with growth factor signaling, amino acid levels are crucial for mTORC1 activation. Investigators
initially observed that amino acid levels controlled protein synthesis in rat skeletal muscle (Preedy and
Garlick 1986). A mixture of all twenty amino acids, in combination with growth factor signaling, were
required for the phosphorylation of mTORC1 substrates, S6K1 and 4EBP1, in mammalian cell culture
(Hara et al. 1998). Despite considerable effort (Jewell, Russell, Guan 2013), a mechanism for amino acid
activation of mTORC1 was only described in 2008. Independently, two groups discovered that this
activation requires the Rag GTPases (Kim et al. 2008; Sancak et al. 2008). Amino acids promote RagA/B
loading with GTP, which enables RagA/B to interact with Raptor (Fig. 1.3) (Sancak et al. 2008). This
allows for the translocation of mTORC1 from a cytoplasmic locale to the lysosome. Here the RagGTPases dock at a pentameric complex called Ragulator (Sancak et al. 2010). Importantly, Ragulator and
the Rags are found only at the lysosome even though Rheb is found throughout the endomembrane
system. This may be explained by an inside-out model of amino acid sensing (Zoncu et al. 2011). In this
model, amino acids accumulate in the lysosomal lumen and initiate signaling via the vacuolar H+adenosine trisphosphate ATPase (v-ATPase) (Zoncu et al. 2011).
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The v-ATPase interacts directly with Ragulator, and its siRNA-depletion prevents amino acid-induced
recruitment of mTORC1 to the lysosome. In turn, the mTORC1 pathway regulates the expression of vATPase, suggesting a feedback control loop (Pena-Llopis et al. 2011).
The Sestrins and the Gators
The GATOR complex acts as a GAP for RagA/B (Bar-Peled et al. 2013). GATOR is composed of GATOR1
and GATOR2, both of which have been found at the lysosome by immunofluorescence, but only GATOR1
interacts directly with the Rags (Bar-Peled et al. 2013; Panchaud, Peli-Gulli, De Virgilio 2013; Schroder et
al. 2007). Surprisingly, loss of function studies showed that the GATORs render cells insensitive to amino
acid starvation, and are positive regulators mTORC1. Sestrins act as p53 target genes that accumulate in
cells under physiologic stress (Fig. 1.3). p53-independent stressors, such as oxidative stress or hypoxia,
can also regulate Sestrin2 expression (Kim, Lee, Kim 2013; Kim et al. 2014). Nevertheless, both Sestrin1
and Sestrin2 were shown to directly interact with AMPK, and promote AMPK-inhibition of mTORC1
(Budanov and Karin 2008). Sestrin2 also binds to GATOR2, releasing GATOR1 from GATOR2-mediated
inhibition (Fig. 1.3) (Kim et al. 2015). GATOR1 can then bind and exert its Gap function towards RagB,
resulting in the suppression of mTORC1 signaling (Parmigiani et al. 2014).

1.5

AMP activated kinase responds to stress signals in the cell

upstream of mTORC1
5’-AMP-activated protein kinase (AMPK) is the central energy sensor in the cell, matching energy stores
with energy demand by maintaining glucose and lipid homeostasis, and protein synthesis. Chiefly, AMPK
detects ratios of AMP:ATP and to a lesser degree, ADP:ATP. If an energy deficit is detected, AMPK acts to
restore the energy balance by turning on catabolic pathways that produce ATP, while also turning off
biosynthetic, ATP-consuming pathways. This regulation is achieved by the phosphorylation of several
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targets that control protein translation, fatty acid oxidation, glucose transport, and glycolysis (Hardie,
Carling, Carlson 1998; Kemp et al. 1999). Activation of AMPK occurs through alterations in nutrient
levels, intracellular Ca2+ concentrations, and genotoxic stress (Hawley et al. 2010). At the level of wholebody energy homeostasis, AMPK is activated by environmental stresses such as ischemia, hypoxia,
nutrient starvation, and exercise (Dyck and Lopaschuk 2006; Dyck and Lopaschuk 2006; Kodiha et al.
2007; Turdi et al. 2010). Furthermore, hormonal signals activate AMPK to regulate food intake and fuel
metabolism, including leptin and adiponectin in adipocytes and peripheral tissues, and ghrelin in the
hypothalamus (Bjorbaek and Kahn 2004; Daval, Foufelle, Ferre 2006). Overall, this leads to the
downregulation of ATP/NADPH-consuming reactions, shifting the cell to engage in ATP production
(Hardie 2008; Steinberg and Kemp 2009).

1.5.1 AMPK subunit structure
AMPK is a heterotrimeric enzyme complex containing a catalytic α-subunit (with isoforms encoded by
the α1 and α2 genes), and regulatory β- (β1 and β2) and γ-subunits (γ1, γ2, and γ3) (Fig. 1.4) (Hardie
2007; Kemp et al. 1999). The isoforms are able to form at least 12 distinct heterotrimeric combinations
(Hardie and Ashford 2014), and their expression is tissue-restricted. Complexes containing the α1
isoform were shown to be expressed mainly in the liver, while AMPKα2 was localized to the brain, heart,
and skeletal muscle (Steinberg and Kemp 2009; Steinberg and Kemp 2009; Steinberg and Kemp 2009).
Functional differences in the subunits dictate responsiveness to upstream kinases and AMP, as well as
subcellular localization (Salt et al. 1998). The year 2013 saw the publication of the first complete crystal
structure of human AMPK, giving added insight into structure-function relationships (Fig. 1.4) (Xiao et al.
2013). The crystal structure clearly divides the molecule into a catalytic module and a nucleotide-binding
module, with the critical phosphorylation site, Thr172 (named for the rat residue) positioned between
these two modules (Xiao et al. 2011; Xiao et al. 2013). This implies that any conformational changes will
potentially mask and unmask this site (Hardie and Ashford 2014).
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A

B

Figure 1.4: AMPK is a heterotrimeric enzyme complex containing a catalytic α-subunit (α1 and
α2), and regulatory β- (β1 and β2) and γ-subunits (γ1, γ2, and γ3). (A) AMPK subunit structure.
AMPKα contains a catalytic domain in the NH2-terminal that can be phosphorylated by AMPKKs
on Thr172. AMPKβ subunits have interacting domains with glycogen, as well as α and γ. AMPKγ
subunits present have four cystathionine β-synthase (CBS) domains interacting with AMP, ADP,
and ATP (image adapted from Sanchez 2012). (B) Two views of a crystal structure of a partial
heterotrimeric complex of mammalian AMPK. The right-hand view is rotated approximately 180°
about the y-axis compared to the left-hand view. The constructs crystallized contained only the
C-terminal domain of the β-subunit (β-CTD) and lacked a flexible loop in the α-CTD. The αsubunit AID = auto-inhibitory domain. KD = kinase domain. (Image adapted from Hardie 2015,
data from Xiao 2011).
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The α-subunit
The N-terminal of the α-subunit holds a typical serine/threonine protein kinase domain (KD) within a
conserved “activation” loop (Fig. 1.4) (Xiao et al. 2007). This is followed by an auto-inhibitory sequence
(AID) and a C-terminal β-subunit-binding domain (Crute BE, 1998). The C-terminal domain terminates in
a nuclear export sequence, which functions as a nuclear export signal for AMPKα2 only (Kazgan et al.
2010). Two nuclear localization sequences (NLS) are also found in AMPKα2 only, and not in AMPKα1.
One of these two sequences is present in the catalytic domain of α2, and the other is in the regulatory
domain of α2 (Suzuki et al. 2007). NLS mutants of these two sequences in human α2 showed that only
the catalytic domain sequence is required for nuclear translocation in response to leptin, even though
Thr172 was phosphorylated in both mutants (Suzuki et al. 2007). In conclusion, AMPKα1 is not shuttled
in and out of the nucleus, a point that is important for Chapter 3 of this thesis.
The β-subunit
The β-subunit contains a carbohydrate-binding module (CBM), as well as a C-terminal segment that
tethers the α- and γ-subunits (Fig. 1.4) (Iseli et al. 2005). The CBM has homology to the noncatalytic
domains of starch- and glycogen-binding enzymes (Hudson et al. 2003). This site may be responsible for
the binding of AMPK to glycogen, and therefore an AMPK target, glycogen synthase (Polekhina et al.
2005). Interestingly, synthetic allosteric activators of AMPK bind in a cleft between the CBM and the αsubunit kinase domain (Xiao et al. 2013). Further, AMPK is modified co-translationally by N-terminal
myristoylation of Gly2 on the β-subunit, and post-translationally by multiple phosphorylation events on
its α- and β-subunits (Mitchelhill et al. 1997; Woods et al. 2003a). Myristoylation of AMPKβ1 and β2 is
necessary for localization to the endomembrane system (Warden et al. 2001; Warden et al. 2001).
The γ-subunit
The γ-subunit contains four tandem cystathione-β-synthase (CBS) repeats that form four symmetrical
clefts where regulatory nucleotides could potentially bind (Fig. 1.4) (Murzin and Bateman 1997; Xiao et
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al. 2013). CBS sites 1 and 3 are known to bind AMP, ADP or ATP, while site 4 only binds AMP, and site 2
appears to be permanently unoccupied (Xiao et al. 2007). This enables discrete control by either
AMP:ATP or ADP:ATP ratios (Xiao et al. 2011).

1.5.2 Regulation of AMPK by phosphorylation and by adenine nucleotides
Allosteric regulation by AMP/ADP binding
Activation of AMPK requires phosphorylation of Thr172 of the α-subunit by an upstream AMPK Kinase
(AMPKK), with allosteric modulation by AMP binding to the γ-subunit (Hardie and Ashford 2014).
Allosteric activation appears to be specific for AMP and related analogs such as ZMP (AICA nucleoside
monophosphate) binding to the CBS site 1 (Xiao et al. 2011). Allosteric activation results in a relatively
modest increase in in vitro kinase activity compared to Thr172 phosphorylation, and the yeast AMPK
homolog, Snf1, is not activated by AMP at all (Xiao et al. 2011). Besides allosteric activation though, AMP
binding may promote Thr172 phosphorylation by LKB1 (Gowans et al. 2013), and binding of AMP/ADP at
CBS site 3 prevents Thr172 dephosphorylation by protein phosphatases (Xiao et al. 2011); (Davies et al.
1995). Hardie et al., also postulate that AMP binding at site 3 may work by forcing the dissociation of the
auto-inhibitory domain from the kinase domain (Hardie and Ashford 2014).
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Figure 1.5: Overview of AMPK signaling. AMPK is activated by increases in AMP/ADP levels, DNA
2+

damage, and intracellular Ca , decreases in oxygen levels, or the presence of pharmacological
inducers. LKB1 activates AMPK in response to AMP/ADP increases, whereas CAMKK2 activates AMPK
2+

in response to increased Ca . AMPK then directly phosphorylates a number of substrates to acutely
affect metabolism and growth, as well as long-term metabolic reprogramming. This diagram outlines
the best-established substrates; those italicized are not as well established. Substrates in red are also
substrates of other AMPK family members (SIK1, SIK2, MARKs, SADs). Asterisks denote substrates that
may be regulated indirectly. (Image adapted from Mihaylova 2011).
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Regulation by upstream AMPKKs
LKB1 responds to metabolic stress
Thr172 phosphorylation by an upstream AMPKK resulted in a 100-fold increase in AMPK activity in vitro
(Suter et al. 2006) (Hawley et al. 1996). The major upstream kinase for this site is the tumor suppressor,
liver kinase B1 (LKB1) (Hawley et al. 2003). LKB1 is part of a heterotrimeric kinase complex that also
includes the pseudokinase, STRAD and the scaffolding protein, MO25 (Shaw et al. 2004a; Shaw et al.
2004b). The LKB1 complex is able to phosphorylate at least 12 AMP-related kinases (Lizcano et al. 2004),
but metabolic stress signals seem to operate solely through the LKB1-AMPK pathway (Fig. 1.5)
(Sakamoto et al. 2005); (Hardie, Schaffer, Brunet 2015). Importantly, in the presence of AMP, LKB1 can
directly phosphorylate Thr172 in a cell-free system (Gowans et al. 2013).
LKB1 appears to be constitutively active, since its activity remains unchanged by treatments that cause
increased AMPK activity (Woods et al. 2003b). Recent work may put this into context: LKB1 was shown
to activate AMPK at the lysosomal surface in a reciprocal manner with mTORC1 (Zhang et al. 2013).
Zhang et al., propose a model where AXIN (a scaffolding protein initially discovered to regulate the Wntsignaling pathway) tethers LKB1 to the lysosomal membrane, AMPK is then recruited upon AMP binding,
and LKB1 phosphorylation of AMPK Thr172 activity is enhanced (Zhang et al. 2013). This work was
followed up with a two-hybrid screen to detect AXIN-interacting proteins (Zhang et al. 2014).
Remarkably, they detected the Ragulator-complex protein, LAMTOR1. LAMTOR1 is tethered to the
lysosomal membrane by N-terminal myristoylation and palmitoylation. Notably, conditional LAMTOR1knockout mice have no AMPK activation upon glucose starvation, or exercise (Zhang et al. 2014). This
strongly suggests that AXIN-LKB1 recruits and activates AMPK under nutrient poor conditions, and that
Ragulator may function as sensor of both amino acid and ATP levels.
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CAMKKβ responds to increases in intracellular Ca2+
The Ca2+/calmodulin-dependent kinase kinase β (CAMKKβ) can also phosphorylate AMPK Thr172 in a
Ca2+-dependent manner, independently of AMP activation (Fig. 1.5) (Fogarty et al. 2010). Ca2+ is a
pervasive second messenger that complexes with the receptor, calmodulin. Upon Ca2+ binding,
calmodulin increases its affinity for a large number of binding proteins (Hook and Means 2001).
Activation of AMPK in response to increases in intracellular Ca 2+ occurs in LKB1-deficient cells and

importantly, this effect was dependent on CAMKKβ (Hawley et al. 2005). Furthermore, AMPK
activation was severely reduced after RNAi knockdown of CAMKK2 in mammalian cells, and purified
CAMKKβ could phosphorylate and activate AMPKα in vitro (Woods et al. 2005).

TAK1
Transforming growth factor-β activated kinase 1 (TAK1) is one of the most recently discovered activators
of AMPK, phosphorylating Thr172 directly (Momcilovic, Hong, Carlson 2006). TAK1 activity is regulated
by cytokines, including interleukin-1, transforming growth factor-β (TGFβ), as well as toll-like receptors,
CD40, and B cell receptors (Landstrom 2010). TAK1 is a member of the mitogen-activated protein kinase
kinase kinase (MAPKKK) family and thus stimulates p38 mitogen-activated protein kinase (p38 MAPK), cJun kinase (JNK), and IκKB kinase (IKK), in addition to AMPK (Quan et al. 2015)(Inokuchi-Shimizu et al.
2014).
ATM mediates the DNA damage response
The ataxia telangiectasia mutated (ATM) kinase is a key sensor of DNA double-strand breaks,
transducing this signal to the DNA-damage response pathway that leads to cell cycle arrest and
activation of DNA repair mechanisms. Mutation of the ATM gene gives rise to ataxia telangiectasia, an
autosomal recessive disorder that appears in early childhood (Bensimon, Aebersold, Shiloh 2011). These
patients show signs of ataxia associated with progressive loss of motor function, as well as increased
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intracellular reactive oxygen species (ROS), hypersensitivity to ionizing radiation, and an increased risk of
developing cancer and type-2 diabetes (Ditch and Paull 2012). AMPK was shown to be rapidly
phosphorylated at Thr172 in response to clinical doses of radiation therapy (Sanli et al. 2010).
Pharmacological inhibition of ATM prevented this rapid activation (Storozhuk et al. 2013). This
mechanism is not well understood since ATM does not phosphorylate Thr172 directly, and LKB1 null
cells still show radiation-induced AMPK activation (Brooks et al. 2012). ATM-activated AMPK stabilizes
ATM in turn, causing regulation of cell cycle checkpoints via the tumor suppressor, p53 (Sanli et al.
2014).

1.5.3 Downstream AMPK targets in the mTORC1 pathway
Once active, AMPK directly phosphorylates a number of downstream substrates that acutely affect
energy metabolism and growth, or induce gene expression that will lead to long-term changes in
metabolic programming (FIG. 1.5) (Mihaylova and Shaw 2011). AMPK was initially described as the
kinase phosphorylating acetyl CoA carboxylase (ACC) and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
reductase, rate-limiting enzymes in fatty-acid and sterol synthesis, respectively (Mihaylova and Shaw
2011). AMPK downregulates ACC enzyme activity, allowing long-chain fatty acids to enter the
mitochondrial matrix for β-oxidation, ultimately generating ATP (Linher-Melville et al. 2011). AMPK also
modulates protein homeostasis, largely by downregulating protein translation and ribosomal RNA
synthesis in nucleoli (Hardie, Schaffer, Brunet 2015). In fact, withdrawal of glucose, amino acids, or
oxygen leads to rapid suppression of mTORC1 activity (Shaw and Cantley 2006). This dissertation will
focus on the AMPK control of Raptor and TSC2, and the subsequent down-regulation of mTORC1
activity.
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TSC2
AMPK can control mTORC1 in response to hypoxia and nutrient withdrawal, by activating the negativeregulator, TSC2, increasing its GAP activity towards Rheb-GTP (Fig. 1.1 and 1.5) (Inoki, Zhu, Guan 2003).
This occurs in a LKB1- and AMP-dependent manner (Inoki et al. 2003). AMPK enhances TSC2 activity via
direct phosphorylation on its Thr1227 and Ser1345 residues2 (Li et al. 2003)(Inoki, Zhu, Guan 2003); (van
Veelen et al. 2011). RNAi knockdown of TSC2, or germline deletion of TSC2, prevents decreases in
phospho-S6K1 seen under energy starvation conditions. Wild type TSC2, but not the AMPKphosphorylation mutant, rescues this phenotype, implying that TSC2 is a link between AMPK and
mTORC1 in response to energy stress (Inoki, Zhu, Guan 2003). In a subsequent paper, Inoki et al.
immunoprecipitated overexpressed TSC1/2 from HEK293 cells, and found that the complex increased
recombinant Rheb-GTP hydrolysis in vitro (Inoki et al. 2003). In vivo Rheb-GTP hydrolysis was also seen
by using cotransfected myc-Rheb immunoprecipitated from
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P-phosphate-labeled cells (Inoki et al.

2003). Overexpressed TSC1/2 also decreased phospho-S6K1 and 4EBP1 levels (Inoki et al. 2003).
Although these data link AMPK activation to TSC2 GAP activity towards Rheb, the precise mechanism of
AMPK-enhanced GAP activity to Rheb remains ambiguous.
Raptor
The activity of mTORC1 still decreases in response to energy stress in TSC2 null cells, suggesting
additional points of control by AMPK (Gwinn et al. 2008); (Hahn-Windgassen et al. 2005). The Shaw
group was the first to show that the mTORC1 scaffolding protein, Raptor, was a direct target for AMPK
(Gwinn et al. 2008). This was accomplished by screening peptide libraries for optimal AMPKphosphorylation motifs (Scott, 2002; Gwinn, 2008). Mass-spectrometry then confirmed Raptor Ser792
as the site phosphorylated by AMPK in vivo, after isolating overexpressed Raptor from resveratrol2

These sites correspond to the mutations made to Rat cDNA before retroviral transduction into HEK293 human
embryonic kidney cells (Inoki, 2003). AMPK phosphorylates at least two sites on human TSC2, Ser1387 and
Thr1271, of which Ser1387 better meets the consensus for an AMPK site (Huang, 2008).
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treated (an AMPK activator) HEK293 cells (Gwinn et al. 2008). This group suggested that mTORC1
activity was diminished because of an increased binding of Raptor to cytosolic 14-3-3 proteins, with its
subsequent inactivation, degradation, or change in subcellular localization (Gwinn et al. 2008). No
further work has been done on this, so the definite path to Raptor/mTOR inactivation requires further
study. Finally, cells expressing wild type Raptor showed less cells entering S-phase after treatment with
the AMPK activator, AICAR. By contrast, cells expressing the mutant failed to arrest and exhibited
increased cell death via apoptosis (Gwinn et al. 2008).

1.7

The significance of aberrant mTORC1/AMPK signaling in cancer

progression and therapeutics
1.7.1 Oncogenic signaling converges on mTORC1
Aberrant growth factor signaling in cancer stimulates the Ras/MAPK and the PI3K/Akt pathways, with
cross talk to the epidermal growth factor receptor (EGFR) pathway. These pathways converge on
mTORC1 making manipulation of this complex crucial in managing cancers where malignant
transformation of these proteins has occurred. Multiple kinases, including Akt and ERK, phosphorylate
TSC2 in response to growth signals, inhibiting its GAP activity to Rheb (Inoki et al. 2002). Many cancer
cells are also resistant to energy stress conditions due to inhibition or mutation of LKB1 (Zheng et al.
2009). AMPK activators could resensitize cells to energy stress, such as the hypoxic conditions found in
solid tumors, leading to growth arrest or cell death. Significantly, the inhibition of mTOR by the
antifolate PTX is distinct from the direct effects of the classical mTOR inhibitor, rapamycin. Resistance to
rapamycin is common (Fasolo and Sessa 2012). PTX, on the other hand, has two main activities in cancer
cells: the direct inhibition of folate dependent enzymes, and the indirect, more prolonged inhibition of
the mTOR pathway.
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Oncogenic effects upstream of mTORC1
It is not surprising, given that mTOR integrates several major growth signals, that it is implicated in an
increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and
neurodegeneration. Many components of the PI3K signaling pathway are mutated in human cancers,
PTEN, Ras, PI3K, and these sit upstream of mTORC1. The loss or mutation of p53, the case in most
cancers, also promotes mTORC1 activation (Agarwal et al. 2015). These all result in oncogenic activation
of mTORC1, which supports many processes required for cancer cell growth, survival and proliferation
(Laplante and Sabatini 2012a).
Familial cancer syndromes are often caused by mutations in TSC1/2, LKB1, and PTEN. LKB1 mutations
are associated with the autosomal dominant Peutz-Jeghers syndrome (PJS), consisting of pigmentation
anomalies, benign gastrointestinal hamartomas, and predisposition to a range of malignant tumor types
(Hemminki et al. 1998). It is also associated with some sporadic lung adenocarcinomas (SanchezCespedes 2011). In addition, LKB1 mutations occur in a large percentage (30%–40%) of sporadic nonsmall-cell lung cancers (NSCLC) (Sanchez-Cespedes 2007). PJS actually shares a number of clinical
features with Cowden's Disease, which is caused by inactivating mutations in the PTEN tumor
suppressor. Mammalian TOR signaling is hyperactivated in LKB1-deficient MEFs (Corradetti et al. 2004).
Similarly, mTOR signaling is hyperactivated in hamartomas from LKB1-heterozygous mice, and in LKB1deficient human lung carcinomas (Shaw et al. 2004a; Carretero et al. 2007).
Oncogenic effects downstream of mTORC1
The aberrant regulation of translation initiation is also linked to neoplastic transformation. Constant
phosphorylation of 4EBP1/2 activates cap-dependent translation and thus cell cycle progression and cell
proliferation (Chuluunbaatar et al. 2010). 4EBP1 also mediates the effects of oncogenic Akt signaling
since eIF4E may promote cancer progression by promoting the translation of mRNA encoding pro-
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oncogenic proteins (Hsieh et al. 2012). The S6K1 target, eIF3, is frequently overexpressed in a variety of
human cancers (Rajasekhar and Holland 2004). The increase in ribosome biogenesis by S6K1 may also
provide the machinery required for the high levels of growth in cancer (Laplante and Sabatini 2012a).

1.7.2 Pharmacological control of mTORC1
Rapamycin analogs, or rapalogs, are frequently used in the clinic. The first of these, temsirolimus was
approved by the FDA in 2007, for the treatment of advanced stage renal cell carcinoma. Everolimus was
then approved for the treatment of TSC (Yalon et al. 2011). Rapalogs were expected to perform well in
the clinic but they have had only limited success. This may be due to the numerous negative feedback
loops on mTORC1; for example, activated mTORC1 causes IRS1 degradation via phosphorylation by
S6K1, thus preventing RTK activation (Harrington et al. 2004). Rapamycin also only partially inhibits the
phosphorylation of 4EBP1, and 4EBP1 is the downstream effector that plays the largest role in
oncogenesis (Thoreen et al. 2012).
ATP-competitive inhibitors of mTOR block the activity of both mTORC1 and 2, blocking cell growth and
proliferation (Thoreen et al. 2009)((Sini et al. 2010). This essentially appears to be the result of blocking
the rapamycin-resistant effects of mTORC1; that is, they completely block 4EBP1 phosphorylation,
inhibiting cap-dependent translation. Because of the similarity between the catalytic domains of mTOR
and PI3K, compounds have been developed that can inhibit both kinases. These decrease the
phosphorylation of S6K1, 4EBP1, and Akt (Brachmann et al. 2009). Such broad application may limit the
therapeutic window of these (Liu et al. 2011) compounds, as they are likely to have considerable
adverse effects. The PI3K/mTOR inhibitors, NVP-BEZ235 (Novartis) and XL-765 (Exelixis) are in phase I
trials (Vilar, Perez-Garcia, Tabernero 2011).
Compounds that cause energy stress will likely indirectly activate AMPK, and this indirectly inhibits
mTORC1 signaling. AMPK activators include AMP-analogs such as AICAR, indirect activators such as
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metformin, and direct allosteric AMPK activators (Hardie 2013). These compounds are discussed in more
detail in Chapter 3.

1.8

Overview

The tumor suppressor TP53 is the most frequently altered gene in human cancers. In fact, it is nearly
impossible for a normal cell to become a cancer cell without inactivating the p53 network (Solomon,
Madar, Rotter 2011). This network dictates the cell’s decision to initiate DNA repair, growth arrest,
senescence, or apoptosis in response to a range of cell stressors. Mammalian TORC1 plays a significant
part of the oncogenic profile that results from altered p53 function. mTORC1 also sits downstream of
other crucial tumor suppressors and oncogenes, including PTEN, LKB1, and Akt. This complex has
therefore garnered much interest for the development of targeted cancer therapies. The work
presented in this thesis will explore the mechanism of mTORC1 activation with p53 loss, mTORC1
inhibition by PTX-induced AMPK activation, and whether the action of other classical antifolates used in
cancer therapy is also partly due to AMPK and mTORC1 signaling.
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2

p53 Deletion Enhances mTORC1 Activity by Altering

the Lysosomal Dynamics of TSC2 and Rheb

2.1

Introduction

2.1.1 Subcellular compartmentalization orchestrates multiple stimuli
The signaling of mTORC1 is modulated by the dynamics of its upstream regulators on intracellular
membranes. The process of protein trafficking, recycling, and degradation involves membranous
vesicular structures formed originally by endocytosis of the plasma membrane. It is now accepted that
the subcellular location of signaling molecules creates dedicated signal transduction compartments
(Creighton 2011). This allows for specific spatial and temporal effects, regulated by microdomainorganization of multiple stimuli.
Protein trafficking to its site of action begins with processing in the ER and the Golgi
apparatus
The cell has extensive sets of intracellular membranes that comprise the endomembrane system.
Proteins use these intracellular membranes as anchors for nutrient sensing and signaling, and traffic
between them along cytoskeleton components such as microtubules and F-actin (Goldenring 2013). The
endoplasmic reticulum (ER) and the Golgi apparatus make up more than half the total membranes in the
cell (Pahl 1999). During translation, proteins are translocated into the ER lumen through surface pores.
Here the ER has two essential functions. Firstly, proteins intended for transport to other organelles, the
plasma membrane (PM), or for secretion, are synthesized, folded, and glycosylated in the ER (Pahl
1999).
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Figure 2.1: The endomembrane system of the mammalian cell. The cell has extensive sets of
intracellular membranes that comprise the endomembrane system. During translation, proteins are
translocated into the ER for proper folding, before trafficking to the Golgi apparatus where they undergo
extensive post-translational modification, including glycosylation, sulfation, phosphorylation, and the
addition of targeting peptide motifs. Cell surface proteins will eventually be internalized by endocytosis.
Most of the endosome contents are recycled back to the plasma membrane, but a fraction is delivered to
late endosomes or multivesicular bodies. These will then fuse with lysosomes where acid hydrolase
enzymes digest proteins, nucleic acids, lipids, and complex sugars. Figure adapted from Goldenring JR,
2013.
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Proteins that are incorrectly folded are retained and ultimately degraded, and ER stress occurs when
there is an accumulation of un- or misfolded proteins (Pahl 1999). Starvation of glucose, for example,
causes protein accumulation in the ER since the proteins cannot be glycosylated. Secondly, de novo lipid
and cholesterol synthesis, important for protein lipidation, occurs on the cytoplasmic side of the ER
membrane. As such, cholesterol starvation also leads to ER stress (Patil and Walter 2001). Newly
synthesized lipids and transmembrane proteins insert in the ER membrane because of their intrinsic
hydrophobicity, and future membrane receptors will bud off on ER membrane. Soluble proteins that
remain in the ER lumen, such as the hormones insulin and erythropoietin, are also transported in these
ER-derived vesicles. Proteins are then trafficked to the Golgi apparatus where they undergo extensive
post-translational modification, including glycosylation, sulfation, phosphorylation, and the addition of
targeting peptide motifs (Malhotra and Mayor 2006).
Endocytosis, recycling, and lysosomal degradation
Cell surface proteins will eventually be internalized by a process termed endocytosis. Endocytosis
involves the uptake of plasma membrane, with integral proteins and ligands, into primary endocytic
vesicles for delivery to endosomes (Huotari and Helenius 2011). Most of the contents are recycled back
to the plasma membrane, but a fraction is delivered to late endosomes or multivesicular bodies (Huotari
and Helenius 2011; Maxfield and Yamashiro 1987). These will then fuse with lysosomes where acid
hydrolase enzymes digest proteins, nucleic acids, lipids, and complex sugars (Luzio, Pryor, Bright 2007).
Some proteins are trafficked back to the Golgi apparatus where they are repaired, as is the case for
proteins with damaged glycosylated residues (Luzio, Pryor, Bright 2007). The lysosome is a subcellular
organelle found in all animal cells that digests cellular debris, damaged organelles and invaded
microorganisms. There are more than 50 soluble acid hydrolases that perform this digestive function,
and over 120 lysosomal membrane proteins that maintain the integrity of lysosomes, regulate lysosomal
trafficking, fusion and intralysosomal pH.
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2.1.2 Small GTPases act as molecular switches for protein trafficking and
signaling
Small GTPases (~21 kDa) are often involved in the decision processes that direct cell signaling and vesicle
trafficking (Schwartz, 2007). They act as positive regulators when GTP-bound, and prevent signal
transmission when GDP-bound (Aspuria and Tamanoi 2004). Thus, the activity of GTPases is driven by
their guanine nucleotide binding state, turning on and off as they cycle between GTP- and GDP-bound
states. These binding states are regulated by the action of guanine nucleotide exchange factors (GEFs)
that cause activation, and GTPase-activating proteins (GAPs) that enhance the hydrolysis of GTP to GDP,
pausing activation (Geyer and Wittinghofer 1997). Each GTP cycle, therefore represents an opportunity
to change signaling decisions: release a tether, change tracks from actin to tubulin, recruit another
regulator (GAP or GEF), or bind an effector, thus setting up the next signaling step (Geyer and
Wittinghofer 1997).
Small GTPases localize to endo- or plasma membranes where they carry out their function. Protein
trafficking, for example, is mostly regulated by the GTPases, Rab and ARF (ADP ribosylation factor), that
localize throughout the endomembrane system (Gargalionis et al. 2015). In general, Rab and ARF act as
anchors for the assembly of protein complexes that in turn mediate vesicle tethering and trafficking (Wu
et al. 2006). Rabs also interact with integrins, myosin and kinesin motor proteins, as well as various
scaffolding proteins (Goldenring 2013). Other small GTPases directly regulate the structure of
cytoskeletal elements, such as Rac and Rho (Jou, Schneeberger, Nelson 1998). The Ras superfamily of
GTPases, which includes the mTOR-activator Rheb, regulates cell growth, proliferation, and
differentiation, and they do so from the membranes of various intracellular compartments.
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Figure 2.2: GAPS, GEFs, and GDIs regulate small GTPase proteins. Small GTPase proteins, such as Ras,
act as molecular switches, turning signaling on when they are GTP-bound, and off when they are GDPbound. GTPase activating proteins (GAPs) enhance the GTPase activity of small G-proteins, turning them
“off”. Guanosine nucleotide dissociation inhibitors (GDIs) bind to the GDP-bound form of the GTPase,
preventing the exchange of GDP to GTP and preventing the small GTPase localization at membranes,
which is their place of action. Guanine nucleotide exchange factors (GEFs) activate GTPases by
stimulating the release of GDP to allow binding of GTP. Ras is active only when tethered to the plasma
membrane by a palmitoyl and farnesyl group (squiggle) and loaded with GTP.
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Canonical trafficking of the small GTPase Ras
Because so much of our understanding of the trafficking of Ras-like family members has been learned
from Ras itself, I will outline the events known to be involved in the trafficking of Ras. Ras-like proteins,
of which there are over 150, act as molecular switches for a variety of cell signals. Ras signaling and
biochemistry has been explored extensively, and thus represents the canonical small GTPase. Ras is
named for the Rat sarcoma viral oncogene that was able to induce oncogenic transformation in NIH 3T3
cells (Scher, Haudenschild, Klagsbrun 1976). Mutations in Ras are found in up to 25% of NSCLC patients
(Riely, Marks, Pao 2009). Ras-like proteins are membrane-bound 21 kDa GTP-binding proteins, which
have low intrinsic GTPase hydrolysis capabilities, and are regulated by GAPs and GEFs (Fig. 2.1). Gproteins are the paradigm for the molecular switch. The molecular switch mechanism involves the
exchange of GDP for GTP by Ras-GEFs results in an allosteric change, in two key regions named Switch I
and Switch II (Hall et al. 2001). The Switch I region is considered the effector loop as it is able to bind
effector proteins when Ras is in its GTP-form. Ras-GTP activates a large repertoire of effector proteins,
with the best characterized being the Raf kinases, PI3K, and the Ral-GEFs (Marshall 1996). Ras activates
Raf kinase by recruiting 14-3-3-bound Raf to the plasma membrane, where Ras proceeds to
dephosphorylate Raf, thus setting off a series of activating phosphorylation events (Marshall 1996).
Phosphatidyl serine and phosphatidic acid are involved in this recruitment of Raf to membranes,
possibly by displacing the 14-3-3 protein, and providing Raf with a lipid anchor (Hancock 2003; Rizzo et
al. 2000). Activated Raf then turns on the MAPK/ERK/MEK (mitogen activated protein kinase/
extracellular regulated kinase/ ERK kinase) growth signaling pathway.
The different Ras isoforms, H-Ras (Harvey Ras), N-Ras (neuroblastoma Ras), and K-Ras (Kirsten Ras)
generate distinct signal outputs despite interacting with a common set of activators and effectors
(Hancock 2003). The Ras GEFs also work on the different isoforms with varying efficiencies (Ehrhardt et
al. 2002). These differences are a result of the C-terminal 25 amino acid sequence named the
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hypervariable domain (HVR). This stretch shares less than 15% sequence homology between isoforms,
as compared with the 90-100% homology over the rest of the protein (Hancock 2003). The HVR is
necessary for Ras localization to the PM, where it is loosely attached to the cytoplasmic side of the PM
by lipid anchors (Schmick, Kraemer, Bastiaens 2015). Mutation of the CAAX motif (C = cysteine, A =
aliphatic amino acid, X = any amino acid) at the C-terminal prevents Ras signaling, and membrane
localization (Willumsen et al. 1984c). Live-cell imaging has since shown that Ras traffics to, and signals
from multiple endomembrane compartments, including the ER and Golgi apparatus (Schmick, Kraemer,
Bastiaens 2015). Ras membrane localization is contingent on changes in membrane affinity via
lipidation, resulting in Ras trapping on endomembranes coupled with unidirectional transport to the PM,
and by simple diffusion via interaction with solubilization factors (Schmick, Kraemer, Bastiaens 2015).
These are discussed below.
Lipidation
Ras is synthesized as a cytosolic precursor before it is post-translationally modified at its C-terminal
CAAX box (Willumsen et al. 1984b). First, a 15-carbon farnesyl group is attached to the CAAX cysteine by
the cytosolic enzyme, farnesyl transferase (Jackson et al. 1990). The farnesyl group targets Ras to the ER
where Rce1 (Ras and a-factor converting enzyme) cleaves off the AAX tripeptide (Kim et al. 1999).
Another ER-bound enzyme, Icmt (isoprenylcysteine carboxyl methyltransferase), then methylates the
terminal farnesylcysteine residue (Dai et al. 1998). Mutation of either of these enzymes prevents
membrane localization of Ras, resulting instead in the cytosolic accumulation of Ras (Kim et al. 1999). A
second targeting lipid can then be added to cysteines within the HVR. H-Ras and N-Ras, but not K-Ras,
are palmitoylated, allowing their entry into the exocytic pathway, through the Golgi, to the PM (Fig. 2.3)
(Brunsveld, Waldmann, Huster 2009; Hancock 2003). H-Ras has two cysteine-palmitoylation sites, while
N-Ras has only one, and this appears to result in more N-Ras on endomembranes and the Golgi
apparatus, than the PM (Willumsen et al. 1984a). In contrast, K-Ras lacks cysteine residues in its HVR,
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and instead has a poly-lysine tract (Choy et al. 1999). K-Ras therefore bypasses the Golgi and traffics to
the PM by an as-yet-unknown mechanism. The poly-lysine tract may also enhance association with PMderived, negatively charged phospholipids of pericentriolar recycling endosomes (Schmick, Kraemer,
Bastiaens 2015).
Palmitoylation1 modifications signal movement from the ER to the PM. For Ras proteins, this is
controlled by the ER-bound Ras palmitoyltransferase (RPT) (Bartels et al. 1999). Hence, mutation or
inhibition of RPT by the brominated analog of palmitate results in the accumulation of H- and N-Ras in
the ER (Davda et al. 2013). The mechanism by which palmitoylation increases PM localization is remains
unclear, but may just involve increased lipophilicity and membrane affinity, or possibly uptake by the
bulk-flow exocytic pathway (Hancock 2003). As mentioned, the polybasic HVR of K-Ras may drive
diffusion down an electrostatic gradient to the negatively charged PM (Roy, Leventis, Silvius 2000).
Alternatively, K-Ras may move along microtubules, since it binds taxol-stabilized microtubules in vitro
(Lapierre et al. 2001).
Lipid groups show differences in their affinity for membranes. Myristate and farnesyl groups have
relatively low membrane-affinity, while geranylgeranyl and palmitate groups have high membrane
affinity (Hancock 2003). Palmitoylation is also an unstable modification, with a half-life of 20 minutes for
N-Ras (Nadolski and Linder 2007). Where and how this turnover occurs in unknown, but it is stimulated
by the S-nitrosylation of Ras cysteine residues (Baker, Booden, Buss 2000; Kaye et al. 2000). Snitrocysteine also decreases Ras GTP-binding in NIH 3T3 cells, suggesting a connection between Ras
activation, and regulation by turnover (Baker, Booden, Buss 2000). Interestingly, the α-subunit of Gproteins also undergo increased de-palmitoylation when GTP-loaded, thus becoming more sensitive to

1

Palmitoylation is the post-translational addition of palmitic acid to a protein. For Ras this is termed S-acylation
since the palmitic acid is attached as a thioester to the thiol group (-SH) of a cysteine.
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regulators that stimulate GTP hydrolysis (Tu, Wang, Ross 1997). This hints at a mechanism for recruiting
GAP proteins to GTPases.
Microlocalization on lipid rafts
Lipid rafts produce areas for microlocalization on membranes, thus further compartmentalizing
regulatory proteins. Palmitoylated proteins localize to detergent-resistant lipid rafts because their
saturated structure allows them to pack into liquid-ordered2 rafts (Melkonian et al. 1999). In contrast,
unsaturated, branched-chain prenyl groups (farnesyls and geranylgeranyls) cannot, adding another level
of localization control. Interestingly, the doubly-palmitoylated H-Ras is tethered to lipid rafts when GDPbound, but diffuses into the disordered PM when GTP-bound (Melkonian et al. 1999). Elegant studies
using FRAP (fluorescence recovery after photobleaching) analysis of GFP-Ras showed that Ras moves
laterally within the PM (i.e., back into photobleached areas), and this is restricted at low levels of
expression, and enhanced at high levels of expression (Niv et al. 2002). Furthermore, microlocalization
could be the result of acidic domains: polybasic peptides can attract acidic phospholipids such as
phosphatidylinositol-4,5-bisphosphate (PIP3) temporarily creating an acidic microdomain (Wang,
Slochower, Janmey 2014). This is reversed by Ca2+-calmodulin binding to, or phosphorylation of, the
polybasic domain (Arbuzova et al. 1997). This theory is bolstered by the fact that K-Ras, in an HVRdependent manner, binds and is inhibited by Ca2+-calmodulin (Villalonga et al. 2002).
Solubilization factors
Protein localization is also determined by interaction with chaperone proteins that act as solubilizing
factors. These solubilization factors are often guanine nucleotide dissociation inhibitors (GDIs), and they
interact with the GDP-bound GTPase with high affinity to allow for diffusion of the GTPase through the
cytosol (Hancock, 2003). Membrane affinity is likely reduced by the binding of the chaperone protein, or

2

Liquid-ordered refers to a state between a fluid and a gel; lipid rafts resemble this because of their tightly packed
molecular structure.
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GDI, thus shielding the GTPase from hydrophobic membranes. Rho-GDIs, for example, solubilize Rhofamily GTPases out of cell membranes (Li et al. 2002). Furthermore, Rab-GTPases are cytosolic in their
inactive GDP-bound form, even though they remain geranylgeranylated, alluding to binding to a
solubilization factor (Soldati, Riederer, Pfeffer 1993).
Phosphodiesterase 6δ (PDE6δ) is another cytosolic solubilization factor that binds farnesylated proteins.
In yeast-two hybrid assays, PDE6δ interacted strongly with H-Ras, weakly with Rheb, and not at all with
K-Ras (Philips 2012). This interaction was dependent on the farnesyl group and the HVR domain of HRas, and was stronger for H-Ras-GDP than -GTP (Philips 2012). PDE6δ has structural homology to RhoGDIs, and overexpression of PDE6δ results in redistribution of H-Ras from the PM to the cytosol (Nancy
et al. 2002). Conversely, knockdown of PDE6δ causes K-Ras enrichment at the PM (Schmick, Kraemer,
Bastiaens 2015). The ARF-like GTPase, Arl2 binds allosterically to PDE6δ in its GTP form, causing PDE6δ
to unload its farnesylated GTPase at membranes (Ismail et al. 2011). Overall, displacing farnesylated
cargo from PDEδ by Arl2 activity in the perinuclear area is responsible for K-Ras and H-Ras enrichment at
the PM, as well as for perinuclear enrichment of Rheb. This unloading at perinuclear membranes occurs
because Arl2-GEFs are enriched at these membranes (Schmick, Kraemer, Bastiaens 2015). GEF proteins
are also cytosolic until activation by growth factor initiates their recruitment to a membrane, where
they colocalize with their specific GTPase (Blumer et al. 2013).

2.1.3 The subcellular localization of the Ras-like GTPase, Rheb
Rheb is an unique Ras-like GTPase
Rheb has several unique structural features that differentiate its function from other Ras-like GTPases.
These differences essentially maintain Rheb in a highly active state by inhibiting its intrinsic GTPase
activity (Mazhab-Jafari et al. 2013).
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Figure 2.3: Ras core structure and C-terminal lipidation motifs of posttranslational completely
processed N-Ras, H-Ras, K-Ras4A, and K-Ras4B. For N-Ras, H-Ras, and K-Ras4A the cysteine
palmitoyl thioesters are reversible posttranslational modifications, regulating membrane affinity
and localization in cooperation with the farnesyl thioether. For K-Ras4B the polybasic lysine
stretch is the second membrane targeting sequence, additional to the farnesyl thioether. Image
adapted from Brunsveld L., 2009.
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Firstly, Rheb does not possess the extra cysteines that are targets for palmitoylation in H- and N-Ras
(Hanker et al. 2010). The lack of these two moieties, and the fact that its C-terminal region lacks any
other features (such as a basic HVR) that would increase PM association, appears to be the reason Rheb
equilibrates to endomembranes without further trafficking to the PM (Schmick, Kraemer, Bastiaens
2015). Indeed, replacing the Rheb HVR with the H-Ras HVR causes the association of Rheb with the
plasma membrane association (Takahashi et al. 2005). The lack of palmitoylation or a poly-lysine tract
allows Rheb to remain concentrated on perinuclear membranes by the PDEδ–Arl2 delivery system
(Schmick, Kraemer, Bastiaens 2015). This enrichment allows Rheb increased access to lysosomes. In fact,
Rheb equilibrates to endomembranes from the perinuclear region, and partitions into the cytosol, much
faster than the other Ras-like proteins (Schmick, Kraemer, Bastiaens 2015).
Crystal structures of Rheb bound with GTP, GDP, or GppNHp3 have been resolved (Yu et al. 2005). These
show that the Switch I region (effector binding region) of Rheb has high similarity to that of Ras, with the
conformation undergoing a change when GDP or GTP bound. Conversely, the Switch II region remains
relatively stable, unlike other Ras-like GTPases (Yu et al. 2005). Rheb is thus able to interact directly with
the kinase domain of mTOR regardless of its guanyl nucleotide state, and GTP charging is only necessary
for effector activation (Inoki et al. 2003; Sato et al. 2009). For Ras, GTP charging is necessary for the
binding to and the activation of its effectors. The GTPases most closely related to Rheb, Ras and Rap1,
exhibit very weak binding to mTOR.
Finally, nuclear magnetic resonance (NMR) has also been used to study the structure of the N-terminal
GTPase domain of Rheb (Mazhab-Jafari et al. 2010). Rheb is distinctive in that its GTP-interacting
glutamine (Gln61 in Ras, Gln64 in Rheb) is buried within a hydrophobic region, and is thus shielded from
GTPase catalytic action. NMR was also used to query the structure of Rheb-GDP (Karassek et al. 2010),
3

5'-Guanylyl imidodiphosphate is an analog of guanosine triphosphate in which one of the oxygen atoms is
replaced with an amine, producing a non-hydrolyzable functional group.
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and to characterize Rheb tethering to synthetic lipid bilayer nanodiscs. This last study in particular
showed that the GTPase domain interacts with the lipid bilayer transiently and in two distinct GTP- or
GDP-bound orientations (Mazhab-Jafari et al. 2013). Importantly, membrane binding decreased the
intrinsic nucleotide exchange rate without changing GTP hydrolysis, suggesting that endomembrane
association appears to influence Rheb’s intrinsic nucleotide exchange rate (Mazhab-Jafari et al. 2013).
Rheb at late endosomal/lysosomal membranes
Overexpression of Rheb and immunofluorescence originally hinted at a perinuclear or vesicular
localization (Saito et al. 2005; Takahashi et al. 2005). It is now thought that a subpopulation of Rheb is
tethered to internal membranes in a farnesyl transferase, CAAX-box dependent manner (Hanker et al.
2010; Takahashi et al. 2005). Recent studies show that Rheb resides predominantly at the lysosomal
surface (Dibble et al. 2012). Moreover, the main purpose of the amino acid signal seems to be to localize
mTOR to its activator, Rheb, on the lysosome. Superior anti-Rheb antibodies have allowed for the
visualization of Rheb and mTOR colocalization with the endosomal/late endosomal protein Rab7, and
the lysosomal protein LAMP2 (Menon et al. 2014; Sancak et al. 2008; Sancak et al. 2010). The fusion of
the CAAX box of Rheb to Raptor results in the colocalization of mTOR to late endosomal/lysosomal
membranes and increased mTORC1 activity even under amino-acid starvation (Sancak et al. 2010). This
suggested that activators of mTORC1 reside on these endomembranes, and that Raptor alone was not
sufficient to increase mTORC1 activity in amino acid starved cells (Sancak et al. 2010). The association of
Rheb, however, at lysosomal membranes was not changed by insulin stimulation or the addition of
amino acids (Menon et al. 2014). The association was sensitive to treatment with farnesyl transferase
inhibitors, which decreased Rheb/LAMP1 colocalization, mTORC1 signaling, and TSC2 lysosomal
localization (Menon et al. 2014). Therefore, even though the farnesyl group provides a relatively weak
membrane anchor, it appears to be essential for activation of mTORC1.
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Another direct but non-essential activator of mTORC1, phosphatidic acid (PA), also happens to be
enriched in late endosomal/lysosomal membranes (Fang et al. 2003; Sancak et al. 2008)(). Rheb
interacts with and activates phospholipase D1 (PLD1) in a GTP-dependent manner, resulting in enhanced
levels of PA (Sun and Chen 2008; Sun et al. 2008). Notably, amino acids also enhance PLD1 activity and
increase the concentration of PA at lysosomes (Yoon et al. 2011).
Rheb localization on peroxisomes and mitochondria
In response to increased levels of ROS, Rheb, as well as TSC1/2 colocalized with peroxisomal membrane
protein 70 (PMP70), and were enriched in peroxisomal cell fractions (Zhang et al. 2013). This localization
inhibited mTORC1 signaling and promoted autophagy in response to oxidative stress. Rheb has also
been shown to be enriched in mitochondrial cell fractions, and to colocalize with the mitochondrial
stain, mitotracker (Ma et al. 2008). At the mitochondria, Rheb is implicated in regulating mitophagy, the
autophagosome-mediated degradation of mitochondria, in response to hypoxia and increased oxidative
phosphorylation (Groenewoud and Zwartkruis 2013a; Groenewoud and Zwartkruis 2013b). In fact, Rheb
has been shown to bind BNIP3s (Bcl-2 homology 3 domain-containing proteins), proteins that are
upregulated under mitophagic and hypoxic conditions (Li Y, 2007). Mutation of the transmembrane
domain of BNIP3, or a farnesylation-defective Rheb, prevented Rheb-BNIP3 binding and their proper
membrane localization (Li et al. 2007). Importantly, BNIP3 overexpression decreased Rheb-GTP/GDP
ratio, and decreased p70-S6K1 and 4EBP1 phosphorylation (Li et al. 2007). This is consistent with the
decreased mTORC1 activity seen under hypoxic conditions (Zou et al. 2011). Conversely, overexpressing
Rheb increases BNIP3L levels and decreases mitochondrial mass (Melser et al. 2013). This study showed
Rheb on the outer mitochondrial membrane where it was bound to BNIP3L and LC3-II (an
autophagosomal membrane marker), and there was also a corresponding increase in mitophagy (Melser
et al. 2013).
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2.1.3 The lysosome as a key site for regulation of mTORC1
Recent advances in the field show that amino acid and growth factor signaling culminate at the
lysosome to activate mTORC1. mTOR is found throughout the endomembrane system, localizing to the
endoplasmic reticulum (ER), Golgi apparatus, and endosomes (Drenan et al. 2004; Mavrakis et al. 2007).
This was initially shown by immunofluorescence, where endogenous and recombinant mTOR proteins
showed colocalization with the ER-marker protein Calnexin, and the Golgi-marker, Golgi-97 (Drenan et
al. 2004). mTOR also co-fractionated with Calnexin (Drenan et al. 2004). Amino acids were known to be
crucial for mTORC1 activation but the precise mechanism was not understood. Sancak et al., (2008) first
noted the striking difference in mTOR localization in the absence and presence of amino acids, rapidly
changing from diffuse and cytoplasmic to perinuclear puncta. This change in localization could only
occur in the presence of the Rag-GTPases and the mTORC1 scaffold, Raptor (Sancak et al. 2008). Amino
acids were also necessary for regulating the translocation of Raptor to the lysosome (Sancak et al. 2008).
In fact, when Raptor is forced to remain on the lysosomal membrane by fusion of Raptor to a lysosomal
targeting sequence, mTORC1 activation can occur in the absence of amino acids, implying that Raptor is
necessary to bring mTOR to the lysosome (Sancak et al. 2010).
As touched on in Chapter 1, cell-free reconstitution assays showed that the signal for mTOR
translocation initiates within the lysosome (Zoncu et al. 2011). Ionophores or detergents that disrupt
lysosomal membranes prevent the recruitment of mTOR to purified lysosomes (Zoncu et al. 2011).
Furthermore, overexpression of the lysosomal amino-acid exporter PAT1 (proton-assisted amino acid
transporter) prevents mTORC1 activation even in the presence of amino acids (Sagne et al. 2001). This
showed that the lysosomal membranes, coupled with internal reserves of amino acids, are essential for
mTOR translocation onto the lysosomes. Interestingly, mTORC1 negatively regulates the biogenesis of
lysosomes through phosphorylation of transcription factor EB (TFEB), a transcription factor that controls
many genes involved in lysosomal function (Settembre et al. 2012). mTORC1-dependent
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phosphorylation of TFEB prevents its nuclear entry, and therefore its action as a transcription factor. In
contrast, nutrient starvation (and mTORC1 inhibition) causes an accumulation of nuclear TFEB and
lysosome production (Yu et al. 2010). Lysosome associated membrane proteins 1 and 2 (LAMP1/2) are
integral membrane proteins that function to protect the lysosomal membrane from degradation, and
are the most commonly used markers in mTORC1 colocalization studies.
The Rag GTPases
Amino acid signaling was initially thought to act through the TSC2/Rheb axis until it was observed that
mTORC1 in MEFs from TSC2 null mice were still sensitive to changes in amino acid levels (Roccio, Bos,
Zwartkruis 2006). Instead, biochemical and genetic screens identified the Rag GTPases as the molecular
players in amino-acid induced mTORC1 activation (Kim et al. 2008; Sancak et al. 2008). Sancak et al.,
(2008) first identified the 44 kDa RagC protein by co-purification with Raptor, avoiding techniques
resulting in antibody heavy chains that would normally obscure this protein size range (Sancak et al.
2008). Their role in cell growth were inferred by the Rag yeast homologs, Gtr1p and Gtr2p, as they were
known to regulate processes that respond to amino acid levels such as the Gap1p amino acid permease
and mitophagy (Dubouloz et al. 2005).
The Rags function as obligate heterodimers, RagA and RagB (RagA/B) must bind to RagC and Rag D
(RagC/D) to be functional (Kim et al. 2008; Sekiguchi et al. 2001). In response to amino acids, the Rags
localize to the lysosomal surface where they recruit Raptor and perhaps act as a docking site for
mTORC1 (Sancak et al. 2008). This action is dependent on the nucleotide binding state of the Rag
heterodimer. To understand the function of the Rag-nucleotide binding state, HA-tagged Rag mutants
restricted to their GTP or GDP bound conformation were expressed in HEK293T cells, along with
mTORC1 components (Dubouloz et al. 2005; Sancak et al. 2008). Intriguingly, RagBGTP associated with
more Raptor and mTOR, than wild type or GDP-bound RagB (Sancak et al. 2008). Further,
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RagBGTP/RagCGDP heterodimers recovered the most endogenous mTOR of any other of the tested
heterodimers. In vitro binding assays also showed that the Raptor/mTOR interaction with
RagBGTP/RagDGDP was likely direct. Expression of RagBGTP/RagDGDP activated the mTORC1 pathway even in
the absence of amino acids. The opposite arrangement, RagBGDP/RagDGTP, however, suppressed mTORC1
activity. Sancak et al., then showed that amino acid starvation causes RagA/B to bind GDP, which is
exchanged for GTP upon amino acid stimulation (Sancak et al. 2008). RagA/B-GTP locked mutants allow
mTORC1 lysosomal localization in the absence of amino acids (Efeyan et al. 2013; Sancak et al. 2008). In
summary, the Raptor-Rag GTPase interaction is mediated by GDP bound RagC, and not RagAGTP. RagA/B,
however, must be in its GTP bound form to activate the pathway in response to amino acid sufficiency
(Tsun et al. 2013).
Rheb on the other hand was not detected in these pull downs and, the nucleotide charge or localization
of Rheb is not changed by amino acids (Roccio, Bos, Zwartkruis 2006; Sancak et al. 2008). In addition,
Rag heterodimers, unlike Rheb, do not stimulate mTORC1 kinase activity in vitro (Long et al. 2005;
Sancak et al. 2007). Growth factors cannot activate mTOR in the absence of amino acids, and lysosomal
localization of mTOR is not sensitive to growth factor stimulation or the presence of Rheb (Groenewoud
and Zwartkruis 2013b; Menon et al. 2014; Sancak et al. 2010). Rag binding therefore does not activate
mTOR kinase activity, but rather brings mTOR in proximity to Rheb, which is activated by growth factors
(Bar-Peled and Sabatini 2014; Kim, Buel, Blenis 2013).
The Rags are unusual in that they do not contain lipid modifications that would normally allow for
membrane anchoring. Instead, they tether to a pentameric lysosomal complex known as Ragulator (BarPeled et al. 2012; Sancak et al. 2010). The Ragulator consists of Lamtor1 (late endosomal/lysosomal
adaptor, MAPK and MTOR activator 1), which scaffolds two other subunits, Lamtor2/2 and Lamtor4/5
(Sancak et al. 2010). Lamtor1 is myristoylated and palmitoylated on its N-terminus, allowing targeting to
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lipid rafts on lysosomal surfaces (Nada et al. 2009). In Ragulator-depleted cells, Rags can no longer
localize to lysosomes and mTORC1 remains inactive (Bar-Peled et al. 2012; Sancak et al. 2010).
Importantly, Ragulator functions as a GEF for RagA/B, displacing GDP and allowing GTP binding (BarPeled et al. 2012). In response to amino acids, Ragulator also interacts with v-ATPases (Forgac 2007),
proposed to be the direct sensor of lysosomal amino acids.
Other subcellular compartments also stage mTOR signaling
The peroxisome and the Golgi complex have been implicated in mTOR signaling. Specifically, reactive
oxygen species (ROS) were able to activate TSC2 and inhibit Rheb on peroxisomes, thus reducing
mTORC1 activity (Zhang et al. 2013). In contrast, PI3K signaling caused the dissociation of TSC2 from
TSC1 at the peroxisomal surface, restoring mTORC1 activity (Zhang et al. 2013). Another study observed
Rheb on Golgi membranes, and here the small GTPase Rab1A and not Rag-GTPase, served to recruit
mTOR to Golgi complex membranes (Thomas et al. 2014). Rab1A is known to regulate trafficking from
the ER to the Golgi (Barral et al. 2012). Interestingly, Rab1A knockdown inhibited Rag-induced mTORC1
signaling and vice versa (Thomas et al. 2014). Taken together this suggests a role for Rab1A in the
trafficking of Rags and conceivably, Rheb since Rheb is known to undergo post-farnesylation processing
on the ER (Winter-Vann and Casey 2005). Mechanical activation of mTORC1 in muscle cells also appears
to be regulated on late endosomal/lysosomal (LEL) surfaces (Jacobs et al. 2013b), independently of PI3K
signaling (Hornberger et al. 2006). Intriguingly, this involves the phosphorylation of TSC2 and
dissociation of TSC2 from LEL membranes (Jacobs et al. 2013a).

2.1.5 Spatial regulation of TSC2 and Rheb-GTPase controls mTORC1 activity
TSC2 subcellular localization is regulated by PI3K signaling
Brendan Mannings’ group showed that growth factor signaling also regulates mTORC1 on the lysosomal
membrane via TSC2 (Menon et al. 2014). TSC2 is displaced from lysosomal membranes by growth factor
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signaling through Akt, and the proper localization of TSC2 appears to be independent of amino acids
(Menon et al. 2014). It is not known how TSC2 physically associates with the lysosomal membrane, but
knockdown of either TSC1 or TBC1D7 does not alter its localization, while farnesyl transferase inhibitors
prevent its localization even under energy-limited conditions (Cai et al. 2006; Dibble et al. 2012; Menon
et al. 2014). Importantly, recombinant Rheb-GDP pulls down more endogenous TSC2 than recombinant
Rheb-GTP, and this interaction is weakened by insulin stimulation (Menon et al. 2014).
TSC2 inhibits Rheb when growth factors or energy levels are limited by enhancing the GTPase activity of
Rheb (Inoki et al. 2003). It follows that kinases that respond to growth factors or low energy conditions
regulate TSC2 GAP activity (Huang and Manning 2008). Akt, ERK, and RSK phosphorylate and inhibit
TSC2 in the presence of growth factors, while AMPK and GSK3 activate TSC2 in response to energy stress
(Huang and Manning 2008). Akt is by far the most established inhibitor of TSC2, phosphorylating TSC2 at
five residues, all of which must be phosphorylated for full activation of mTORC1 (Inoki et al. 2002;
Manning et al. 2002; Potter, Pedraza, Xu 2002). The mechanism of Akt-inhibition of TSC2 does not
involve degradation of TSC2, or any alteration to the GAP activity of TSC2 in vitro (Cai et al. 2006; Inoki et
al. 2003; Menon et al. 2014). Instead, Akt was found to trigger the translocation of TSC2 off lysosomes
and into the cytoplasm (Menon et al. 2014). Mutation of the five Akt-phosphorylation sites, or fusion of
TSC2 to a lysosomal targeting sequence, is enough to make mTORC1 insensitive to growth factor
signaling (Menon et al. 2014). In conclusion, TSC2 may associate with the lysosome in a TSC1- and Rhebdependent manner, Akt phosphorylation of TSC2 triggers its translocation from lysosomal membranes
to the cytosol, and the effects of energy stress or DNA-damage signals on TSC2 subcellular localization
have yet to be established.
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2.1.6 Loss or mutation of TP53 upregulates mTORC1 activity
The tumor suppressor protein, p53
TP53 is best known for its role as a transcriptional activator and tumor suppressor. The majority of
human cancers show loss or mutation of TP53 (Hollstein et al. 1991). Patients that inherit one mutant
TP53 allele have an increased risk of developing cancer, a condition known as Li-Fraumeni syndrome
(Varley 2003). p53 is activated in response to most intra- and extracellular stresses, including DNA
damage, oncogene activation, loss of normal cell-cell contact, and nutrient or oxygen deprivation (Horn
and Vousden 2007). Canonical p53 signaling results in the induction of cell-cycle arrest, senescence, and
apoptotic cell death (Horn and Vousden 2007). p53 also has cytosolic functions, such as inhibition of
autophagy (Maiuri et al. 2010), apoptosis and necrosis via Bcl2 proteins (Green and Kroemer 2009), and
glucose metabolism via binding to G6PDH (glucose-6-phosphate dehydrogenase) (Jiang et al. 2011). The
outcome of p53 activation is incredibly complex, depending on the level of p53 expression, the suite of
post-translational modifications, and the cell type. Severe or sustained p53-mediated stress leads to cell
death or senescence. Mild stress leads to p53-directed cell cycle arrest and DNA damage repair, or
decreases in harmful ROS levels (Berkers et al. 2013). This type of adaptive response is also triggered by
fluctuations in nutrient availability, implicating both mTORC1 and AMPK signaling.
Crosstalk between p53 and mTORC1
p53 generally acts as a negative regulator towards mTORC1, shutting down cell growth and energy
consumption (Fig. 2.4). The inhibition of mTORC1 in parallel to cell cycle arrest is important in
determining the eventual outcome of p53 activation (Berkers et al. 2013). The transcriptional targets of
p53 that act on mTORC1 include AMPKβ, TSC2, Sestrin1/2, IGF-BP3 (insulin-like growth factor binding
protein 3), PTEN (phosphatase and tensin homolog deleted on chromosome 10), and Plk2 (polo-like
kinase2), and their transcriptional upregulation occurs in response to genotoxic stress
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Figure 2.4: Crosstalk between p53, AMPK, and mTORC1. A variety of stresses regulates mTORC1 signaling
including DNA damage activated p53. Activated p53 stimulates AMPK signaling to TSC2, which inhibits
mTORC1 via GAP activity towards Rheb. Hypoxia induces the expression of REDD1 and REDD2, which
activate TSC1/TSC2 through an unknown mechanism. Energy stress activates AMPK via LKB1. Mitogenic
signaling through Ras counters these signals by inhibiting TSC2. High levels of S6K1 signaling can inhibit
IRS1, blocking PI3K/Akt inhibition of TSC2, and Akt activation of MDM2, which increases the degradation
of p53 (not shown).
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(Budanov et al. 2002; Feng et al. 2007). DNA damage, for example, induces the expression of TSC2 and
PTEN, causing downregulation of the PI3K-mTORC1 axis (Feng et al. 2005). Abnormal mTORC1 signaling
also influences p53. Oncogenic PI3K signaling induced by a constitutively active Notch1 receptor inhibits
p53 activity via the mTORC1 target, eIF4E (Mungamuri et al. 2006).
AMPK can also act upstream and downstream of p53. In response to genotoxic or oxidative stress, p53
promotes the expression of Sestrins, which can activate AMPK, thus inhibiting mTORC1 (Budanov and
Karin 2008). p53 also mediates AMPK activation in response to the topoisomerase inhibitor, VP16 (Feng
et al. 2005). This causes a G1/S checkpoint halt, preventing S-phase entry when energy levels are low. In
liver cancer cells, AMPK has also been shown to inhibit the p53 deacetylase, Sirt1, thus augmenting p53
acetylation and activation (Lee et al. 2012). The metabolic functions of p53, mediated by AMPK and
mTORC1, provide an additional layer of protection against tumor development. These include restoring
the cell’s redox balance, and inducing autophagy to rid the cell of dysfunctional organelles (Berkers et al.
2013). Via AMPK, p53 will also indirectly counteract the Warburg effect4 by inhibiting glycolysis and
promoting oxidative phosphorylation.
Loss or mutation of p53 increases the basal levels of mTORC1
In our recent paper, we describe the massive increases in mTORC1 signaling in p53 null HCT116 cells, in
NSCLC cells treated with p53 siRNA, and in cells expressing p53 with mutations in their DNA binding
domains (Agarwal et al. 2015). In this context, the loss of p53 affected the basal levels of mTORC1
activity, as opposed to the decreased levels of kinase activity seen when p53 is induced by DNA
damaging agents (Budanov and Karin 2008; Feng et al. 2005). As such, AMPK activation did not change
when p53 was lost, implying loss of AMPK activation was not the mechanism of overactive mTORC1.

4

The Warburg effect was observed and described by Nobel laureate, Otto Warburg in 1924. This phenomenon is
seen in most cancer cells where they rely on aerobic glycolysis instead of mitochondrial oxidative phosphorylation
to metabolize glucose. Although aerobic glycolysis produces much less ATP per molecule of glucose, it occurs at a
much higher rate, which may be favored by highly proliferative cancer cells.
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Nevertheless, the enhanced mTOR kinase activity against 4EBP1 was retained in vitro using complexes
immunoprecipitated with an anti-Raptor antibody. The proteins that co-immunoprecipitated with
Raptor hinted at a mechanism, as there was a decrease in the inhibitor proteins, PRAS40 and TSC2, and
an increase in the activating protein, Rheb, as well as mTOR itself. The decreased levels of TSC2 were
seen in total cell lysates from p53 null cells as well, prompting us to look for the expression levels of this
known p53 transcriptional target. Not surprisingly, mRNA levels of TSC2 and Sestrin2 (the other p53
target in the mTORC1 pathway), were decreased when p53 was lost or mutated. Consequently, control
of mTORC1 was rescued by overexpressing TSC2 and/or Sestrin2 in p53 null cells. The work described in
this chapter delves into the mechanism of hyperactive mTORC1 produced when p53 targets, TSC2 and
Sestrin2, are diminished.
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2.2

Materials and Methods

2.2.1 Chemicals and Reagents
Chemical GDP and GTP, PEI-TLC plates, tetrabutylammonium bromide (TBAB), and other general buffer
reagents were from Sigma Aldrich (St. Louis, MO, USA.). The Luna C18, 4.6 mm HPLC column, and HPLC
SecurityGuard precolumn cartridges were from Phenomenex (Torrance, CA, USA). Radioisotopes
including [3H]-guanosine, [32P]-orthophosphate, [γ32P]-ATP, and [α32P]-GTP were from Perkin-Elmer
(Waltham, MA, USA). Ni-NTA beads, Protein G Sepharose 4 Fast Flow beads and m7GTP-sepharose beads
were from GE Healthcare Life Sciences (Pittsburgh, PA, USA). Complete EDTA-free Protease Inhibitor
Cocktail tablets (PI) were from Roche Applied Science (Indianapolis, IN, USA). Laemmli sample buffer,
Dual Color Precision Plus Protein Standard, and 4-20% Gradient SDS-PAGE gels were from BioRad
laboratories (Hercules, CA, USA).

2.2.2 Cell culture
HCT116 p53 wild type and null cell lines were a gift from Dr Bert Vogelstein (Johns Hopkins University).
H460, A549, H358, and SH-SY5Y cell lines were purchased from ATCC (Manassas, VA, USA.). Cells were
grown in RPMI 1640 with 10% dialyzed fetal bovine serum (dFBS). Immortalized p53-/- TSC2-/- MEFs
were a kind gift from Dr. Andrei Budanov, and were grown in DMEM supplemented with 10% dFBS. All
cell lines were frozen upon receipt and genetically modified cells were phenotypically verified.

2.2.3 Immunoblotting
Total cellular protein was extracted in 1% SDS lysis buffer and immunoblotted using 20 µg of protein.
Antibodies were generally from Cell Signaling Technology (CST) (Danvers, Massachusetts, USA): 4EBP1
(Cat# 9644P), P-T70 4EBP1 (Cat# 9455S), P-T37/46 4EBP1 (Cat# 2855L), eIF4E (Cat# 2067S), AMPK (Cat#

56

2793S), P-T172 AMPK (Cat# 2531S), mTOR (Cat# 2983S), P-2448 mTOR (Cat# 2971S), S), TSC2 (Cat#
3990S), P-S1387 TSC2 (Cat# 5584S), PRAS40 (Cat# 2610S), P-T246 PRAS40 (Cat# 2640S). The p53
antibody (Cat# OP43) was from Calbiochem (EMD, Darmstadt, Germany). The Sestrin2 antibody was
(Cat# 10795-1-AP) from Proteintech Group Inc. (Chicago, USA). Chemiluminescence was detected using
SuperSignal Substrate (Thermo Scientific, Rockford, IL, USA.). Densitometry was done using Licor Image
Studio Lite 5.0. software.

2.2.4 Guanine nucleotide binding assays
Measurements of the GTP/GDP-charged state of Rheb GTPase were performed as described
previously (Wolthuis et al. 1997).
Metabolic labeling
In brief, cells were grown to 70% confluency in dFBS-containing media in 15 cm dishes. For metabolic
labeling with [3H]-guanosine, cells were incubated with 1 µCi [3H]-guanosine for 24 h. This time was
determined to yield the best labeling: cells were incubated with [3H]-guanosine for increasing periods,
before measuring the radioactivity in whole cell lysates by scintillation counting. For [32P]orthophosphate labeling, cells were washed with phosphate-free DMEM, before being labelled in
phosphate‐free DMEM containing 5 mCi [32P]-orthophosphate for 4 h.
Rheb immunoprecipitation
After labeling, cells were washed with ice cold PBS + 1x PI before being lysed in Rheb lysis buffer (750 μl
of 50 mM Tris, pH 7.4, 140 mM NaCl, 1% Triton X‐100, 1% NP‐40, 1 mM KCl, 2 mM MgCl2, 1 mM PMSF,
and 1x PI). Lysates were precleared for 1 h with 50 µl of 50% protein G–Sepharose slurry. Endogenous
Rheb was immunoprecipitated using 40 µl of the protein G-bead slurry and 10 µg of the C-19 antibody
from Santa Cruz (sc-6341), by rotating at 4°C for 3 h. Immunoprecipitates were washed four times in
Rheb lysis buffer, before subsequent assays.
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HPLC
For HPLC separation of GDP and GTP, nucleotides were extracted from immunoprecipitates using 6%
perchloric acid, followed by neutralization with 1N KOH. Twenty μl of sample was resolved by a Luna
C18 reversed phase column equipped with a pre-column of the same material. Nucleotides were
resolved using 10 mM TBAB, 100 mM K2HPO4/KH2PO4 (pH 6.5) and a methanol gradient increasing to
70% over 27 min, at 1 ml/min flow. Nucleotide standards were used to verify the identity and retention
times of unknown peaks. Nucleotides were detected at 254 nm, and separated into discrete peaks with
GDP at 8 min and GTP at 10 min (Fig. 2.5). Absolute amounts of GDP or GTP were obtained by peak
integration and concentrations were determined by comparison to calibration curves developed using
chemical standards (Fig. 2.6). Labelled fractions eluting off the column were quantified by liquid
scintillation counting. Data was graphed using SigmaPlot 13.0.
To determine the limits of detection and quantitation, we injected increasing amounts of GDP and GTP
standard onto the HPLC column, and quantitated the area under the curve (AUC) for each peak (Fig.
2.6). Two ρmoles of standard was determined to be the limit of detection and quantitation (Fig. 2.6A,
left). Ten nmoles shows the peaks starting to broaden (Fig. 2.6A, right), and the corresponding standard
curve shows AUC values for concentrations above 10 nmoles plateauing (Fig. 2.6B). Thus, for accurate
quantitation, sample concentrations should optimally fall within the linear range from 2 pmoles to 5
nmoles (Fig. 2.6C).
TLC
The Rheb-bound nucleotides were eluted off protein G beads with TLC elution buffer (2 mM EDTA, 0.2%
SDS, 1 mM GDP, 1 mM GTP) at 68°C for 20 min as described previously (Inoki et al. 2003). The eluted
nucleotides were subjected to thin layer chromatography (TLC) using polyethylenimine-modified (PEI)
cellulose plates in 0.75 M KH2PO4 (pH 3.4).
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GTP

mAU

GDP

Retention time, min

Figure 2.5: Representative chromatogram of a standard aqueous mixture of GDP and GTP separated and
analyzed using paired-ion reverse-phase HPLC coupled to a UV detector. Two nmoles of each nucleotide
was injected onto the column. GDP was detected at 8 min and GTP at 10 min. mAU = milli absorbance units.

59

A
GDP

GTP
GDP

2 pmoles of std

GTP

10 nmoles of std

B

C

2

R = 0.943

2

R = 0.949

Figure 2.6: Detection and quantitation limits of the HPLC protocol for quantitation of Rheb guanine
nucleotides. A calibration curve was performed for GDP and GTP by injecting increasing amounts of
nucleotide onto the column, run using the same experimental conditions. (A) Representative HPLC traces at
254 nm for 2 pmoles and 10 nmoles standard. Each peak was integrated to determine the area under the
curve (AUC). Peak area was plotted vs nmoles nucleotide (B). Linear regression curves for the working
concentrations of GDP and GTP standards are shown in (C).
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Coupled enzyme assays
GTP, and the sum of GTP plus GDP, was measured in coupled enzymatic assays (Scheele, 1995). GTP was
converted to ATP by nucleoside diphosphate kinase (NDPK) in the presence of excess ADP with the
resulting ATP measured by the luciferase method (Luciferase assay reagent, Promega, Madison, WI,
USA). This assay is sensitive to 1 fmol ATP, and because the second reaction is irreversible due to light
generation, both reactions go to completion making the entire system quantitative (Sharma, 1998). GDP
was measured by converting GDP to [γ32P]-GTP using NDPK in the presence of [γ32P]-ATP. Assays were
syringe-filtered (Acrodisc Syringe Filters, Pall Corporation, Port Washington, NY, USA) before applying to
the RP-HPLC column. Nucleotides were separated using the HPLC method described above. [γ32P]-GTP in
fractions eluted off the column were quantified by liquid scintillation counting.

2.2.5 TSC2 GAP assay
TSC1 was immunoprecipitated from HCT116 cells using the D43E2 anti-TSC1 antibody from CST (#6935).
The immune complexes were washed three times with wash buffer (20 mM Tris at pH 7.4, 800 mM
NaCl, 2 mM EDTA, 1% NP-40) and two times with GAP assay wash buffer (20 mM Tris at pH 8, 100 mM
NaCl, 5 mM MgCl2, 1 mM DTT). The final GAP assays included 0.5 μg of 32P-γ-GTP loaded recombinant
His-tagged Rheb (Sigma-Aldrich, #SRP0225), and immunoprecipitated TSC1/TSC2 from 2 × 107 cells.
Reactions were carried out in 40 μL of GAP assay buffer (20 mM Tris at pH 8, 10 mM MgCl 2, and 4 mM
DTT), at room temperature for 20 min. The reaction was stopped with 300 μL cold GTP. Rheb was
isolated for the reaction mix using Ni-NTA beads, before bound nucleotides were eluted at 68°C for 20
min. Ten μL of supernatant was resolved by TLC as above.

2.2.6 Subcellular Fractionation
Cells from two near-confluent 15 cm dishes per sample were washed and scraped into cold PBS with 1X
PI. Separation of total membrane from cytosolic fractions was adapted from Cai et al. (Cai et al. 2006).
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Cells were resuspended in 3 ml cold hypotonic buffer 1 (10 mM Hepes, pH 7.2, 10 mM KCL, 1.5 mM
MgCl2, 0.1 mM EGTA, 20 mM NaF, 100 µM NA orthovanadate, and 1X PI), and incubated on ice for 15
min before being Dounce homogenized for 1 min. The post-nuclear supernatant (PNS) was separated
from crude nuclei and unbroken cells at 3000 rpm for 5 min at 4°C. The PNS was subjected to
ultracentrifugation at 100,000xg for 1 hr at 4°C to separate out the soluble cytosolic fraction from the
membrane pellet. The pellet was washed in hypotonic buffer 1 for a further 45 min at 100,000xg before
lysis in 100 µl membrane lysis buffer 1 (20 mM Tris-HCL, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 2.5 mM Na4P2O7, 1 mM β-glycerophosphate, 1 mM Na orthovanadate, and 1X PI).
Separation of heavy and light membrane fractions was adapted as follows (Menon et al. 2014): Cells
were pelleted at 800xg for 5 min at 4°C and resuspended in 300 µl cold hypotonic buffer 2 (10 mM
HEPES, pH 7.2, 10 mM KCL, 1.5 mM MgCl2, 20 mM NaF, 100 µM Na orthovanadate, 250 mM sucrose,
and 1X PI). Cells were left on ice for 15 min before mechanical lysis through a 23G needle 4X. The PNS
was obtained after centrifugation of the lysate at 500xg for 10 min at 4°C. The PNS was centrifuged at
20,000xg for 2 hr at 4°C to separate the soluble supernatant (light membrane and cytosol) from the
insoluble heavy membrane pellet. The pellet was washed by adding 400 µl hypotonic buffer and
centrifuged at 20,000xg for a further 45 min. The pellet was then resuspended in 100 µl membrane lysis
buffer 2 (40 mM HEPES, pH 7.4, 120 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Na
deoxycholate, 5% glycerol, 10 mM Na pyrophosphate, 10 mM β-glycerophosphate, 50 mM NaF, 0.5 mM
Na orthovanadate, and 1X PI). Protein concentrations for each fraction were normalized separately,
boiled for 5 min in Laemmli sample buffer, and resolved by SDS-PAGE before immunoblotting.
Membrane fractions were not boiled.
Antibodies for subcellular fractionation analysis included: TSC2 rabbit mAB (CST, 3990), Rheb rabbit mAB
(Abcam, 92313), LDHA rabbit pAB (CST, 2012), LAMP1 rabbit mAB (CST, 9091), Integrin β1 rabbit mAB
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(CST, 9699), mTOR rabbit mAB (CST, 2983), Raptor rabbit mAB (CST, 2880), and PRAS40 rabbit pAB (CST,
2610).

2.2.7 Immunofluorescence microscopy
Primary antibodies
Cells were prepared for immunofluorescence as described (Menon et al. 2014). Primary antibodies used
for immunofluorescence were validated previously (Menon et al. 2014). They included rabbit anti-TSC2
(CST, 4308, 1:800), mouse anti-Rheb (Abnova, H00006009-M01, 1:1000, Walnut, CA, USA.), rabbit antimTOR (CST, 2983, 1:400), rabbit anti-LAMP1 (CST, 9091, 1:200), and mouse anti-LAMP2 (Santa Cruz,
18822, 1:100, Dallas, TX, USA.). p53 knockdown studies used mouse anti-p53 (Calbiochem, OP43, 1:100).
Sestrin2 was probed with rabbit anti-Sestrin2 (Proteintech group, 10795-1-AP, 1:100). AMPK activation
studies used rabbit anti-AMPKβ1/2 (CST, 4150, 1:50), and mouse anti-Raptor clone 1H6.2 (EMD
Millipore, 05-1470, 1:500).
Secondary antibodies
Secondary antibodies for immunofluorescence were anti-rabbit Alexa Fluor 488 (Life Tech., A21206),
and anti-mouse Alexa Fluor 568 (Life Technologies, A11004). Coverslips were mounted in VECTASHIELD
mounting medium with DAPI (Vector laboratories, H-1200, Burlingame, CA, USA.).
Image acquisition
Confocal images were acquired with a Zeiss LSM 700, Axio Imager 2 microscope (Zeiss, Thornwood, NY),
through a 63X oil immersion objective, using sequential scanning to capture each channel.
Representative cell images reflect identical detector and display settings. Optical slice thickness was set
to 0.7 µm (1 Airy unit, pinhole size green = 41.07 µm, red = 43.43 µm), pixel depth 16-bit, scan speed 6,
and line averaging 4. The images were 1368 x 1368 pixels (scaled = 101.61 x 101.61 µm) with a pixel size
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of 0.7 x 0.7 µm. Quantitative analyses were done using the colocalization function of the Zeiss Zen 2014
software. Intensity thresholds were set using single color controls for each antibody (detailed below).
Controls used to set signal thresholds
Accurate colocalization analysis is only possible when fluorescent emission spectra are sufficiently
separated. If not, spectral bleed-through artifacts will result in false positive colocalization data. Once a
confocal image is captured, colocalization analysis is performed on a pixel-by-pixel basis using the Zeiss
Zen software (Fig. 2.7). Every pixel in the image is plotted on a scatterplot, with one channel plotted on
the ordinate and the other on the abscissa, thus showing the correlation between the two sets of data.
Pixel intensity increases along each axis, with pure “red” or “green” pixels falling closer to each axis
(quadrant 1 and 2), and pixels that have a combination of high red and high green intensity fall in the
center (quadrant 3) (Fig. 2.7). To establish true colocalization, thresholds must be set manually to cut off
background signal (pixels near zero in quadrant 4), as well as pure “red” and pure “green” signal
(quadrant 1 and 2) (Fig. 2.7). To do this, a number of control samples were prepared. No-primary or secondary antibody controls set a threshold for background fluorescence. Single label controls were also
prepared for each protein analyzed to determine the (X,Y) position of the crosshair on each scatterplot
(Fig. 2.8) The acquisition settings (lamp power, filter sets, acquisition speed, detector levels) chosen for
these controls then remain the same for all subsequent data acquisition.
Colocalization measurements
Manders’ colocalization coefficient was reported as percent colocalization (Manders EM, 1991 and
1993), using 50 to 80 cells, representing five separate fields for each condition. Overlap coefficients are
calculated for each channel by dividing the sum of pixels in quadrant 3 by the sum of quadrant 1 + 3, or
quadrant 2 + 3. Each pixel has a value of 1, so that the coefficient ranges from 0 to 1, and this can be
expressed as a percent overlap from 0 to 100%. The colocalization coefficients of 40-50 wild type cells
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Figure 2.7: Setting the thresholds for colocalization analysis after confocal microscopy. For colocalization
analysis, every pixel in the image is plotted by Zeiss Zen software on a scatterplot (left), with one channel
plotted on the ordinate and the other on the abscissa. Pixel intensity increases along each axis, with pure
“red” or “green” pixels falling closer to each axis (quadrant 1 and 2), and pixels that have a combination of
high red and high green intensity falling in the center (quadrant 3). To establish true colocalization,
thresholds must be set manually to cut off background signal (pixels near zero in quadrant 4), as well as pure
“red” and pure “green” signal (quadrant 1 and 2). The image on the right shows the image represented by
the data in the scatterplot on the left. Here, a region of interest (ROI) is defined by the red box. For our
experiments, we defined each cell as a ROI.
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Figure 2.8: Single color antibody controls for immunofluorescence. (A) No primary or no secondary
antibody (shown here) controls used to set the threshold for background fluorescence. (B) Single label
controls for Sestrin2 labelled with anti-rabbit Alexa Fluor 488.
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(each defined as a region of interest or ROI), were compared to that of p53 null cells, and a Student’s ttest was used to determine if the averaged values were significantly different. This allows one to get
valuable data from single planes of cells without Z-stack analysis.

2.2.8 p53 siRNA transfection
DharmaFECT transfection reagent no. 2, siGENOME SMARTpool siRNAs targeting human p53 and
scrambled siRNA pool no. 1 were purchased from Dharmacon (GE Healthcare, Lafayette, CO, USA.). Cells
were plated and allowed to grow for 24 hrs, before being transfected with 50 nM siRNA in 0.1%
DharmaFECT for 48 hrs.

2.2.9 Overexpression of HA-TSC2 and Flag-Sestrin2
HCT116 p53 null cells were transfected with 3 µg DNA using Polyjet (DNA:Polyjet at 1:3). Cells were
lysed and immunoblotted 48 hr after transfection (23,24). For m7GTP pulldowns, cells were plated in 10
cm dishes and transfected using 3 μg DNA; 48 hr later, cells were lysed in m 7GTP buffer. 4EBP1-eIF4E
complexes were captured on m7GTP beads, as described (25). Samples were resolved on 12.5% SDSPAGE gels. Flag-Sestrin2 plasmid was obtained from Dr. Andrei Budanov and HA-TSC2 was purchased
from Addgene (Plasmid 24939, deposited by Dr Kunliang Guan (29)).

2.2.10

Statistics

Fractionation and colocalization data is presented as ±SEM. Significance was set at p<0.05 and
determined using unpaired two-tailed Student’s t-tests, assuming equal variance. Graphs were
generated using Prism 6.
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2.3

Results

2.3.1 Introduction
TSC2 and Rheb represent key negative and positive regulators of mTORC1. Hyperactive mTORC1 activity
is correlated with high levels of Rheb-GTP produced by transient overexpression of Rheb, or by
inhibition of the Rheb GTPase activating protein (GAP), TSC2 (Garami et al. 2003; Inoki et al. 2003). Rheb
overexpression is also able to efficiently induce the oncogenic transformation of NIH3T3 cells (Jiang and
Vogt 2008). In contrast, overexpression of TSC2 constrains mitogen- and nutrient-induced activation of
mTORC1 (Garami et al. 2003). Measuring Rheb and TSC2 activity became an important tool for studying
mTORC1 activity.
The initial characterization of Rheb involved differential cloning to identify genes that were induced in
rat brain neurons by synaptic activity (Yamagata et al. 1994). Rheb took its name from this
characterization, Ras homology expressed in brain. Rheb had homology to Ras GTPases so its ability to
bind GTP and have intrinsic GTPase activity was confirmed (Yamagata et al. 1994). The GTPase activity
was confirmed in vitro by loading bacterially expressed His-Rheb with [γ32P]-GTP, before assaying GTP
hydrolysis by thin layer chromatography (TLC) (Yamagata et al. 1994). Biochemical studies later
confirmed Rheb as a substrate for TSC2 GAP activity (Garami et al. 2003; Inoki, Zhu, Guan 2003). The
standard assay for Rheb GTPase activity involves transient transfection of tagged-Rheb cDNA into cells,
followed by metabolic labeling with [32P]-orthophosphate, Rheb immunoprecipitation, and TLC analysis
of bound nucleotides (Inoki, Zhu, Guan 2003; Li, Inoki, Guan 2004). GAP activity is measured by transient
transfection of cells with tagged-TSC2 cDNA, TSC2 immunoprecipitation, and incubation with GST-Rheb[γ32P]-GTP, followed by TLC analysis (Garami et al. 2003; Inoki, Zhu, Guan 2003; Tee, Anjum, Blenis
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2003). These GAP experiments therefore demonstrated the enhancement of the basal GTPase activity of
Rheb by exogenous TSC2.
More recently, it has become clear that mTORC1 activity is contingent on its localization to lysosomal
membranes (Sancak et al. 2008). A series of studies that took advantage of immunofluorescence and
confocal microscopy revealed the colocalization between mTOR, Rheb, and TSC2 with lysosomal
membrane proteins. The studies described below thus sought to determine the mechanism of mTORC1
hyperactivation in p53 null cells, by looking at endogenous Rheb-GTP binding, TSC2 GAP activity, and
lysosomal colocalization.

2.3.2 Measurement of absolute amounts of Rheb-bound GTP in wild type and
p53 null HCT116 cells
Previous work had shown that mTORC1 activity was upregulated with the loss or mutation of p53. We
therefore expected that a higher proportion of the obligate activator, Rheb would be in its GTP-bound
form. To test this we evaluated a series of available techniques in order to detect the one most sensitive
to the levels of endogenous Rheb-bound nucleotides. We chose not to use overexpressed Rheb in our
assays in order to avoid the non-physiological effects of high levels of Rheb on mTORC1 activation. The
following guanine nucleotide binding assays were assessed:
1. Spectrophotometric high-performance liquid chromatography (HPLC) analysis of nucleotides
bound to Rheb immunoprecipitates (IPs).
2. Metabolic labeling with [3H]-guanosine, Rheb immunoprecipitation (IP), followed by HPLC or TLC
separation and liquid scintillation counting.
3. Metabolic labeling with [32P]-orthophosphate, Rheb IP, followed by HPLC or TLC separation and
liquid scintillation counting.
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4. Coupled enzyme assays using nucleoside diphosphate kinase (NDPK) and luciferase to measure
GTP, or NDPK and [γ32P]-GTP to measure GDP.
Estimating the amount of endogenous Rheb that can be immunoprecipitated
To assess the sensitivity required for these experiments, we first estimated the amount of endogenous
Rheb that could be immunoprecipitated from HCT116 cells. To do this we compared western blots of
Rheb from anti-Rheb immunoprecipitations, to a serial dilution of a commercially available recombinant
Rheb (Fig. 2.9). By semi-quantitative comparison with these diluted standards on the western blot, the
amount of Rheb immunoprecipitated from 10 million cells was about 1.5 ng. The moles of Rheb pulleddown per 1 million cells were calculated as follows:
Rheb MW = 21 000 Daltons = 21 000 g/mol
Thus, 1500 pg Rheb in IP/21 000 pg.pmol-1 Rheb
= 0.07 pmoles Rheb per 10 million cells
= 7.14 fmoles Rheb per 1 million cells
Since it was difficult to consistently detect Rheb in the IP by western blot, we knew we were expecting
7.14 fmoles or less of Rheb to come down from 1 million cells, with no more than a stoichiometric
amount of GTP. We scaled up the number of starting cells to 50 million, to expect around 300 fmoles of
Rheb-GTP per pull-down.
Nucleotide quantitation by reverse-phase HPLC
Prior to analysis of the Rheb IP, we tried to directly quantitate Rheb-GTP spectrophotometrically by
HPLC. We developed an HPLC protocol that made use of paired-ion, reverse-phase liquid
chromatography. A C18 (reverse-phase) column was chosen because of its robust nature across a range
of pH values, and for its ability to be easily regenerated between runs.
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Since we required separation of charged nucleotides, we included a positively charged ion-pair,TBAB in
the running buffer. This reagent has four nonpolar groups that bind to the nonpolar stationary phase,
and an ionic center that stably binds ionic species of the opposite charge in the mobile phase. Separated
nucleotides were eluted off the column in a gradient of increasing methanol.
We initially compared the HPLC detection of nucleotides extracted from whole cell lysates with Rheb
immunoprecipitates to determine whether GDP or GTP could be detected directly by
spectrophotometric means (Fig. 2.10). The HPLC trace for detection at 254 nm of whole cell lysates was
overlaid with traces from a range of nucleotide standards, and peaks were resolved for GDP and GTP, as
well as for ATP (Fig. 2.10A). The nucleotides eluted off Rheb; however, did not resolve into clear peaks at
the positions of the chemical standards (Fig. 2.10B). This was expected since 3 pmoles was the
determined to be the limit of quantitation (Fig. 2.6), and from the Rheb IP analysis we were assuming
the recovery of only 300 ƭmoles of nucleotide.
Labeling of GDP and GTP pools with [3H]-guanosine
To increase the sensitivity of detection, HCT116 cells were grown in the presence of [3H]-guanosine prior
to Rheb immunoprecipitation and HPLC separation. Fractions were collected for every minute of the
run, and the tritium counts per minute (CPM) determined by scintillation counting. Corresponding to the
standards detected by the HPLC at 254 nm, fractions collected at minute 8 and 10 showed high counts
of tritium, and were GDP and GTP respectively (Fig. 2.11A). A number of earlier fractions also contained
counts higher than background, and are likely other guanosine-containing molecules, such as
hypoxanthine and GMP. Fractions from Rheb IPs; however, did not show corresponding increases in
tritium CPM over background when applying sample from 50 million cells (Fig. 2.11B). The counts in
figure 2.11B were about 100 fold less, so background is the equivalent to detection of ~500 µM GTP.
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We were expecting ~7 fmoles of Rheb recovered by immunoprecipitation per 106 cells. Therefore, this
was significantly lower than could be detected here, as reflected by figure 2.11B.
Overall, we concluded that the Rheb IP was not very efficient, or that the bound nucleotides did not
remain stable through the IP/elution process. To troubleshoot this, recombinant His-Rheb protein was
loaded with [3H]-GTP, pulled-down with the anti-Rheb antibody, and the eluate resolved by HPLC.
Collected fractions showed that only about 20% [3H]-GTP is recovered off the IP (Fig. 2.12A), relative to
the input concentration (Fig. 2.12B), and half of this remains trapped on the sepharose beads used in
the IP.
Metabolic labeling and nucleotide quantitation by TLC
Precedent literature used [32P]-orthophosphate labeling of cells that had been transfected with taggedRheb cDNA. In these experiments, cells were seeded into 6-well plates prior to transfection and labeling
with 0.15 µCi [32P] per well. These data showed that overexpressed Rheb had high levels of bound GTP
(~50% of total bound nucleotide), and that these levels were decreased to ~10% in the presence of
overexpressed TSC2 (Li, Inoki, Guan 2004). We decided to duplicate these assays using IPs of
endogenous Rheb rather than overexpressed Rheb. Cells were grown in either [3H]-Guanosine for 24
hours, or [32P]-orthophosphate for 4 hours, before immunoprecipitation of endogenous Rheb.
Nucleotides were extracted off the IP and spotted 1 μl at a time onto a PEI cellulose TLC plate. Sample
resolved until the front of the mobile phase (0.75 M KH2PO4 pH 3.4) reached the upper edge of the
plate. A UV lamp was used to visualize the position of GDP and GTP standards, and they were found to
migrate to positions 15 cm and 8 cm below the buffer front respectively (Fig. 2.13A). Spots of
radioactivity on the TLC plate were visualized on a Phosphorimager, and quantitated using ImageQuant
software (Fig. 2.13B).
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As a positive control, endogenous Rheb was immunoprecipitated from cells known to have high levels of
Rheb-GTP: TSC2 null MEFs that lack GAP activity towards Rheb (Inoki et al. 2002), and SH-SY5Y cells (a
human neuroblastoma cell line) were shown to have high levels of Rheb protein (Santa Cruz data sheet).
Overall, the percent GTP bound to Rheb was found to be high (>40%), corresponding to prior literature
demonstrating that Rheb is a weak GTPase (Inoki et al. 2003) (Fig. 2.13B). Nonetheless, the percent GTP
for the positive control cells (TSC2-/- and SH-SY5Y) was not significantly different from that of the wildtype MEFs or the HCT116 cells (Fig. 2.13B).
To allow for even greater sensitivity of detection, wild type and p53 null cells were labeled with [ 32P]orthophosphate. We also transfected cells with a FLAG-Rheb cDNA construct prior to metabolic labeling,
and compared the amount GDP/GTP bound to pulled down from control and transfected cells. As
expected, overexpression of Rheb increases the levels of phospho-S6K1 T389 (Fig. 2.14A), indicating
stimulation of mTORC1 activity. There was also more Rheb in anti-Rheb pull-downs from transfected
p53 wild type and null cells (Fig. 2.14B) than was seen previously for untransfected cells (Fig. 2.9). The
[32P]-signals on TLC plates were compared between control and transfected cells (Fig. 2.15C). The ratio
of GTP/GDP was calculated from phosphorimaging, using the formula: (GTP counts/3) ∕ (GDP counts/2).
A slight increase in [32P]-GTP was seen in IPs from Rheb-overexpressing p53 null samples (ratio = 1.7
versus 0.9 for p53+/+, Fig. 2.14C, right), but no significant difference in [32P]-GTP levels was noted
between untransfected wild type and p53 null cells (Fig. 2.14C, left).
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Nucleotide quantitation by coupled enzyme assays
Although we increased our sensitivity by labelling cells with [32P]-orthophosphate, massive amounts of
isotope (5 mCi/15 cm dish, five dishes per IP) was required to detect signal above background. We
decided to employ a luciferase- based enzyme assay that had been established to study Ras-GTP, as well
as Rheb-GTP in neural cell lines (Im et al. 2002). Im et al. showed that endogenous Rheb was highly
activated compared to Ras and Rap1 GTPases, even under basal conditions. Furthermore, this activation
state remained high, even after serum starvation, and barely increased after insulin stimulation (Im et al.
2002).
These assays used nucleoside diphosphate kinase (NDPK) to convert GTP to ATP, before ATP was
converted to oxyluciferin, AMP, and light in the presence of luciferin (see Fig. 2.15A). Light output was
measured using a luminometer. GDP can also be converted to GTP in the presence of NDPK and ATP. By
labeling the ATP with [γ-32P], we could quantitate GDP by collecting the [γ-32P]GTP fraction off an HPLC
column (see Fig. 2.15B). These enzyme assays proved to be more sensitive and have less background
than the metabolic labeling experiments. Standard curves were compiled using known concentrations of
chemical GDP and GTP. These showed detection for GDP and GTP down to 2 fmoles (Fig. 2.15A and B).
Since we were expecting 300 fmoles per Rheb IP, this assay was deemed appropriate for quantifying
Rheb nucleotide charge. The positive control cells, TSC2 null MEFs, as well as the p53 null HCT116s, had
significantly higher amounts of GTP in Rheb IPs (Fig. 2.16A and B). It was noted that these levels were
very low, falling below the 2 fmole limit of detection (Fig. 2.15). GDP levels for both cell lines were much
higher overall (100 to 1000 fold) than for the corresponding GTP levels, but there was no significant
difference between wild type and TSC2 null or p53 null cells (Fig. 2.16 C and D). This suggests that RhebGDP exists at much higher levels than Rheb-GTP. Earlier experiments using overexpressed Rheb showed
that the percentage of GTP and GDP was about 40% and 60% of total (Inoki, 2004).
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In conclusion, the Rheb-bound GTP amounts detected here are not reliable since they fall below the
limit of detection, and are 100 fold lower than Rheb-GDP levels instead of the precedent two-fold lower
levels.

2.3.3 In vitro GAP assays measure TSC2 function
To confirm whether this increase in Rheb-GTP in p53 null cells could account for the higher mTORC1
activity seen in p53 null cells, we decided to measure TSC2 GAP activity. If Rheb-GTP levels were truly
higher, one would expect TSC2 GAP activity to be lower in p53 null cells. TSC1 and TSC2 were pulled
down using an anti-TSC1 antibody, and used in an in vitro GAP assay against recombinant Rheb loaded
with [α32 P]-GTP (see materials and methods). Reactions were loaded onto TLC plates to look for
differences in Rheb GTP hydrolysis. Three biological repeats show no difference in TSC2 GAP activity
between wild type and p53 null cells (Fig. 2.12). These data matched GAP assays in Menon et al. (2014),
who went on to show that TSC2 activity was actually a function of subcellular localization (Menon et al.
2014).
In summary, radioisotope labeling of nucleotides prior to immunoprecipitation of endogenous Rheb
showed no differences between p53 wild type and null cells. Metabolic [32P]-labeling resulted in
enhanced detection by TLC, but again no difference was seen using IPs of endogenous Rheb. Metabolic
[32P]-labeling was also problematic since large quantities of isotope were required, and cells were
required to be starved of both serum and phosphate prior to labeling to maximize signal. The
AMPK/mTORC1 pathway is extremely sensitive to changes in nutrient levels so these labeling conditions
are far from ideal. Rheb-GTP levels are significantly higher in p53 null cells when measured with
luciferase-based enzyme assays, but these results were deemed unreliable since they fell below the limit
of detection.
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We concluded that endogenous Rheb is found at very low levels in the cell, and that the available
antibody for immunoprecipitation lacks the required efficiency to enrich these low levels. Nevertheless,
the levels of Rheb-GTP in p53 null cells appears to be higher than wild type cells, and preparation of
more starting material would likely provide more convincing evidence for this. TSC2 GAP activity was
unchanged in p53 wild type and null cells, agreeing with previous literature (Menon et al. 2014). Menon
et al. presented data showing that subcellular localization of TSC2 and Rheb was paramount to the
control of mTORC1 signaling (Menon et al. 2014). We therefore decided to explore the subcellular
localization of these proteins, and hypothesized that the increased mTORC1 activity in p53 null cells was
linked to TSC2 and Rheb levels at lysosomes.

2.3.4 Subcellular localization of components of the mTORC1 complex in p53
wild type and null cells
Subcellular fractionation shows Rheb is enriched in the same fraction as the lysosomal
protein LAMP1

Membrane partitioning of TSC2 was first shown to be necessary for its function in 2006 (Cai et
al. 2006). The phosphorylation of TSC2 by Akt triggered the translocation of TSC2 off
membranes and into the cytosol (Cai et al. 2006). Akt had previously been known to
phosphorylate TSC2 and reduce its GAP activity towards Rheb in vitro, but the mechanism of
this inactivation remained unknown (Inoki et al. 2002; Manning et al. 2002; Potter, Pedraza, Xu
2002). Cai et al. (2006) showed that Akt activation by insulin resulted in hyperphosphorylated
TSC2, 14-3-3 protein binding to TSC2, and TSC2 translocation from membranes to the
cytoplasm (Cai et al. 2006). Conspicuously, TSC2 GAP activity was not affected by Akt activation,
even though S6K1 phosphorylation increased. Menon et al., reported the same phenomena in
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their 2014 paper, where TSC2 GAP activity remained unchanged by insulin stimulation, but still
caused TSC2 to partition into a heavy membrane fraction (Menon et al. 2014). In this later
study, by using different subcellular compartment protein markers, the specific subcellular
localization of TSC2 was shown to be at lysosomes (Menon et al. 2014). This corresponded with
a flood of data showing control of mTORC1 by amino acids (Bar-Peled and Sabatini 2014), thus
linking amino acid stimulation to mitogenic stimulation of cell growth.
Total membrane fractionations

Given our inconclusive Rheb-GTP data, the lack of change in TSC2 GAP activity, and the
importance of TSC2 membrane localization, we decided to focus our efforts on uncovering the
subcellular location of mTORC1, Rheb, and TSC2. We investigated this in HCT116 p53 wt cells
and asked whether these factors changed in the isogenic p53 null cells. Initially, total
membrane fractions were separated from cytoplasmic fractions using the conditions applied by
Walker and her colleagues (Cai et al. 2006) (Fig. 2.18A). Specifically, this method called for cell
lysis by Dounce homogenization, and high-speed centrifugation at 100,000 x g to isolate total
membrane proteins from soluble proteins. Fractions from HCT116 cells were normalized
separately by Bradford assay, before being subjected to immunoblotting. Lactate
dehydrogenase (LDH) was used as an indicator for cytoplasmic contamination, and Integrin β1
for total membrane fraction purity (2.18B and C). In concordance with the literature, the
majority of mTOR and its partner protein Raptor were found in membrane fractions (Fig. 2.1B).
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Interestingly, Raptor Ser792 was mostly in the cytosol, agreeing with data from Gwinn et al.,
which showed that AMPK-induced phosphorylation of Raptor at this site increased its binding
to cytosolic 14-3-3 proteins (Gwinn et al. 2008). The mTORC1 inhibitor protein, PRAS40, was
also found in cytoplasmic fractions in these fast-growing carcinoma cells (Fig. 2.18B). Strikingly
though, the only difference between p53 wild type and null cells was the fractionation of Rheb
and TSC2. There was more of the mTORC1 activator, Rheb and less of the inhibitor, TSC2 in the
membrane fraction of p53 null cells. There was also less TSC2 overall in p53 null cells (Fig.
2.18C). This experiment was performed at least three times with similar results.
Heavy and light membrane fractionations

To determine whether this difference could be seen in lysosomal fractions, we used the
fractionation conditions applied by Menon and his colleagues (Fig. 2.19A) (Menon et al. 2014).
This method takes advantage of gentle cell lysis, and lower speed centrifugation (20,000 x g) to
separate out heavy membranes containing lysosomal components from a fraction containing
light membranes and cytosolic components1. In this case, the protein marker lysosomalassociated membrane protein 1 (LAMP1) was used to indicate lysosomal membrane containing
fractions (Fig. 2.19B). As a positive control for the translocation of TSC2, HeLa cells were
stimulated with insulin for 15 minutes prior to cell lysis and fractionation, following what was
done previously (Menon et al. 2014). Insulin stimulation resulted in less heavy membrane TSC2
and more cytoplasmic TSC2 (Fig 2.19B). This is in agreement with the previous studies showing
Akt activation and TSC2 loss from membranes (Cai et al. 2006; Menon et al. 2014), and showed
that the assay was working in my hands.
1

The heavy membrane fraction includes lysosomes, peroxisomes, and mitochondria. Light membrane fractions
include plasma membrane, microsomes, and fragments of the ER, ribosomal subunits, and cytosol.
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Heavy and light membrane fractions were then isolated from untreated wild type and p53 null
HCT116 cells. The loss of p53 resulted in less TSC2 in heavy membranes (Fig. 2.20A). In contrast,
Rheb levels were higher in the heavy membrane fractions of p53 null cells (Fig. 2.20B).
Fractionations were performed three separate times and the levels of protein in each fraction
quantified by densitometry on a Licor Odyssey Fc Imager. The differences between p53 wild
type and null cells, for both TSC2 and Rheb, were found to be significant by a Student’s t-test
(Fig. 2.20). We concluded that the loss of p53 resulted in a loss of TSC2 from the lysosomecontaining fractions, with a parallel increase in Rheb levels in these fractions.
To test whether the increase in Rheb in lysosome-containing membranes could be correlated to
the lack of TSC2, wild type and TSC2 null MEFs were fractionated into heavy and light
membrane fractions. Although TSC2 knockout MEFs must also be p53 null to be viable, these
cells still represent an absolute loss of TSC2. This total loss of TSC2 resulted in very high levels of
Rheb in the heavy membrane fraction of TSC2 null MEFs, as opposed to the partial loss seen
from p53-/- HCT116 cells (Fig. 2.21).
p53 loss changes the colocalization of TSC2 and Rheb with lysosomal membrane proteins

Since membrane fractions also contained mTOR, the higher levels of Rheb, unrestrained by
TSC2 GAP activity, suggested increased mTORC1 activation in these fractions. To better define
the subcellular position of Rheb and TSC2 we chose to determine their degree of colocalization
with lysosomal membrane proteins by immunofluorescence and confocal microscopy. Confocal
microscopy offers several advantages over standard fluorescent microscopy. These include the
ability to control the depth of field, and to eliminate background signal (out-of-focus light or
glare) from the focal plane, which would normally result in image degradation.
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This increased resolution of very thin optical sections (0.5 to 1.5 µm), combined with multiple
laser lines, allows one to determine a more precise spatial position of two (or more) molecules.
This in turn allows for colocalization analysis, or the determination of whether two molecules
reside in the same physical location in the cell (with a theoretical resolution of 0.2 µm).
The movement of TSC2 and Rheb on and off lysosomes is inversely related

To determine the degree of overlap of TSC2 or Rheb with the lysosomal membrane in wild type
and p53 null cells, we labelled for LAMP1/22 in tandem with these proteins. Initial observations
showed that both LAMP1 and LAMP2 form distinct and overlapping perinuclear foci in HCT116
cells. TSC2 showed a similar perinuclear pattern of distribution, while Rheb showed a more
diffuse pattern of fluorescence (Fig.2.22 and Fig.2.23). Wild type cells showed TSC2
concentrated at the lysosomal membrane, as seen by the bright yellow color when the
channels are merged (Fig. 2.22). Some diffuse staining for TSC2 was also observed in the
cytoplasm. In p53 null cells, there was less TSC2 fluorescence overall, and much less overlap
with LAMP2. This agreed with our subcellular fractionation experiments that showed less TSC2
in the heavy membrane fraction of p53 null cells. Manders’ colocalization coefficient was
calculated for >50 cells and graphed as a percentage for each cell type. This showed a small but
significant decrease in TSC2/LAMP2 colocalization in p53 null cells (Fig. 2.22).

2

LAMP1 and LAMP2 are distinct proteins encoded off different chromosomes, but they share
about 37% homology, are present in equal amounts in lysosomal membranes, and their
functions appear to be redundant (Eskelinen 2006).
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Rheb showed much higher cytosolic staining than TSC2, again in accord with our fractionation
data. In contrast to TSC2, Rheb displayed a high degree of overlap with LAMP1 in p53 null cells
that was significantly different to wild type Rheb (Fig. 2.23). Overall, these results once more
imply a reciprocal relationship between TSC2 and Rheb when p53 is lost, with less TSC2 and
more Rheb localized with lysosomal membrane protein in p53 null cells. Interestingly, Rheb was
found to be associated with Raptor, albeit weakly, in IPs from p53 null cells (Agarwal, 2015).
Since Raptor and mTOR are likely on lysosomal membranes, this agreed with the higher levels
of Rheb colocalized with LAMP1 in p53 null cells (Fig. 2.23).
siRNA knockdown of p53 recapitulates this data

To determine whether the effects on TSC2 and Rheb colocalization in HCT116 cells could be
generalized to other cells, p53 was knocked down by siRNA in A549 and H460 lung carcinoma
cells. Immunoblots of lysates from p53 siRNA treated cells showed substantially increased levels
of phospho-S6K1 and an increase in the phospho-4EBP1 species that were able to be separated
by SDS-PAGE (Fig. 2.24) (Agarwal et al. 2015). The same experiment was repeated for
immunofluorescence and confocal analysis (Fig. 2.25). Remarkably, transient depletion of p53
caused a substantial decrease in TSC2/LAMP2 colocalization with a concurrent increase in
Rheb/LAMP1 colocalization (Fig. 2.25), consistent with the increased phospho-S6K1 seen on
western blots of these cells transfected with p53 siRNA (Agarwal, 2015). This clearly
demonstrates a relationship between lysosomal TSC2 and Rheb, with the implication being that
higher levels of TSC2 at the lysosome decreases the levels of lysosomal Rheb, and therefore
downregulates Rheb activation of mTORC1.
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2.3.5 Complementation of the control of the mTORC1 activity in p53 null cells
by exogenous expression of TSC2 and Sestrin2
TSC2 and Sestrin2 are both known targets for p53 transcriptional control, and both transcripts
were found to be diminished when p53 was lost from, or mutated in HCT116 cells (Agarwal et
al. 2015). Overexpression of TSC2 and/or Sestrin2 in p53 null cells caused mTORC1 activity to
return to normal, wild type levels (phospho-S6K1 in Fig. 2.26). We therefore asked whether this
control of mTORC1 was a result of changes to TSC2 and Rheb localization on lysosomal
membranes.
HA-TSC2 forces Rheb off lysosomes

FLAG-tagged Sestrin2 (FLAG-SESN2) or HA-TSC2 were transiently transfected into p53 null
HCT116s prior to immunofluorescence and confocal microscopy. As expected, p53 null cells
transfected with an empty-vector control showed low levels of TSC2 and Sestrin2 (Fig. 2.27).
The transfection efficiency of HA-TSC2 was about 40%, as seen by the bright green fluorescent
stain for TSC2 in cells under low magnification (Fig. 2.27 right). This was also reflected in the
increased TSC2 seen by immunoblotting (Fig. 2.27 left). Forced expression of HA-TSC2 resulted
in increased TSC2 signal throughout the cell, with a similar increase in LAMP2 signal (Fig. 2.28
left). Rheb in empty-vector transfected cells was cytoplasmic with perinuclear foci that overlap
with LAMP1. The introduction of HA-TSC causes these foci to disperse (Fig. 2.28 right).
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FLAG-SESTRIN forces mTOR off lysosomes

The transfection efficiency of FLAG-SESN2 was comparable to that of HA-TSC2 as seen by
immunofluorescence at low magnification and by western blot (Fig. 2.27 bottom).
Overexpression of FLAG-SESN2 results in very high levels of Sestrin2 signal throughout the cell,
with a corresponding increase in the amount of LAMP2 signal (Fig 2.29 left). Despite reports
that endogenous TSC2 can be pulled-down with FLAG-SESN2 in HEK293 cells (Budanov and
Karin 2008), no change was seen in TSC2 signal when Sestrin2 was increased (Fig 2.29 right).
Instead, we saw that FLAG-SESN2 dramatically changed the colocalization of mTOR/LAMP2 (Fig
2.30 left). In control cells, mTOR formed distinct foci overlapping lysosomal protein. With the
forced expression of Sestrin2, mTOR foci largely disappear (Fig. 2.30 left). This data agrees with
newly published work that shows Sestrin2 prevents mTOR translocation to lysosomes when
amino acids are low (Chantranupong et al. 2014; Parmigiani et al. 2014). On the other hand,
when we looked for differences in mTOR localization in untransfected wild type and p53 null
cells, we found no difference in colocalization with LAMP2 or in the total intensity of
fluorescence, which would indicate total protein levels (Fig. 2.30 right). This suggests that the
loss of Sestrin2 transcription with a loss of p53 is not sufficient to cause a matching increase in
mTOR on lysosomes. Current literature suggests that Sestrin2 levels must be induced by
activated p53 before it is able to prevent mTOR recruitment to the lysosome (Parmigiani et al.
2014). We hypothesized that the substantial mTOR/LAMP2 colocalization in both wild type and
p53 null cells was due to the high levels of amino acids in serum-containing medium, in which
both cell types were maintained.
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2.3.5 Proposed model
Overall, we concluded that with the loss of p53, the protein levels of the Rheb GAP, TSC2 are
diminished, resulting in less distribution of TSC2 to lysosomes, presumably where it has contact
with Rheb and mTOR. At the same time, lysosomal Rheb levels are increased (Fig. 2.20 and
2.23). This relationship appears to be reciprocal since MEFs devoid of TSC2 have membrane
levels of Rheb almost as high as seen in the rest of the cell (Fig 2.21), while transfection of TSC2
back into p53 null cells causes Rheb to disperse out of lysosomal foci (Fig. 2.28). These data
supplement western blot data that show enhanced mTORC1 activity in p53 null or knockeddown HCT116s, as well as TSC2 null MEFs (Agarwal, 2015 and Fig. 2.24). This elevated mTORC1
activity was returned to baseline when TSC2 was overexpressed, corresponding to the loss of
Rheb from lysosomes with transfection of HA-TSC2 (Agarwal, 2015 and Fig. 2.28). Moreover,
the diminished levels of Sestrin2 seen in p53 null cells (Agarwal, 2015), did not result in lower
lysosomal mTOR (Fig. 2.30 right). In contrast, overexpression of Sestrin2 forced mTOR off
lysosomal membranes (Fig. 2.30 left). We therefore propose a model that details the dynamic
nature of mTORC1 assembly on the lysosomal membrane in response to loss of p53, insulin or
amino levels, and high Sestrin2 levels (Fig. 2.31).
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2.4

Discussion

TSC2 is lost from the lysosomal membrane with loss of p53
The importance of Rheb-GTPase and TSC2 GAP activity for mTORC1 kinase activity was recognized early
on in Rheb research (Castro et al. 2003; Garami et al. 2003). Studies using loss- or gain-of-function
mutants of Rheb or TSC2 cemented their involvement in mTORC1 insulin-stimulation or serumstarvation. In this study, we showed the importance of Rheb and TSC2 subcellular localization in the
hyperactivation of mTORC1 that was caused by loss of p53. Using crude subcellular fractionation
techniques the only difference we saw between wild type and p53 null HCT116s was the membrane
levels of TSC2 and Rheb, with less TSC2 and more Rheb in lysosomal protein containing fractions. This
was demonstrated more elegantly with immunofluorescence and confocal microscopy, which showed
significant decreases in TSC2/LAMP2 colocalization, in parallel with significant increases in Rheb/LAMP1
colocalization after loss of p53. The major driver seemed to be the reduction in total levels of TSC2 with
loss of p53, since TSC2 is a transcriptional target of p53-transactivation. This results in much less
lysosomal TSC2 and presumably much less GAP activity towards Rheb-GTP. In fact, replacing diminished
levels of TSC2 in p53 null cells brings the levels of phopho-S6K1 back down to the levels seen in wild type
cells (Fig. 2.28; (Agarwal et al. 2015b)). The lysosomal distribution of TSC2 is a means of regulating its
GAP function since no difference was noted in %GDP recovery in in vitro GAP assays using TSC2 from
wildtype or p53 null cells (Fig. 2.17). This agrees with data from the Walker group (Cai et al. 2006) and
the Manning group (Menon et al. 2014), who showed that insulin stimulation did not change TSC2’s
intrinsic GAP activity but rather its subcellular distribution was shifted away from that of Rheb.
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Rheb is also a dynamic protein, moving on and off the lysosomal membrane
Intriguingly, Rheb was also dynamic in our studies, and this appeared to be a function of TSC2 presence
at lysosomal membranes. Evidence for this was seen in fractionations of MEFs with germline deletions
of TSC2. In these cells, a tremendous amount of Rheb was seen in heavy membrane fractions compared
to wild type MEFs. Furthermore, when TSC2 was overexpressed in p53 null cells, Rheb colocalization
with lysosomal membrane proteins was significantly reduced. Cai et al. showed Rheb exclusively in
membrane fractions of HEK293 cells (Cai et al. 2006), despite reports that only a subpopulation of Rheb
is membrane tethered (Schmick, Kraemer, Bastiaens 2015). This latter work agrees with our
fractionation data and confocal images (as well as the images in Menon et al., 2014), where it was
observed that a fair amount of Rheb is dispersed throughout the cytosol (Menon et al. 2014). The ability
of farnesylated Rheb to tether onto endomembranes, though, has been reported to be critical for its
function as an mTORC1 activator and for its oncogenicity. Farnesyl transferase inhibitors prevent
membrane localization of Rheb, and severely diminish mTORC1 activity (Basso AD, 2005). Therefore, the
action of farnesyl transferase is necessary for the endomembrane localization of Rheb, but it is not well
understood how Rheb moves off these endomembranes. It is known that the acylation of Ras is
dynamic, with the palmitate modifications having a much shorter half-life than the Ras polypeptide,
undergoing repeated cycles of removal and replacement (Schmick, Kraemer, Bastiaens 2015). Ras has
been reported to turnover every 40 minutes, but how or where this occurs is not known. Interestingly,
exogenous addition of S-nitrocysteine replaces the S-acylated cysteines of Ras, thereby increasing Ras
turnover as well as decreasing its GTP-binding (Baker, Booden, Buss 2000). Furthermore, the α-subunit
of G-proteins also undergoes increased de-palmitoylation when GTP-loaded (Tu, Wang, Ross 1997).
Together, these data suggest that a reduction in GTP-loading may be a signal for GTPase turnover by delipidation. This may link TSC2 GAP activity to the decrease in Rheb seen at lysosomes when TSC2 is
overexpressed (Fig. 2.28).
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Rheb-GTP levels would still be an useful indicator of mTORC1 activation
TSC2 may also act as a solubilization factor, shielding Rheb from, or replacing Rheb at hydrophobic
membranes. This is seen for Rab-GTPases, which localize to the cytosol when GDP-bound, even though
they remain lipidated (Baetz and Goldenring 2014). The phosphodiesterase, PDE6δ is another cytosolic
solubilization factor that was shown to interact with Rheb in yeast-two hybrid assays (Hanzal-Bayer et al.
2002; Ismail et al. 2011). Tellingly, the interaction of PDE6δ with H-Ras was stronger when H-Ras was
GDP-bound that when it was loaded with GTP (Hanzal-Bayer et al. 2002). Overall, this may point to the
TSC2 enhanced conversion of Rheb-GTP to GDP, being a signal for Rheb movement off the lysosomal
membrane in our experiments. This hypothesis would require knowledge of the degree of Rheb-GTP or
GDP-binding in each subcellular fraction. It has been noted that overexpressed Rheb may have nonphysiological consequences on amino acid signaling to mTORC1 (Garami et al. 2003), rendering S6K
activity less dependent on the presence of amino acids (Garami et al. 2003; Inoki et al. 2003). Studying
endogenous Rheb seems especially important when looking at the fine control involved in subcellular
dynamics. Determination of endogenous Rheb-GTP binding; however, has proved challenging to study.
Total Rheb protein levels vary in different cells, from almost undetectable low in Chinese Hamster Ovary
cells to high in brain-derived cell lines (Im et al. 2002). Still, Rheb can be detected in cell fractions of the
cells used in these studies by western blot (WB), in fixed cells by immunofluorescence (IF), but not in
anti-Rheb IPs. These three assays required the use of three different antibodies: western blotting makes
use of antibodies that recognize denatured epitopes and are therefore unsuitable for IPs, while IP and IF
antibodies recognize multiple native protein epitopes. The WB antibody for Rheb was raised against a
short synthetic peptide corresponding to residues in human Rheb (Abcam, 92313), and the IP antibody is
a polyclonal IgG raised against a 50 amino acid peptide representing the C-terminus of human Rheb
(Santa Cruz, 6341). Finally, the newly available IF antibody for Rheb was raised against full-length
recombinant GST-Rheb (Abnova, H00006009-M010), but has not been validated for IP. These three
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different approaches in antibody development could explain the differences in detection of Rheb in
these studies. It would be interesting to repeat the Rheb IP experiments with the IF antibody since it was
raised against full-length Rheb and not just a peptide, possibly endowing it with more specificity.

Studying the spatiotemporal dynamics of mTORC1 requires live-cell imaging
Although our subcellular fractionation and confocal data show that Rheb and TSC2 are spatially related
to lysosomal membrane proteins, they cannot say whether binding actually occurs at the same protein
complex on the membrane. For example, subcellular fractionation by differential centrifugation enriches
for multiple membrane types, as opposed to sucrose gradient-based fractionation that would eliminate
contamination from mitochondrial and endosomal membranes. Confocal microscopy also only says that
two molecules are near each other, with an actually resolution of 500-600 nm. In their supplementary
data, Menon et al. (2014), show that a subpopulation of TSC2 colocalizes with the Golgi, but is not
affected by insulin stimulation (Menon et al. 2014). They also show no colocalization with mitochondrial
proteins or peroxisomal proteins under normal or insulin-stimulated growth conditions.
Ideally, live cell imaging coupled to FRET- or FRAP- (Fluorescence Recovery After Photobleaching) based
assays could be employed to look at dynamic mTORC1 interactions. A recent paper described a
genetically encoded activity reporter (named TORCAR) for mTORC1 that exhibits a change in FRET in
response to phosphorylation by mTORC1 (Zhou et al. 2015). Activity maps generated using differentially
targeted reporters showed mTORC1 activity was not only in the cytosol and at the lysosome but also in
the nucleus and at the plasma membrane. A wide distribution of mTORC1 activity was also observed
upon growth factor stimulation, whereas amino acid stimulation caused a more compartmentalized
pattern at the lysosome and in the nucleus (Zhou et al. 2015). This suggests that mTORC1 activity is
probably regulated in a signal-specific manner, with amino acids inducing lysosomal activity, and
reactive oxygen species inducing peroxisomal activity.
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Sestrin2 affects mTOR when induced by cell stress, but not when its levels are
low
Finally, our Sestrin2 overexpression data, although in line with the literature, says a great deal about the
effects of protein levels in cells. We see that at very high levels, Sestrin2 prevents mTOR localization at
lysosomal membranes. This implies that a loss in Sestrin2 would cause the opposite effect – more mTOR
colocalization with LAMP2. With the genetic loss of p53 in HCT116 cells we see a dramatic decrease in
the levels of Sestrin2, an effect that is transcriptional given that the Sestrins are targets for p53 (Agarwal
et al. 2015a; Budanov et al. 2002). Yet, this loss of Sestrin2 in p53 null cells does not significantly change
the degree of mTOR/LAMP2 colocalization nor does it change the overall signal or expression of mTOR
(Fig. 2.30). It stands to reason that Sestrin2 must be induced to carry out its negative regulation of
mTORC1. This is bolstered by data from the Budanov et al. (2008) that showed that Sestrin1/2
expression was induced by genotoxic and oxidative stress via p53 transactivation (Budanov and Karin
2008). They then showed that the Sestrin proteins could reduce phospho-S6K1 levels via AMPK and TSC2
activation in response to DNA-damaging agents (Budanov and Karin 2008). Sestrins also appear to inhibit
mTORC1 independently of TSC2, via interaction with GATOR2 and the Rag-GTPase system (Parmigiani,
2014). The cells in this study were grown in complete media with full serum, indicating that mTOR is
localized on lysosomes since amino acids are plentiful (Fig. 2.30). In the absence of any cell stress, the
lack of p53 and Sestrin2 does not appear to affect mTOR localization at lysosomes (Fig. 2.30). The
decrease in TSC2 levels on the other hand is sufficient to undermine control of Rheb and cause mTORC1
activation (Agarwal et al. 2015a). TSC2 is also upregulated by irradiation and p53 activation ((Feng et al.
2007)), and this would likely have a more extreme effect on lysosomal Rheb, and Rheb-GTP levels.
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Conclusions
In conclusion, the loss or mutation of p53 results in cells with high levels of mTORC1 kinase activity. The
control of mTORC1 is lost because of lower levels of TSC2 in the cell, with significantly less TSC2 at
lysosomal membranes where mTOR and Raptor reside. This loss of lysosomal TSC2 is accompanied by an
increase in lysosomal Rheb, the obligate mTORC1 activator. Future experiments would explore RhebGTP levels at subcellular compartments in conjunction with lysosomally targeted TSC2 or GAP mutants
of TSC2. Inducible expression or stable transfection of TSC2 and Sestrin2 would also be useful in
describing mTORC1 dynamics with loss of p53, rather than transient transfection studies. Loss or
mutation of p53 is common to the majority of human cancers, and mTORC1 activity is clearly part of the
oncogenic progression when p53 function is lost. Understanding the control of mTORC1 is therefore
critical for how these cancers are managed in the clinic.
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3

AMPK activation alters the dynamics of Rheb at the

lysosomal membrane, modulating mTORC1 kinase activity.

3.1

Introduction

3.1.1 AMPK activation occurs via direct binding, activation of upstream
kinases, or decreases in ATP levels
Endogenous activation of AMPK
AMPK is activated during times of cell stress, leading to the downregulation of ATP/NADPH-consuming
reactions, and an increase in catabolic processes to increase ATP production (Hardie 2007; Steinberg and
Kemp 2009). As discussed in Chapter 1, this activation is mediated via upstream kinase activity in
response to decreased nutrient availability, increases in intracellular Ca2+, hypoxia, ROS, and DNA
damage (Hawley et al. 2010). AMP also allosterically activates phosphorylated AMPK, and inhibits
Thr172 dephosphorylation, effects that are necessary for the overall response of AMPK to cellular
stresses (Gowans et al. 2013).
Pharmacological activation of AMPK
Compounds that cause energy stress will likely activate AMPK. In fact, over 50 plant-derived compounds
indirectly activate AMPK, and many of these compounds are mitochondrial poisons produced by the
plants as a defensive mechanism (Zaks, Getter, Gruzman 2014). Compounds that are analogs of AMP are
an obvious choice to activate AMPK, by mimicking direct binding to the γ-subunit. Lastly, numerous
high-throughput screens for allosteric AMPK activators have been performed (Hardie 2013).
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Figure 3.1: Structures of the three different classes of AMPK activating compounds.
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Many of the compounds identified preferentially activate β1 containing AMPK, and bind a site between
the α- and β-subunits that is distinct from the AMP binding site on the γ-subunit (Hardie, Schaffer,
Brunet 2015). Pharmacological activators can therefore be divided into three classes according to their
mechanism of action: indirect activators, direct activators, and AMP analogs.
Indirect AMPK activators
The antihyperglycemic biguanide compounds, such as metformin, inhibit the first component of the
electron transport chain, mitochondrial complex I (or NADH ubiquinone oxidoreductase) (Drahota et al.
2014). This decreases proton-driven ATP production, altering the AMP/ATP ratio, and indirectly
activating AMPK. AMPK is thought to mediate at least some of metformin’s antidiabetic effects by
increasing glycolysis and inhibiting gluconeogenesis (Hardie 2013). The mechanism of AMPK activation
by these biguanides was originally studied using a R531G γ-subunit mutant form of AMPK that cannot
bind AMP (Hawley et al. 2010). Besides metformin, this mutation also prevented AMPK activation by
resveratrol, quercetin, oligomycin and 2-deoxyglucose (Hawley et al. 2010). Resveratrol, a polyphenol
found in red wine, is a calorie restriction mimetic that has been reported to inhibit cyclooxygenases, and
activate cAMP phosphodiesterase as well as the deactylase, Sirtuin1 (Bitterman and Chung 2015).
Despite these assorted targets, the metabolic effects of resveratrol in mice require AMPK (Bitterman
and Chung 2015). Quercetin, a plant-derived flavonol, and the macrolide oligomycin inhibit
mitochondrial ATP synthase (Gledhill et al. 2007). 2-Deoxyglucose is a glucose molecule that is
converted to deoxyglucose-6-phosphate by hexokinase, whereby it no longer acts as a substrate in
glycolysis (Ben Sahra, Tanti, Bost 2010).
Direct AMPK activators
Direct AMPK activators bind to the carbohydrate-binding module (CBM) of the AMPK β-subunit. The first
such activator to be described was the thienopyridone, A-769662. This drug binds the CBM and
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allosterically activates AMPK, as well as preventing Thr172 dephosphorylation (Sanders et al. 2007).
Surprisingly, upstream signaling and Thr172 phosphorylation are not required for AMPK activity if AMP
and A-769662 are bound to AMPK simultaneously (Scott et al. 2014). This suggests that using Thr172
phosphorylation as a marker of AMPK activity may not always be valid. A-769662 also has an AMPindependent mechanism since AMPK activity is still enhanced in cells expressing the AMP-binding γsubunit mutant, R531G (Hawley et al. 2010). Two new compounds have been described: 991 binds the
same site as A-769662 (Xiao et al. 2013), and MT-63-78 likely binds the same site even though it shows
greater selectivity for AMPKβ1 (Zadra et al. 2014). A few natural products are also believed to bind this
site on the CBM. Salicylate, derived originally from the bark of the white willow Salix alba, activates
AMPK via a mechanism that is blocked by a S108A mutation in the β1 subunit (Hawley et al. 2012).
Salicylate is the acetyl ester product of the prodrug aspirin, and is generally thought to be a cyclooxygenase inhibitor, preventing prostaglandin production (Steinberg, Dandapani, Hardie 2013). The
binding to AMPK, however, may explain the myriad clinical effects of aspirin. It also suggests that there
is an endogenous ligand for this site.
Prodrugs that are converted to AMP analogs
The prototypical member of this family is 5’-aminoimidazole-4-carboxamide-ribonucleoside (AICAR).
AICAR is a nucleoside that is taken up into cells by adenosine transporters before being phosphorylated
by adenosine kinase to produce the nucleotide, ZMP (Gadalla et al. 2004). The adenosine kinase
inhibitor, 5-iodotubericidin, can reverse AICAR-mediated growth arrest, pointing to ZMP as the
corresponding effector molecule (Rattan et al. 2005). As an AMP analog, ZMP binds the same sites on
the γ-subunit of AMPK, and its effects are blocked by the aforementioned R531G mutation (Hawley et
al. 2010). AICAR thus causes allosteric activation of AMPK, and protects phospho-Thr172 from
phosphatase action. A new analog, 5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phospahte (C2), has been
reported to be 100-fold more potent as an AMPK activator than AMP, and 1000-fold more potent than
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ZMP, in cell-free assays (Hunter et al. 2014). C2 is selective for AMPKα1 over AMPKα2 (Hunter et al.
2014). Furthermore, C2 does not affect other AMP-binding enzymes such as glycogen phosphorylase or
fructose-1-6-bisphophatase (Gomez-Galeno et al. 2010). The antifolate drug, pemetrexed, also activates
AMPK by causing an increase in ZMP levels. Pemetrexed was shown by our lab to block the second
folate-dependent enzyme in de novo purine synthesis, AICAR formyl transferase (AICART) (Racanelli et
al. 2009). The substrate of this enzyme, AICAR builds up behind this block, and is converted to the AMP
analog ZMP by adenosine kinase (Racanelli et al. 2009; Rothbart, Racanelli, Moran 2010). Pemetrexed
has been the focus of this lab’s research for many years, and is discussed in more detail below.

3.1.2 Discovery of pemetrexed as an AMPK activator
Folates are one-carbon donors in crucial biosynthetic pathways
Folates serve as one-carbon donors in de novo purine and thymidylate synthesis, amino acid metabolism
and methylation reactions (Fig. 3.2) (Blom and Smulders 2011). Folates can only be used by the cell once
they are reduced, and are therefore found as either 7,8-dihydrofolate (DHF) or 5,6,7,8-tetrahydrofolate
(THF). The cofactor, 5,10-methylene-THF (5,10-CH2-THF) is used for the reductive methylation of 2’deoxyuridine monophosphate (dUMP) to 2’-deoxythymidine monophosphate (dTMP) by thymidylate
synthase (Fig. 3.3) (Blom and Smulders 2011). Dihydrofolate reductase (DHFR) recycles the DHF
byproduct of this reaction to THF. In de novo purine synthesis, 10-formyl-THF (10-CHO-THF or
leucovorin) is used first by glycineamide ribonucleotide formyltransferase (GART) to form the imidazole
ring of the purine (Fig. 3.3) (Blom and Smulders 2011). This cofactor is used once again in the
penultimate step of purine synthesis by AICART, ultimately generating the purine intermediate, inosine
5’-monophosphate (IMP). The purine nucleotides, AMP and GMP, are derived from IMP, as is ATP
(Gonen and Assaraf 2012) (Fig. 3.2).
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Figure 3.2: Overview of folate metabolism. Folates serve as one-carbon donors in de novo
purine and thymidylate synthesis, amino acid metabolism and methylation reactions. 5,10CH2-THF is the cofactor used by thymidylate synthase (TS) that catalyzes the conversion of 2′deoxyuridine monophosphate (dUMP) to 2′-deoxythymidine monophosphate (dTMP). The
byproduct of this reaction is DHF, which is recycled to THF by dihydrofolate reductase (DHFR).
In de novo purine synthesis 10-CHO-THF is first used by glycineamide ribonucleotide
formyltransferase (GART), for the formation of the imidazole ring; the second enzyme is 5aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICART) to form inosine 5′monophosphate (IMP). 5-CH3-THF serves as a cofactor for methionine synthase (MS) which
converts homocysteine to methionine. ATP is then conjugated to methionine to form Sadenosylmethionine (AdoMet), which serves as the universal methyl group donor in multiple
methylation reactions. (Adapted from Gonen, N et al. Drug Resistance Updates, Vol 15, Issue
4, Aug 2012, p183–210).
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Figure 3.3: Chemical structures of oxidized and reduced folates. The one-carbon units that are
transferred during a multitude of folate-dependent reactions are highlighted in gray. Image
adpated from Gonen, 2012.
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The evolution of antifolates as chemotherapeutics
Antifolate drugs are folate analogs that disrupt cellular proliferation by blocking folate-dependent, onecarbon biosynthetic and methylation reactions. Folic acid (vitamin B9) was initially isolated in the 1940s
as the bacterial-growth promoting compound in beef liver (Fig. 3.3) (Rosenberg 2012). Derivatives of this
compound were found to inhibit folate-dependent bacterial growth, including the folate analog,
aminopterin (4-amino-folic acid) (Rosenberg 2012). Not long after, Sidney Farber, at the Children’s
Hospital in Boston, famously reported that aminopterin could produce complete remission in children
with acute leukemia (Farber et al. 1948). The less toxic derivative, methotrexate (2-amino-10-methylfolic acid) replaced aminopterin in the clinic, and was shown to potently inhibit DHFR (MISRA et al.
1961). To this day, methotrexate remains a standard part of the multi-drug therapy used for acute
childhood leukemia, and it is widely used alone for the treatment of rheumatoid arthritis, and psoriasis
(Furst 1997; Pui, Relling, Evans 2006). Since its discovery, several rationally designed antifolates have
been produced to target and inhibit key folate-dependent enzymes (Walling 2006).
As with folic acid, antifolate drugs are converted to their active polyglutamate derivatives by folypoly-γglutamate synthetase (FPGS) (Habeck et al. 1995). FPGS catalyzes the sequential addition of glutamic
acid to the γ-carboxyl chain of THF cofactors and glutamate-containing antifolates. This allows for
prolonged cellular retention, enhanced substrate activity, and sustained inhibition of their target
enzymes (Fry, Yalowich, Goldman 1982; Lawrence et al. 2014; Rosenblatt et al. 1978). These
polyglutamated forms may also accumulate to a higher degree in tumor cells, than in bone marrow or
intestinal progenitor cells, although definitive proof is lacking (Fry, Yalowich, Goldman 1982).
Origins of pemetrexed
Pemetrexed is a rationally designed antifolate based on the glycinamide ribonucleotide transferase
(GART) inhibitor, 5,10-dideazatetrahydrofolate (DDATHF or lomotrexol) (Sanghani and Moran 1997; Shih
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et al. 1997). The replacement of the 5-deazapteridine ring of DDATHF with a pyrrolopyrimidine ring
yielded potent inhibition towards thymidylate synthase, and much less towards GART (Schultz et al.
1999; Shih et al. 1997; Shih et al. 1997). Pemetrexed is rapidly taken up in cells by the proton-coupled
folate transporter, and less so by the reduced folate carrier (Shih et al. 1997; Tonkinson et al. 1997),
where it acts as an excellent substrate for FPGS. Pemetrexed in particular exhibits a 100-fold lower Km
towards FPGS than does methotrexate, meaning that pemetrexed is rapidly polyglutamated at very low
concentrations (Shih et al. 1997). The pentaglutamate form thus shows an 84-fold increase in
thymidylate inhibition compared to the parent drug (Shih et al. 1997). In 2004, PTX was approved by the
FDA for the treatment of mesothelioma, and in 2008, for first-line treatment of non-small cell lung
cancer in combination with cisplatin (Jarmula 2010). It is also being assessed in more than 132 ongoing
clinical trials for the treatment of various solid tumors (Jarmula 2010).
Pemetrexed has an important secondary target
Kinetic studies performed first in our lab, and eight years later by Eli Lilly, reported direct inhibition of TS
(Ki = 1.3 nM). The Lilly studies also reported inhibition of DHFR (Ki = 7.2 nM), and GART (Ki = 65 nM)
(Hanauske et al. 2001). This group also reported that the Ki of the pentaglutamated-PTX for AICART was
only 260 nM, signifying an insignificant inhibition (Shih et al. 1997). However, in cells that overexpress
thymidylate synthase and are resistant to direct inhibition by 5-fluorouracil (5-FU), there is 1000-fold
less resistance to pemetrexed than to 5-FU (Hanauske et al. 2001). End-product reversal studies also
showed that an exogenous supply of thymidine and the purine, hypoxanthine was required to reverse
the drug’s cytotoxicity to leukemic cells in culture (Racanelli et al. 2009). This alluded to an important
secondary site of action in the activity of pemetrexed. Our lab has since demonstrated in whole cells
that AICART, the second folate-dependent enzyme in de novo purine synthesis, is an important target of
pemetrexed. As such, addition of a precursor for this enzyme, AICA failed to reverse the growth
inhibition (Racanelli et al. 2009). ZMP thus accumulates in excess of 2 mmol/L cell water in the presence
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of pemetrexed (Racanelli et al. 2009). This massive accumulation of ZMP was shown to induce AMPK
activity, and consequently suppress mTORC1 in an AMPK-dependent manner (Racanelli et al. 2009). This
highlighted the importance of blocking AICART over GART inhibition, since this type of “metabolic
inhibition” represents a unique way to control the mTOR pathway and impede tumor growth.

3.1.3 AMPK activation regulates mTORC1 signaling
AMPK counters mTORC1 activity by phosphorylation of TSC2 and Raptor
AMPK modulates protein homeostasis by downregulating protein translation (Bolster et al. 2002; Reiter
et al. 2008) and ribosomal RNA synthesis in nucleoli (Hoppe et al. 2009). As such, withdrawal of glucose,
amino acids, or oxygen leads to rapid suppression of mTORC1 activity largely through the activation of
AMPK (Shaw and Cantley 2006). Two phosphorylation events catalyzed by AMPK lead to decreased
mTORC1 kinase activity: TSC2 Ser1387 phosphorylation, which activates conversion of Rheb-GTP to
Rheb-GDP (Inoki, Zhu, Guan 2003), and Raptor Ser792 phosphorylation, which inhibits mTORC1 kinase
activity directly (Gwinn et al. 2008). These phosphorylation events lead to a decrease in phospho-4EBP1
and -p70-S6K1 by poorly understood mechanisms.
Evidence for TSC2 protein interactions modulated by energy signals
TSC2 null cells transiently transfected with either wild type TSC2 or a S1387A mutant, showed that 2-DG
significantly decreased S6K and 4EBP1 phosphorylation in wild type TSC2-expressing cells, but not
mutant cells. AMPK-phosphorylation at this site is therefore necessary for the decrease in mTORC1
activity (Inoki, Zhu, Guan 2003). In contrast, the inhibition of mTORC1 is relieved by phosphorylation of
TSC2 by Akt (Inoki et al. 2002; Manning et al. 2002). TSC2, and not TSC1, has been shown to associate
with 14-3-3 proteins in vivo and this association upregulates phosphorylation of S6K1 and 4EBP1 by
mTORC1 (Li et al. 2002). The 14-3-3 proteins often signal protein degradation, and it has been shown
that the E3-ubiquitin ligase, HERC1, also interacts directly with TSC2, possibly signaling its proteasomal
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degradation (Chong-Kopera et al. 2006). Interestingly, TSC1 stabilizes TSC2 by excluding HERC1 from the
complex (Chong-Kopera et al. 2006). It was later determined that TSC2 was bound by 14-3-3 proteins in
response to AKT phosphorylation (Cai et al. 2006). This resulted in the sequestering of TSC2 into the
cytoplasm, away from TSC1 and its membrane-bound target, Rheb (Cai et al. 2006). Menon et al.
ultimately showed that TSC2 is found on lysosomal membranes until insulin stimulation causes its
translocation away from lysosomes in an Akt-dependent fashion (Menon et al. 2014). TSC2 can also be
precipitated by GST-Rheb, but not HA-Ral, -Ras- or -Rap (Castro et al. 2003). The Rheb-TSC2 association
is strongest when Rheb is GDP-bound, and this is lessened after insulin stimulation (Menon et al. 2014).
Lysosomal TSC2 levels also decrease when cells are treated with farnesyl-transferase inhibitors (Menon
et al. 2014).
Raptor protein interaction modulated by energy signals
The mTORC1 scaffolding protein, Raptor may possess opposing cell condition-dependent functions in
mTORC1 regulation. Activated AMPK phosphorylates Raptor to suppress mTORC1 signaling. The
mechanism of this suppression remains unclear, but may involve the sequestration of Raptor away from
mTOR by 14-3-3 proteins (Gwinn et al. 2008). In contrast, David Sabatini’s group had shown previously
that nutrient deprivation and mitochondrial uncoupling were able to stabilize the mTOR-Raptor
association, and this stabilization negatively regulated mTORC1 activity (Kim et al. 2002). This group
proposed that mTOR and Raptor are held together in a constitutive, easily disrupted association, which
under nutrient-poor conditions is strengthened leading to the repression of mTORC1 (Kim et al.
2002). Rapamycin, on the other hand, weakens the interaction between mTOR and Raptor (Oshiro et al.
2004; Yonezawa et al. 2004).
Raptor also binds directly to TOS motifs on downstream targets, including S6K1 and 4EBP1, as well as
PRAS40 and Hif1α (Dunlop et al. 2009; Nojima et al. 2003; Schalm et al. 2003). This TOS motif is required
for mTOR/Raptor-mediated phosphorylation of S6K1 on its hydrophobic motif site (Thr389) and 4EBP1
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on multiple sites (Thr37/46, Thr70, Ser65) (Dunlop et al. 2009). Mutation of the N-terminal domain of
Raptor abrogates these phosphorylation events, even though its interaction with mTOR remains stable,
highlighting the importance of Raptor-4EBP1 for mTORC1 signaling (Dunlop et al. 2009). TOS motifbinding may thus confer sensitivity to rapamycin and amino acid sufficiency (Nojima et al. 2003).

3.1.4 Evidence for compartment specific effects of AMPK activation
Mammalian AMPK exists as heterotrimeric αβγ complexes, and the isoforms have different tissuespecific distribution patterns. Western blotting of subcellular fractions, indirect immunofluorescence,
and transfection of GFP-fusion constructs have also shown that there are isoform-specific differences in
subcellular localization. AMPK is able to phosphorylate proteins in the nucleus and the cytoplasmic, and
is able to translocate between the two compartments in a stimulus dependent manner via the nuclear
exporter, Crm1 (Kodiha et al. 2007; Kodiha, Ho-Wo-Cheong, Stochaj 2011). Heat shock or ROS exposure
cause nuclear accumulation of AMPK, while treatment with 2-DG (resulting in energy stress) increases
cytosolic AMPK. AMPK thus functions in the cytoplasm to phosphorylate cytoplasmic targets such as
ACC1, and in the nucleus, AMPK regulates gene expression, mRNA stability, and mitosis (Eberhardt et al.
2007; Viollet et al. 2006; Yang et al. 2001). AMPK subcellular localization has become an important facet
of my ongoing research.
Nuclear/cytoplasmic localization is dictated by the α-subunit
In numerous cell lines, as well as cells of the central nervous system, immunofluorescence has shown
that AMPKα2 localizes to the nucleus and/or the cytoplasm, while AMPKα1 was restricted to the
cytoplasm (Culmsee et al. 2001; Salt et al. 1998). The minimum requirement for a nuclear localization
signal is Lys-(Lys/Arg)-X-(Lys/Arg), and two amino acid sequences in human α2 but not α1 meet this
criterion (Hodel, Corbett, Hodel 2001). The hormone leptin, for example, activates AMPK and results in
changes to its subcellular localization, with fatty acid oxidation occurring in the cytoplasm and PPARα
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gene expression occurring in the nucleus. That is, AMPKα1 and α2 were present in the cytoplasm of
C2C12 muscle cells under basal conditions, and after leptin stimulation, AMPKα1 remained
unphosphorylated and localized in the cytoplasm, while AMPKα2 moved to the nucleus (Suzuki et al.
2007). Glucose deprivation, however, causes the phosphorylation of AMPKα1 and not AMPKα2, with no
change in the subcellular localization of either (Suzuki et al. 2007). Exercise causes only the AMPKα2
subunit to translocate to nuclei (Kodiha et al. 2007; McGee et al. 2003), where it acts as a transcription
factor modulating gene expression to enhance glucose uptake and increase sensitivity to insulin (Canto
and Auwerx 2010). In summary, the presence of a α2-subunit allows nuclear translocation of AMPK,
while AMPK containing an α1-subunit remains localized in the cytosol.
Specific pharmacological activators of AMPK can also determine compartment specific activation of
phospho-AMPKα1/2, total AMPKα1/2, and total AMPKβ1/2 (Kodiha, Ho-Wo-Cheong, Stochaj 2011). The
AMPK activators phenformin, resveratrol, and AICAR have been used to see differences in cytoplasmic
and nuclear AMPK (Kodiha, Ho-Wo-Cheong, Stochaj 2011). In this work, activity of AMPK in the
cytoplasm was measured by assaying the levels phospho-ACC1, while nuclear activity was determined
by quantifying de novo RNA synthesis in nucleoli. Phenformin and resveratrol caused strong activation of
AMPK in the cytoplasm, whereas AICAR increased phospho-Thr172 AMPK in both compartments. All
compounds led to the inactivation of ACC1 in the cytoplasm. Specifically, AICAR activated both FLAGtagged AMPKα1 and AMPKα2 (Hardie and Sakamoto 2006), but only induced the translocation of FLAGα2, not FLAG-α1 AMPK to the nucleus of 3T3-L1, L6 and 2C12 muscle cells (Suzuki et al. 2007). Thr172
phosphorylation and the α2-subunit were essential for this nuclear translocation (Suzuki et al. 2007).
Endomembrane localization is dictated by the β-subunit
Myristoylation of the β-subunit is also crucial for the intracellular distribution and response of AMPK to
increased AMP (Oakhill et al. 2010). Wild type myristoylated or mutant non-myristoylated AMPKβ1 or
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β2 showed that Thr172 phosphorylation was lost when the β-subunit could not be modified (Oakhill et
al. 2010). Furthermore, AMPK transfected HEK293 cells showed that this β1-mutation resulted in a
diffuse cytoplasmic distribution of AMPK, rather than the membrane-associated, wild type myristoylated
AMPKβ1 (Warden et al. 2001). In fact, myristoylation of AMPK alone caused partitioning into prepared
liposome membranes, and the addition of AMP increases this association by 56% (Oakhill et al. 2010).
Fluorescence microscopy of COS7 cells transfected with GFP-tagged α1, γ1, and wild type or mutant β1
AMPK demonstrated that glucose-deprivation caused the movement of diffuse cytoplasmic wild type
AMPK to endomembrane- or nuclear-bound foci (Oakhill et al. 2010). In contrast, mutant
unmyristoylated β1 AMPK remained diffuse (Oakhill et al. 2010). In skeletal muscle, α2β2 containing
AMPK translocates to the nucleus in response to leptin, while α2β1 AMPK remains anchored to
membranes within the cytosol (Suzuki A, 2007). In conclusion, myristoylation of the β1-subunit dictates
endomembrane localization, and in this species of AMPK, phosphorylation of Thr172 can only occur with
translocation to an endomembrane. AMPK containing a β2-subunit or an unmyristoylated β1-subunit,
however, is free to translocate to the nucleus as long as there is also an α2-subunit. The different
combinations of isoforms thus affords AMPK a larger degree of functionality in response to the
numerous and varied upstream signals.
LKB1 recruits AMPK to the lysosomal membrane
AMPK translocation may also be linked to the distribution of upstream kinases, such as LKB1 on
lysosomal membranes (Zhang et al. 2014). AXIN was found to tether LKB1 onto late endosomes and
lysosomes. AMP-treatment of cell lysates and AICAR-treatment of whole cells triggered the recruitment
of AMPK to LKB1 to form a complex with membrane-bound-AXIN (Zhang et al. 2013).
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Figure 3.4: Summary of AMPK subcellular localization. Under basal cell conditions,
AMPKα1/2β1/2 isoforms are cytosolic. Upon stresses such as heat shock, α2β2 (or
unmyristoylated β1) containing AMPK translocates to the nucleus where it increases the
gene expression of proteins controlling glucose uptake and β-oxidation. In contrast, low
energy signals cause endomembrane or plasma membrane localization of AMPKα1/2 with a
myristoylated β1-subunit.
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As such, increasing AMP caused an increase in the amount of AMPK pulled down with AXIN. AXIN
knockdown also impaired the colocalization of HA-LKB1 with AMPK in L02 muscle cells starved of
glucose, and this exacerbated fatty-liver development in the livers of mice (Zhang et al. 2013).
This group later showed that glucose starvation caused the AXIN/LKB1 complex to bind the Ragulator
complex on lysosomes, preventing Ragulator GEF activity towards the Rag GTPases (Zhang et al. 2014).
This effectively links amino acid stimulation of mTORC1 to energy stress inhibition of mTORC1 by AMPK.
Other AMPK substrates that are membrane associated include ACC at mitochondria, endothelial NO
synthase at plasma membranes, and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG CoA) at ER
membranes (Steinberg 2009). These proteins may all be able to recruit AMPK in response to different
upstream signals.

3.1.5 Pemetrexed treatment results in a functionally inactive p53
Our lab has recently published research showing that pemetrexed treatment results in a species of p53
that is transcriptionally inactive (Agarwal et al. 2015). Accordingly, transcription of the p53 targets, p21,
MDM2, and PUMA, were not initiated in response to pemetrexed treatment, as they were with AICAR
treatment. Pemetrexed pretreatment was also able to block AICAR-mediated p53 transactivation. This
mechanism appears to be mediated by a checkpoint kinase 1 (chk1)-induced block on chk2 activation.
Furthermore, AMPK-mTORC1 signaling was modified since TSC2 is a p53 transcriptional target. In
contrast to AMPK-activation by AICAR, low levels of TSC2 are seen in pemetrexed-treated cells,
mimicking what was seen in p53 null cells. There was also a dearth of TSC2 ser1387, the AMPK
phosphorylation site. Remarkably, mTORC1 activity is efficiently blocked by pemetrexed, and by using
the AMPK-site mutant Raptor, we found that this occurs solely through a robust phosphorylation of
Raptor at Thr172. This is significant since the most frequent genetic change in lung cancers is the loss
and/or mutation of p53. Therefore, pemetrexed used a single agent, molecularly targets mTORC1 and
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cell growth, and activates cell death via inhibition of thymidylate synthase. Interestingly, this is the third
drug reported to cause the accumulation of a transcriptionally inactive p53. Lometrexol and
hydroxyurea both cause the accumulation of p53 without transcription of its target genes (Bronder and
Moran 2003; Gottifredi et al. 2001). Overall, although pemetrexed mimics a p53-null phenotype,
substantial mTORC1 inhibition is still observed in both p53 wild type and null carcinoma cells. This is
solely through the AMPK-mediated phosphorylation of Raptor. The effects of AMPK-activating drugs on
lysosomal localization and mTORC1 activity have not yet been determined. This chapter will explore the
effects of pemetrexed- and AICAR-induced activation of AMPK on the lysosomal dynamics of the
mTORC1 complex.
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3.2 Results
Differences in AMPK signaling activated by PTX and by AICAR
AICAR is converted to the AMP mimetic, ZMP in several human cancer cell lines (Racanelli et al. 2009;
Sengupta et al. 2007). Similarly, we have shown previously that the antifolate pemetrexed (PTX) causes
a substantial accumulation of ZMP with subsequent activation of AMPK signaling in lung and colon
cancer cell lines (Racanelli et al. 2009; Rothbart, Racanelli, Moran 2010). This activation resulted in the
sustained inhibition of mTORC1 kinase activity, and this inhibition could be reversed by the AMPK
inhibitor, Compound C, or by siRNA knockdown of AMPK1 (Rothbart, Racanelli, Moran 2010). In these
studies, thymidine (TdR) is used in the culture medium to circumvent the primary effect of PTX on
thymidylate synthase and, thus, to isolate PTX effects on AMPK activation. Classically activated AMPK
inhibits mTORC1 by phosphorylation of TSC2 at Ser1387, enhancing its GAP activity towards Rheb (Inoki,
Zhu, Guan 2003), and by the phosphorylation of Raptor at Ser792, inhibiting the association of RaptormTOR (Gwinn et al. 2008). AICAR represents the canonical inhibition of AMPK-mediated mTORC1
inhibition, and therefore causes the phosphorylation of both TSC2 and Raptor (Fig. 3.5). AICAR also
results in an increase in total TSC2 protein, in cells with wild type p53. Surprisingly, activation of AMPK
by PTX did not stimulate phosphorylation of TSC2 Ser1387, nor did it result in higher TSC2 levels in
p53+/+ cells (Fig. 3.5). PTX does induce Raptor phosphorylation to a greater degree than AICAR at
concentrations equi-inhibitory to cell growth (1 µM and 250 µM respectively) (Fig. 3.5).
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The differences in AICAR- and PTX-mediated AMPK signaling were dependent
on p53 function
Both PTX and AICAR activate AMPK by causing the accumulation of ZMP, but show major differences in
TSC2 phosphorylation. It was noted that in p53 null cells, neither drug could phosphorylate TSC2, nor
the levels of total TSC2 protein were very low (Fig. 3.5). Prior studies from this and other labs have
shown that TSC2 is a transcriptional target for p53, raising the question of why TSC2 was not increased
in wild type p53 cells (Agarwal et al. 2015a; Feng et al. 2007). In our studies, we therefore looked for p53
activation in AICAR and PTX (+TdR) treated cells by immunoblotting and qRT-PCR. The levels of p53
protein did increase after treatment with the positive control drug, VP16 (etoposide, a topoisomerase II
inhibitor), which caused a robust DNA damage response. P53 also accumulated with either AICAR or PTX
(Fig. 3.6A). Activation of p53 by VP16 resulted in the expected increase in its target gene products, p21,
Sestrin2, hDM2, and Bax. This was also the case for AICAR treatment, but not PTX treatment (Fig. 3.6A).
These results were also seen in qRT-PCR analyses, where PTX treatment did not cause an increase in the
transcription of p53 targets, p21, hDM2, Puma, Pig3, Bax, or Sestrin2 (Fig. 3.6B). This indicated that the
deficiency in PTX-treated cells was at the level of transcription. TSC2 was also among the target genes
assayed, and again the increase in TSC2 mRNA seen with VP16 or AICAR, was not seen with PTX (+TdR)
treatment (Fig. 3.6B). The increased TSC2 protein levels induced by AICAR were therefore a direct
consequence of p53 activation, while the complete lack of TSC2 phosphorylation by PTX is likewise
attributable to a transcriptionally nonfunctional p53 (Fig. 3.5). We concluded that the p53 that
accumulated in AICAR-treated cells showed the same functionality as the DNA damage-causing drug
VP16, but that the p53 accumulating in cells treated with PTX did not function as an efficient
transcriptional activator. Paradoxically, the levels of the mTORC1 inhibitor, TSC2 were vastly different
after AICAR or PTX treatment, despite a common means of AMPK activation.
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Figure 3.6: PTX does not activate TSC2 because it causes a deficiency in p53 transactivation. (A)
WT HCT116 cells were treated with VP16 (20 μM), TdR (5.6 μM), PTX (1 μM) + TdR, or AICAR (500
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The PTX induced loss of TSC2 is reflected in lysosomal membranes
Since we had previously shown that loss of p53 resulted in hyperactive mTORC1 because of a loss of
TSC2 from lysosome-containing membrane fractions (Chapter 2), we wondered whether this could be
reiterated in PTX (+TdR) treated cells. Three cell lines were fractionated into heavy and light membrane
fractions to compare TSC2 levels and subcellular distributions across a range of phenotypes. These
included the colon cancer cell line, HCT116, the cervical cancer cell line, HeLa, and the mouse embryonic
fibroblasts, NIH3T3 (Fig. 3.7). All three cell lines have wild type p53. Immunoblotting for TSC2 in each
fraction showed that TSC2 is diminished in the heavy membranes of PTX-treated HCT116 cells, and
NIH3T3 cells (Fig. 3.7 A, B). A clear decrease in TSC2 in HeLa cells was obscured by higher loading in the
PTX (+TdR) lane, as verified by higher LAMP1 lysosomal marker (Fig. 3.7C). Importantly, the levels of
TSC2 in the light membrane/cytosolic fractions were decreased in all three cell lines (Fig. 3.7 A, B, C).
Densitometry of heavy membranes blots from three experiments in HCT116s showed a downward trend
in TSC2 levels with PTX treatment that did not reach significance (Fig. 3.7C).
To question the significance of this non-significant result, we analyzed the colocalization of TSC2 with
the lysosomal protein, LAMP2 in control, TdR treated, and PTX (+TdR) treated HCT116s by confocal
microscopy. Immunofluorescence of LAMP2 in control cells revealed characteristic lysosomal foci that sit
on the edge of the nucleus (Fig. 3.8 top panel, red). TSC2 was seen in areas that overlap these foci, as
well as in a diffuse pattern in the cytoplasm (Fig. 3.8 top panel, green). The merged image showed clear
colocalization of TSC2 and LAMP2 (Fig. 3.4 top right panel, yellow). PTX treatment changed both the
distribution of the LAMP2 protein, as well as the levels of TSC2 in the cell overall. The LAMP2 in PTXtreated cells took on a crescent-shaped profile (Fig. 3.8, bottom panel, red). The TSC2 in these cells still
overlapped the LAMP2-containing regions, but showed less fluorescent intensity in the cytoplasm (Fig.
3.8, bottom panel, green). The merge showed some yellow and some orange areas, indicating less
colocalization than the control cells.
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Figure 3.8: PTX+TdR decreases the distribution of TSC2 to lysosomal membranes. Endogenous TSC2
(green) and LAMP2 (red) were subjected to immunofluorescence labeling in TdR or PTX+TdR treated
HCT116 cells. Bar graph shows Manders’ colocalization coefficient for >50 cells expressed as a
percentage ±SEM; the differences between TdR and PTX treated cells are significant for both
comparisons (*p<0.0001).
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The merged data was summarized in a bar graph, which shows the percent colocalization of TSC2 with
LAMP2 for 85 individual cells after TdR and PTX (+TdR) treatment (Fig. 3.8, right). This more rigorous
quantitation showed a significant decrease (p<0.0001) in TSC2 colocalization with LAMP2 in PTX-treated
cells. These data indicated that TSC2 was lost from lysosome-containing compartments with PTXtreatment, and that this was due to the lack of p53 transcriptional activity and minimal TSC2 mRNA
observed after PTX treatment.

AICAR activation of AMPK increases the levels of TSC2 at lysosomes and
overall
Immunofluorescence and confocal microscopy was repeated on HCT116 cells treated with and without
250 µM AICAR for 24 hours. AICAR treatment did not change the structure of the perinuclear lysosomal
foci (Fig. 3.9 bottom, red), as was seen with PTX treatment. In accordance with the high levels of TSC2
seen after AICAR treatment (Fig. 3.9), TSC2 fluorescence was increased overall in AICAR treated cells
(Fig. 3.9 bottom, green). This was likely due to an increase in p53 transcriptional activity. The merged
image showed a striking overlap of TSC2 with LAMP2 (Fig. 3.9 bottom, yellow), and this was reflected in
the quantitation of 50 cells that showed a significant increase (p=0.0002) in TSC2 percent colocalization
with LAMP2 (Fig. 3.9, left graph). Quantifying the TSC2 green fluorescence in no drug and AICAR treated
cells also showed a significant increase in total TSC2 level after AICAR treatment (Fig. 3.9, right graph).
This is in line with AICAR activation of p53 with the subsequent increase in TSC2.

AMPK activation by AICAR or PTX reduces lysosomal Rheb levels
TSC2 has been well established as the GAP for the essential mTORC1 activator, Rheb (Inoki et al. 2003).
In fact, GST-Rheb was able to pull-down endogenous TSC2, and this association was enhanced when
Rheb was in its GDP-bound form, rather than its GTP-bound form (Menon et al. 2014).
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Figure 3.9: AMPK activation by AICAR increases the distribution of TSC2 to lysosomal membranes,
and the increases total TSC2. Endogenous TSC2 (green) and LAMP2 (red) were subjected to
immunofluorescence labeling in ND and AICAR treated HCT116 cells. Bar graphs show Manders’
colocalization coefficient for >50 cells expressed as a percentage ±SEM (left), and total green
fluorescent intensity (right); the difference between treatments is significant for both comparisons
(*p=0.0001 and p=0.0086 respectively). ND = no drug treatment.
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Furthermore, we have shown that the loss of TSC2 from lysosomes in p53 null cells is accompanied by a
concomitant increase in lysosomal Rheb (Chapter 2 and (Agarwal et al. 2015b)). Conversely,
overexpression of TSC2 shifted Rheb out of lysosomal compartments (Chapter 2 and (Agarwal et al.
2015b)).
Since we saw a loss of TSC2 from lysosomes in PTX-treated cells, we probed for Rheb in membrane
fractions of PTX-treated cells to determine whether a similar increase in Rheb would be detected. To our
surprise, Rheb levels decreased in the membrane fractions from PTX-treated cells, the first time we saw
a break in the reciprocal relationship between TSC2 and Rheb. This was initially observed in total
membrane fractions from PTX (+TdR) treated HEK293T cells (Fig. 3.10A). Even though the membrane
marker, Integrin β1 was higher in the PTX-treated HEK293T membranes, much lower Rheb levels were
observed in this fraction (Fig. 3.10A, lane 2). Hence, if the level of Rheb had been normalized to Integrin
β1, the decrease in Rheb would have been more conspicuous. Heavy membrane fractions containing the
lysosomal protein, LAMP1 had the same decrease in Rheb in HCT116, HeLa and NIH3T3 cells (Fig. 3.10B,
C, D). To compare heavy membrane associated Rheb after PTX treatment with Rheb after AICAR
treatment, we treated and fractionated HCT116 cells in parallel (Fig. 3.11A). Even though the bulk of
Rheb was seen in the light membrane/cytosolic fractions, the Rheb content was decreased in the heavy
membrane fractions from cells treated with either AMPK-activator (Fig. 3.11A). Rheb blots from three
separate experiments in HCT116 cells were quantitated by densitometry, and both treatments showed a
significant decrease in heavy membrane Rheb levels (Fig. 3.11B, C). Thus, AMPK activation by AICAR or
PTX (+TdR) caused a loss of Rheb from lysosomal containing compartments.
To determine whether this observation could be reproduced in fixed whole cells, we immunostained
Rheb and LAMP1 after 24 h treatment of HCT116 cells with PTX (+TdR) or AICAR, and looked for
colocalization by confocal microscopy (Fig. 3.12).
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LAMP1 occupied the same lysosomal foci seen with LAMP2 staining, of note since each protein is found
in high amounts in lysosome membranes (Fig. 3.12 top panels, green). Rheb was seen throughout the
cytosol, including areas that overlapped with LAMP1 in control cells (Fig. 3.12 top panels, red). The
merged images of drug treated cells both show a decrease in yellow color (Fig. 3.12, bottom panels).
When the colocalization of Rheb and LAMP1 of more than 80 cells was quantified, a significant decrease
in Rheb overlap with the lysosome was calculated for both treatments (Fig. 3.12 right). The decrease in
Rheb was greater for AICAR treated cells, and more marked than with PTX-treated cells, but both were
significant (Fig. 3.12, bottom right). Overall, we showed that AICAR- or PTX (+TdR)-activated AMPK
reduces Rheb on lysosomal membranes. This occurs even though PTX treatment was shown to result in
significantly less lysosomal TSC2. This suggests that PTX treatment may be reducing lysosomal Rheb by a
mechanism other than increased TSC2.

PTX does not diminish lysosomal mTOR
Since we had seen the surprising loss of Rheb from lysosomes, along with the loss of TSC2, after PTX
treatment, we decided to look for lysosomal mTOR after ZMP-induced AMPK activation. Our lab and
others have seen that mTOR distribution to the lysosome can be modified (Agarwal et al. 2015b;
Parmigiani et al. 2014), and that Rheb is known to bind mTOR specifically and independently of TSC2
(Long et al. 2005). This binding is also independent of guanine nucleotide charge (Long, 2005). We
therefore hypothesized that a reduction in mTOR at lysosomes would be followed by a reduction in
Rheb. Immunostaining was performed for mTOR and LAMP2 after AICAR and PTX (+TdR) treatment.
Confocal micrographs show that mTOR overlaps with LAMP2 in control cells (Fig 3.13, upper panel,
merged), as was seen previously in p53 wild type and null cells (Chapter 2 and (Agarwal et al. 2015b)).
AICAR treatment, showed significantly lower levels of mTOR colocalization with LAMP2 (Fig. 3.13,
bottom right). PTX treatment, however, showed no change in lysosomal localization of mTOR at all (Fig.
3.13, top right).
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Figure 3.12: Both AICAR and PTX+TdR cause a reduction in the occupancy of Rheb at lysosomes.
LAMP2 (green) and endogenous RHEB (red) were subjected to immunofluorescence labeling in
drug treated HCT116 cells. Bar graphs show Manders’ colocalization coefficient for >50 cells
expressed as a percentage ±SEM; the difference between treatments are significant for both
comparisons.
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mTOR is recruited to lysosomes by amino acid signaling via the Rag-GTPases (Sancak et al. 2008).
Genotoxic stress has since been shown to antagonize this recruitment by the p53-induced expression of
Sestrin1/2 that blocks Rag-GTP loading (Parmigiani et al. 2014). We showed that Sestrin2 expression is
increased after AICAR-induced activation of p53 (Fig. 3.6A and B, Agarwal, 2015), so it follows that mTOR
may be prevented from localizing at the lysosome in a Sestrin2-dependent manner. Since PTX does not
activate p53 or Sestrin2 production, the lack of change in mTOR/LAMP2 colocalization may not be
surprising (Fig. 3.13, top). In contrast, AICAR activated p53 and Sestrin2 production (Fig. 3.6), and
decreased lysosomal mTOR levels (Fig. 2.13, bottom). Overall, PTX still caused a loss of Rheb from
lysosomes, and we showed that this is not due to a loss in lysosomal TSC2 or mTOR (Fig. 3.12 and 3.13).

Phosphorylation of Raptor by PTX-activated AMPK is sufficient to suppress
mTORC1 kinase
We questioned whether the robust p53-independent phosphorylation of Raptor seen in PTX-treated
cells (Fig. 3.5) was sufficient for suppression of mTORC1 in the absence of TSC2 or p53 function. p53-/TSC2-/- MEFs were transfected with an expression vector encoding wild type human Raptor or a
construct for Raptor in which the two amino acids phosphorylated by AMPK (ser722 and ser792) were
mutated to alanines (AA Raptor) (Gwinn et al. 2008). The vectors carrying wild type or AA Raptor caused
expression of recombinant Raptor in excess over endogenous Raptor levels (Fig. 3.14, lanes 3-6). Raptor
was phosphorylated at Ser792 in empty vector transfected cells after PTX treatment, and even more so
in cells transfected with wild type Raptor, but not in cells transfected with AA Raptor (Fig. 3.14, lane 6).
We drew the conclusion that the Raptor expressed from transfected Raptor constructs was competing
successfully with endogenous Raptor for binding to mTORC1 complexes. PTX treatment resulted in
suppression of mTORC1 kinase activity as seen by lower levels of phospho-S6K1 ser389 and phospho4EBP1 Thr70 (Fig. 3.14 lane 2 and 4).
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Figure 3.13: AICAR and PTX+TdR cause separate effects on lysosomal mTOR. Endogenous mTOR
(green) and LAMP2 (red) were subjected to immunofluorescence labeling in drug treated HCT116 cells.
Bar graphs show Manders’ colocalization coefficient expressed as a percentage ±SEM; the difference in
the decrease in mTOR after AICAR treatment is significant *p=0.0003).
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Figure 3.14: Phosphorylation of Raptor is necessary and sufficient for inhibition of mTORC1 by
PTX-activated AMPK. p53-/- TSC2-/- MEFs were transfected with pBABE-Hygro (empty vector),
or this vector containing WT or mutant AA Raptor, for 36 h before being treated with TdR or PTX
(+TdR) for 24 h. Immunoblots for P-T389 S6K1 and P-T70 4EBP1 were used as an index of
mTORC1 activity. This experiment was performed by Stuti Agarwal and is reported in Agarwal,
Bell, et al. J Biol Chem. 2015 Nov 13; 290(46):27473-86. doi: 10.1074/jbc.M115.665133.
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However, neither of these phosphorylation events was suppressed in AA Raptor-transfected cells (Fig.
3.14, lane 6). We concluded that the suppression of mTORC1 following PTX was mediated by AMPK
phosphorylation of Raptor and when endogenous Raptor in mTORC1 complexes was replaced by a
mutant Raptor incapable of AMPK mediated phosphorylation, mTORC1 suppression after PTX treatment
did not occur. It appeared that AMPK phosphorylation of Raptor was necessary and sufficient to
suppress mTORC1 in the absence of TSC2.

AMPK activation by PTX or AICAR does not change lysosomal Raptor levels
Given that we saw AMPK-phosphorylation of Raptor after PTX treatment was sufficient to reduce
mTORC1 activity, we questioned whether this robust phosphorylation changed the lysosomal
localization of Raptor. Immunoblots for Raptor after total and heavy membrane fractionation showed
that Raptor was found in heavy membrane fractions (Fig. 3.15 A and B), while phospho-Raptor ser792
was mostly in the cytosol after total membrane isolation (chapter2, Fig. 2.18A and Fig. 3.15A).
Quantitation of three individual fractionation blots showed a slight but non-significant increase in PTX
heavy membrane Raptor (Fig. 3.15C). Confocal microscopy showed that Raptor was mostly cytosolic
after TdR or PTX (+TdR) treatment (Fig. 3.15D, red). Even though LAMP1 staining after PTX no longer
showed a discrete focal pattern, slightly more yellow was seen in the overlapped image (Fig. 3.15D,
bottom merge). Colocalization analysis of 60 cells reiterated the upward trend with PTX treatment, but
was not found to be statistically significant (Fig. 3.15, right). AICAR treatment showed minimal Raptor
ser792 phosphorylation in heavy or light membrane fractions (Fig. 3.16A). This was despite evidence for
AMPK activation as judged by whole cell levels of phospho-Raptor ser792 and phospho-AMPK thr172
(Fig. 3.16B; Agarwal, 2015). This suggests that phospho-Raptor may accumulate in the nucleus, plasma
membrane, or cytosol, or that phospho-Raptor is in fact degraded after 14-3-3 protein binding (Gwinn et
al. 2008). Total Raptor levels in heavy membranes were unchanged with AICAR (Fig. 3.16A).
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Figure 3.15: AMPK activation by PTX results in a slight increase in lysosomal Raptor. Total or heavy
membranes were separated from light membrane and/or cytosol in HCT116, or HeLa cells, before
immunoblotting for mTORC1 components. The experiment was repeated at least 3 times. Examples of
Raptor and P-Raptor Ser792 in membranes are shown in the top panel. Endogenous LAMP1 (green)
and RAPTOR (red) were subjected to immunofluorescence labeling in PTX+TdR treated HCT116 cells.
Bar graphs show Manders’ colocalization coefficient for >50 cells expressed as a percentage ±SEM.
Although the difference is not significant, PTX+TdR treatment shows a increasing trend in lysosomal
Raptor.
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Figure 3.16: AMPK activation by AICAR results in no significant change to lysosomal Raptor. Heavy
membranes were separated from light membrane and cytosol in HCT116 cells, and whole cell lysates
(WCL)were prepared, before immunoblotting for Raptor and activation of AMPK. An example of Raptor and
P-Raptor Ser792 in membranes is shown in the top panel, compared to P-Raptor and P-AMPK in whole cell
lysates. In the bottom panel, endogenous LAMP1 (green) and RAPTOR (red) were subjected to
immunofluorescence labeling in ND and AICAR treated HCT116 cells. Bar graph show Manders’
colocalization coefficient expressed as a percentage ±SEM.
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Confocal microscopy after AICAR treatment also showed no significant change in Raptor colocalization
with LAMP1 (Fig. 3.16C). In summary, AMPK activation did not change the degree of Raptor/LAMP1
colocalization. It has been shown that nutrient deprivation and mitochondrial uncoupling stabilized the
mTOR-Raptor association, and this stabilization negatively regulated mTORC1 activity (Kim et al. 2002).
This may explain the slight increase in lysosomal Raptor seen with PTX treatment, given that PTX does
not change lysosomal mTOR, and causes a robust AMPK mediated phosphorylation of Raptor.

PTX and AICAR treatment increase the translocation of AMPK to the nucleus
Immunoblots of subcellular fractionations showed that the majority of phospho-AMPK Thr172 is in
heavy membranes. Nevertheless, AMPK levels did not change with AICAR activation, and actually
decreased with PTX treatment (Fig. 3.17, lanes 2 and 4). This corresponds with reports that AICAR
activation caused both light membrane/cytosolic and nuclear localization of AMPK (Kodiha, Ho-WoCheong, Stochaj 2011; Suzuki et al. 2007). Interestingly, LKB1 was also missing from heavy membrane
fractions after PTX treatment (Fig. 3.17, lane 4). Confocal microscopy showed that AMPK is cytosolic and
perinuclear in control cells (Fig. 3.18, top panels green). Remarkably, AMPK activation by ZMP did not
increase lysosomal AMPK (Fig. 3.18, bottom panels merge). In fact there was a decrease in AICAR
activated AMPK/LAMP2 colocalization (Fig. 3.18A, right). This decrease was much more dramatic after
PTX treatment (Fig. 3.18B, right). Bright areas of green fluorescence were also noted over the DAPIstained nuclei of treated cells (Fig. 3.18, bottom panels green). Since it has been well documented that
some isoforms of AMPK translocate to the nucleus upon glucose starvation, increased leptin, or
phenformin treatment, we analyzed the colocalization of AMPK with DAPI after AICAR or PTX treatment.
Nuclear AMPK increased significantly with AICAR and even more so with PTX (Fig. 3.19).
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Figure 3.17: AMPK activation by AICAR or PTX+TdR does not increase AMPK in heavy membranes.
Heavy membranes were separated from light membrane and cytosol in HCT116 cells, before
immunoblotting for total and phospho-AMPK, LKB1, and subcellular markers.
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Figure 3.18: AMPK activation decreases lysosomal levels of AMPK. Endogenous AMPKβ1/2 (green)
and LAMP2 (red) were subjected to immunofluorescence labeling in ND and AICAR, and PTX (+TdR)
treated HCT116 cells. Bar graph show Manders’ colocalization coefficient of AMPK/LAMP2 expressed
as a percentage ±SEM.
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Figure 3.19: AMPK translocates to the nucleus after activation by ZMP. Endogenous AMPKβ1/2
(green) and DAPI (blue) in figure 3.18 are shown here blown up 3x (top), and 40 cells were
analyzed for evidence of colocalization. Bar graphs (bottom) show Manders’ colocalization
coefficient of AMPK/LAMP2 expressed as a percentage ±SEM. The difference from control is
significant for both treatments.
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In short, AICAR and PTX (+TdR) treatment decreased lysosomal Rheb, despite the low amounts of TSC2
seen after PTX treatment, and in accordance with the decreased mTORC1 activity. AICAR prevented
mTOR localization at lysosomes, possibly via induction of Sestrin2. Finally, ZMP-activated AMPK
translocates to the nucleus not the lysosomal membrane.
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3.3

Discussion

Nutrient and energy sensing occur at two critical signaling nodes: AMPK senses energy and cell stress,
and mTORC1 senses growth factor signaling and amino acid sufficiency. These two pathways therefore
maintain energy homeostasis, and their dysregulation contributes to multiple disease states including
obesity, type-2 diabetes, and cancer. Activation of AMPK offers an attractive means of controlling
mTORC1 in cancer cells since it regulates the kinase via activation of the Rheb GAP, TSC2 and inhibition
of the mTOR scaffolding protein, Raptor. AICAR has been widely used to study the effects of AMPK
activation on downstream targets. In its nucleotide form, ZMP, it behaves as an AMP analog, causing
canonical allosteric activation of AMPK via binding to the γ-subunit. PTX treatment was carried out in
the presence of thymidine to avoid the effects of PTX on thymidylate synthase. PTX (+TdR) thus behaved
as an AMPK activator by causing a substantial increase in ZMP behind the block of AICART. We have
shown that activation of AMPK by AICAR or by the antifolate, PTX changes the dynamics of lysosomal
mTORC1 activation. These findings are discussed below.

TSC2 and Rheb
Our key finding was that both drugs diminished the amount of Rheb at lysosomal membranes (Fig. 3.10,
3.11, and 3.12). This was a surprise since increases in Rheb in p53 null cells were correlated with
decreased levels of TSC2 (chapter 2 and Agarwal, 2015). This implies that some mechanism other than
increased TSC2 at lysosomes is causing the decrease in lysosomal Rheb. TSC2 levels are low in PTXtreated cells because PTC causes the accumulation of a transcriptionally inactive species of p53. As a
result, the mRNA and protein levels of established p53 targets, including p21 were reduced (Fig. 3.6A
and B). Correspondingly, the p53 targets in the AMPK/mTORC1 pathway, TSC2 and Sestrin2, were also
diminished (Fig. 3.6B). The reduction in p53-driven TSC2 production after PTX treatment was reflected
by a reduction of TSC2 in lysosome-containing cell fractions (heavy membrane lanes in Fig. 3.7) and in
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TSC2 colocalization with the lysosomal protein, LAMP2 (Fig. 3.8). The latter analysis was performed for
over 80 cells, and the reduction with PTX was significant. This mirrors the results seen in p53 null cells
(chapter 2 and Agarwal, 2015). This was in stark contrast to AICAR treatment that showed a significant
increase in total TSC2 levels (Fig. 3.6) and TSC2 colocalization with LAMP2 (Fig. 3.9).
The activation of AMPK by AICAR increases lysosomal TSC2, and reduces lysosomal Rheb levels (Fig. 3.8,
3.9, and 3.12). AICAR-activated p53 leads to increased total cell TSC2, and perhaps this increases
lysosomal TSC2, leading to the control of Rheb and cell growth under conditions of cell stress. Similar
phenomena have been described previously by Feng et al., (2007) who showed that irradiation of p53
wild type cells, or treatment with DNA-damaging agents, caused an approximately two-fold increase in
TSC2 gene induction(Feng et al. 2007). The increase in lysosomal TSC2 in our studies may reflect
decreased binding driven simply by mass action, but it would be important to determine whether the
phosphorylation of TSC2 ser1387 is essential for the translocation of TSC2 to lysosomes. Transfection of
an AMPK-site phosphorylation mutant of TSC2 would give an indication of the importance of this
phospho-site after AMPK activation. One would expect less TSC2 localization at lysosomes with the
mutant protein compared to the wild type protein after AICAR treatment. If Rheb truly exists at
lysosomes in a reciprocal and competitive manner to TSC2, the levels of Rheb at lysosomes would not
decrease with AICAR treatment.
Conversely, a TSC2 GAP-site mutant would show whether enhanced TSC2 GAP activity is the mechanism
behind the loss of Rheb from lysosomes after AICAR treatment. This hypothesis would imply that
cleavage of GTP back to GDP on Rheb caused the release of Rheb from lysosomes. TSC2 GAP activity
may change the orientation of Rheb in the lysosomal membrane by promoting the conversion of RhebGTP to Rheb-GDP. Evidence for this comes from NMR measurements that show that the GTPase domain
of Rheb interacts transiently with the surface of lipid bilayer nanodiscs in two distinct orientations,
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determined by the bound nucleotide (Mazhab-Jafari et al. 2013). Specifically, GTP-bound Rheb exists in a
semi-parallel orientation to the lipid bilayer, while Rheb-GDP prefers an open, semi-perpendicular
orientation (Fig. 3.20). Importantly, the C-terminal switch II region of Rheb sits at the interface of the
Rheb and the lipid bilayer, and GTP binding exposes this region (Mazhab-Jafari et al. 2013). Mutation of
this switch II region do not impair nucleotide binding but do prevent the rescue of mTORC1 signaling in
nutrient starved cells, suggesting that GTP-binding uncovers a surface for mTOR binding (Long et al.
2005). TSC2-induced conversion of Rheb-GTP to Rheb-GDP may therefore block mTOR binding to and
activation by Rheb-GTP.
This does not explain the loss of lysosomal Rheb, however, seen with increases of lysosomal TSC2 after
AICAR treatment (Fig. 3.10-3.12). The conversion to Rheb-GDP by TSC2 may produce an orientation of
Rheb that favors binding to a cytoplasmic protein, such as 14-3-3 proteins or a yet unidentified GDI.
Interestingly, a recent structure of Rheb in complex with PDEδ, the GDI-like protein described in chapter
2, reveals that PDEδ encapsulates the farnesyl tail of Rheb within a deep hydrophobic pocket (Ismail et
al. 2011). Overlaying the Rheb-PDEδ structure with the Rheb-nanodisc models shows that there are
steric clashes between PDEδ and the membrane bilayer that would block PDEδ from binding Rheb in its
GTP, semi-parallel conformation (Mazhab-Jafari et al. 2013). Conversely, a change in Rheb to the GDPbound orientation would allow the C-terminal loop of switch II to interact with PDEδ. Formation of a
Rheb-PDEδ complex may therefore initiate solubilization of Rheb, by a process involving extraction of
the farnesyl moiety from the bilayer into the hydrophobic pocket of PDEδ (Ismail et al. 2011; MazhabJafari et al. 2013).
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Figure 3.20: Proposed model for orientation of Rheb-GDP and Rheb-GTP in lipid-bilayer
nanodiscs based on NMR measurements. The GTPase domain of Rheb interacts transiently with
the surface of the bilayer in two distinct orientations, which are determined by the bound
nucleotide. Rheb GDP (left) and -GTP (right) were bound in semi-perpendicular and semi-parallel
orientations. Arrows reflect the favored conformation in each nucleotide bound state. GTP
binding by Rheb uncovers the switch II region, which is necessary for mTOR binding. Figure
adapted from Mazhab-Jafari, M.T. J. Am. Chem. Soc. 2013, 135, 3367-3370. DOI:
10.1021/ja312508w
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PTX treatment also results in a loss of Rheb from lysosomes (Fig. 3.12). The lack of lysosomal TSC2 under
these conditions (Fig. 3.6) indicates that TSC2 phosphorylation or GAP activity is not the mechanism
behind these effects. Confocal microscopy revealed distinct changes to the pattern of LAMP1 and
LAMP2 distribution. PTX (+TdR) treatment changed the appearance of LAMP fluorescence from a
distinct perinuclear focus in each cell (Fig. 3.6 top panel, red), to a dispersed pattern around the edge of
the nucleus (Fig. 3.6 bottom panel, red). This may be due to induction of ER stress and activation of the
unfolded protein response. ER stress is the result of the accumulation of unfolded or misfolded proteins
in the ER lumen (Patil and Walter 2001). It is triggered by high protein demand, viral infection,
xenobiotics, inflammatory cytokines, and mutant protein expression (Minami et al. 2007; Patil and
Walter 2001).
Another antifolate drug, methotrexate has been reported to induce apoptosis through the production of
ROS and oxidative stress, which triggered an ER stress response (Herman S, 2005; Guan L, 2009).
Nevertheless, the evidence for methotrexate-induced apoptosis is stronger for a DNA-damage based
mechanism via the excision of dUTP misincorporated into DNA. One report has also shown that PTX at
2.5 µM (a 2.5 fold higher concentration than used in these studies) can promote apoptosis via
upregulation of Death Receptor 5 (DR5) and ER stress (Su et al. 2011). In light of these data, PTX
treatment may be disrupting lysosomal architecture via induction of ER stress. ER stress may also affect
the ER-bound enzymes that post-translationally modify Rheb. Rce1, the enzyme that cleaves off the Cterminal AAX peptide, and Icmt, the enzyme that methylates the terminal farnesylcysteine, are both ERbound proteins. Perturbation to the ER membrane by PTX-induced ER stress may prevent the proper
processing of Rheb, and thereby prevent Rheb from tethering to the lysosomal membrane. This could be
assessed by measuring the levels of farnesylated Rheb after PTX treatment. Alternatively, the robust
phosphorylation of Raptor at ser792 may result in a conformational change that prevents mTOR
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association with Rheb. For this, transfection of the AA Raptor mutant would be useful to show whether
this decreased lysosomal Rheb.

mTOR
PTX treatment does not change the levels of lysosomal mTOR, but AICAR treatment causes a significant
reduction in the levels of mTOR at lysosomes (Fig. 3.13). This was similar to what was seen in p53 null
cells with overexpressed FLAG-Sestrin2 (chapter 2 and (Agarwal et al. 2015b)). Sestrin1 and Sestrin2 are
also p53 targets, and have been shown to activate AMPK in response to genotoxic stress, and enhance
the phosphorylation of TSC2 as well as its GAP activity (Budanov and Karin 2008). Sestrin2 levels are not
stimulated by PTX treatment (Fig. 3.6, (Agarwal et al. 2015a)) because of the resultant nonfunctional
p53. This leads us to hypothesize that TSC2 remains unphosphorylated by PTX-activated AMPK because
their association is weakened by a lack of Sestrin2. AICAR, on the other hand, induces Sestrin2
expression via p53 activation (Fig. 3.6, (Agarwal et al. 2015a)). Sestrin2 has been shown to prevent Ragdependent recruitment of mTOR to the lysosomal membrane in response to cell stress (Parmigiani et al.
2014). We believe that this is the mechanism driving the AICAR-dependent decrease in lysosomal mTOR
(Fig. 3.13, bottom).

Raptor
PTX appears to decrease mTORC1 signaling solely through a robust phosphorylation of Raptor, since
signaling resumes in the presence of a Raptor mutant that cannot be phosphorylated by AMPK (Fig.
3.14; Agarwal, 2015b). AMPK phosphorylation of Raptor on ser792 has been shown by multiple groups
to decrease mTORC1 activity. Nevertheless, the mechanism behind this negative regulation remains
ambiguous. Gwinn et al. showed that ser792 phosphorylation stimulated its binding to 14-3-3 proteins
(Gwinn et al. 2008). Phosphorylation-dependent binding to the 14-3-3 protein family is a common
mechanism for phosphorylation-based inactivation of proteins (Bridges and Moorhead 2005). Binding to
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14-3-3 proteins has been shown to trigger conformational changes in other target proteins, leading to
the allosteric reduction of catalytic activity. Interactions with 14-3-3 proteins have also been shown to
disrupt protein-protein interactions, or change subcellular localization (Yaffe 2002). Nutrient withdrawal
has been shown to increase the binding of mTOR to Raptor (Kim et al. 2002). It would be useful to show
drug-induced differences in mTOR binding to Raptor after anti-raptor immunoprecipitation.
Alternatively, phospho-Raptor ser792 may perturb its association to other known binding partners,
S6K1, 4EBP1, and Rag-GTP (Dunlop et al. 2009; Nojima et al. 2003; Sancak et al. 2008). Amino acid
withdrawal did not prevent these associations (Long et al. 2005), but energy stress-activated Raptor
binding to these proteins has not been studied. In our work, AMPK activation by AICAR or PTX did not
cause a significant change in Raptor/LAMP1 colocalization, even though mTORC1 signaling is decreased
(Fig. 3.15 and 3.16, (Agarwal et al. 2015a)). This differs from the degree of phosphorylation seen after
each treatment. That is, PTX induces higher levels of Raptor ser792 phosphorylation than AICAR. This
implies that the phosphorylation of Raptor seen in Figure 3.5 does not reduce mTORC1 activity by
changes to the lysosomal localization of Raptor but it may change access of mTOR to its substrates, S6K1
and 4EBP1.

AMPK
The final key observation from this work was that AICAR and PTX treatment triggered the translocation
of AMPK to the nucleus (Fig. 3.19). Activated AMPK also appeared to be shunted off lysosomal
membranes (Fig. 3.18). Work done mainly in muscle cells has shown that in response to exercise, leptin,
or AICAR, α1-containing AMPK remains in the cytosol, while α2-containing AMPK translocates to the
nucleus. In contrast, myristoylated β1-subunits cause the localization of AMPKα1/2 to membranes
within the cytoplasm (Fig. 3.8).
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Taken as a whole, AICAR and PTX have effects that are mediated by p53 and/or by AMPK. Figure 3.21
outlines these changes. In brief, TSC2 is lost from the lysosome with loss of p53 or treatment with PTX.
AICAR treatment activates p53 and increases the amount of lysosomal TSC2. Rheb is lost from the
lysosome with AICAR or PTX treatment, or increased levels of TSC2. Loss of p53 on the other hand
increases lysosomal Rheb. mTOR is lost from lysosomes after AICAR treatment, or with increased levels
of Sestrin2. Raptor is phosphorylated by both drugs, substantially by PTX, but Raptor remains on
lysosomes. Finally, AMPK is lost from lysosomes after AMPK activation by AICAR or PTX, and translocates
to the nucleus.
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Figure 3.21: Model for the subcellular dynamics of AMPK and mTORC1 components after PTX
(+TdR) or AICAR treatment.
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4

The effect of cytotoxic antifolates on the

metabolic kinases, AMPK and mTORC1
4.1 Introduction
Folates are critical one-carbon donors in the synthesis of purines, pyrimidines, serine, and methionine.
These molecules are essential for the de novo synthesis of DNA in mammalian cells, and since mammals
cannot synthesize their own folates, they must be obtained from the diet. Folates are anionic,
hydrophilic molecules that are transported into the cell via specialized transport systems such as the
reduced folate carrier (RFC). Antifolates, on the other hand, are structural analogs of folates that inhibit
key enzymes in folate metabolism. Aminopterin and then methotrexate (MTX) (Fig. 4.1) were the
earliest antifolates, developed in the 1940s (Farber et al. 1948). Today MTX is still used extensively in the
treatment of many tumors including lymphoma, acute lymphoblastic leukemia (ALL), breast cancer and
osteosarcoma (Bonadonna et al. 1995; Fuchs et al. 1998; Weiser et al. 2004). MTX is also used
frequently in the treatment of autoimmune disorders, such as rheumatoid arthritis and psoriasis.
Subsequently, raltitrexed (RTX), lometrexol (LTX), and pemetrexed (PTX) (Fig. 4.1) have been developed.
RTX is approved in many countries, not including the United States, for the treatment of 5-FU-resistant
advanced colorectal cancer. PTX is used in combination with cisplatin to treat non-squamous-cell lung
cancer and pleural mesothelioma, and as a single agent in relapsed non-small cell lung cancer after
platinum-containing chemotherapy (Scagliotti et al. 2008; Vogelzang et al. 2003).
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Figure 4.1: Chemical structures of the four classical antifolates compared to folic acid.
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4.1.1 Cellular folate metabolism
Pteroylglutamates form a family of cofactors based on the structure of folic acid. The enzyme,
dihydrofolate reductase (DHFR), converts folates to their biologically active forms, dihydrofolate (DHF)
and tetrahydrofolate (THF). The major dietary form of folates is 5-methyl-THF (5-MTHF), which together
with homocysteine is converted to methionine and THF by methionine synthase (Fig. 4.2).
Folypolyglutamate synthetase (FPGS) adds a series of glutamates to the γ-carboxyl residues of THFs,
resulting in polyanionic molecules that cannot pass back through the plasma membrane. These folate
polyglutamates act as the one-carbon donors to the de novo synthesis of purines, thymidylate,
polyamines, and S-adenosyl methionine, which promotes methylation of DNA, histones, and lipids
(Moran, Werkheiser, Zakrzewski 1976).

4.1.2 Antifolate drug metabolism
Since antifolates are structural analogs of folate, they are able to enter the cell via the same transport
systems: the reduced folate carrier (RFC), the folate receptor (FR), and the proton-coupled folate
transporter (PCFT) (Gonen and Assaraf 2012). FRs are overexpressed on the membranes of some tumor
cells, making these tumors susceptible to antifolates. Transport by the FR is via endocytosis, after which
transport into intracellular compartments occurs via the PCFT. The PCFT also acts as a high-affinity
folate-proton symporter responsible for the intestinal absorption of folates (Shayeghi et al. 2005). So
called “classical antifolates” are polyglutamated by FPGS, and are thereby effectively retained in the cell
and have increased affinity at their target enzyme (Kisliuk, Gaumont, Baugh 1974). Non-classical,
lipophilic antifolates do not require polyglutamation for their anti-cancer activity (Cody, Pace, Rosowsky
2008). Lastly, a number of transport systems, including the multidrug resistance-associated proteins
(MRP1-5) and the breast cancer-resistance protein (BCRP or ABCG2), have been reported to carry out
antifolate efflux. Antifolate resistance is therefore often the result of reduced influx, increased efflux,
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impaired polyglutamation, and/or mutation or overexpression of folate-dependent targets (Hagner and
Joerger 2010).

4.1.3 Targets of antifolates in the cell
Dihydrofolate reductase
DHFR catalyzes the reduction of DHF to 5,6,7,8-THF, which is then converted to 5’,10’methylenetetrahydrofolate (methylene-THF) (Fig. 4.2). DHFR was the first enzyme to be identified as a
cellular target for aminopterin and MTX (OSBORN, FREEMAN, HUENNEKENS 1958). By inhibition of
DHFR, MTX disrupts both purine and pyrimidine synthesis (Johnson et al. 1997). The newer, non-classical
antifolate, talotrexin, has a 15-fold increased affinity for DHFR than MTX (Rosowsky et al. 2000a;
Rosowsky et al. 2000b). The gene encoding DHFR is often amplified in ALL, ovarian cancer, and softtissue sarcoma, presenting a mechanism of resistance to MTX (Cario et al. 2011).
Thymidylate synthetase
Thymidylate synthetase (TS) catalyzes the initial step in de novo synthesis of thymidine nucleotides for
DNA synthesis (Fig. 4.2). TS uses 5,10-methylene-THF to generate deoxythymidine monophosphate
(dTMP) from deoxyuridine monophosphate (dUMP). This results in the oxidation of methylene-THF to
DHF.
GART and AICART
De novo purine synthesis starts with phophoribosyl pyrophosphate, which is converted to inosine
monophosphate (IMP) in ten successive steps (HARTMAN and BUCHANAN 1959). Two folate-dependent
enzymes operate in de novo purine synthesis, β-glycinamide ribonucleotide transformylase (GART) and
5’-amino-4’-imidazolecarboxamide ribonucleotide (AICART) (Fig. 4.2).
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PTX

LTX (DDATHF)
MTX

RTX, PTX

Figure 4.2: Cellular targets of antifolate drugs. Folates serve as one-carbon donors in de novo purine and
thymidylate synthesis, amino acid metabolism and methylation reactions. Antifolates, as structural
analogs, block the action of folate-dependent enzymes. Key enzymes are shown highlighted in black, and
the four classical antifolates are shown in red at their target enzyme. Image adapted from Gonen, N et al.
Drug Resistance Updates, Vol 15, Issue 4, Aug 2012, p183–210.
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GART is a trifunctional protein, containing three enzymatic activities on a single polypeptide chain:
glycinamide ribonucleotide synthetase, aminoamidazole ribonucleotide synthetase, and glycinamide
ribonucleotide transformylase (GARS-AIRS-GART). GART catalyzes the formation of the imidazole ring of
purines using 10-formyl-THF.
AICART catalyzes the penultimate step to generate IMP, the precursor molecule for the purine
nucleotides, adenylate (AMP) and guanylate (GMP).

4.1.4 Classical antifolates
Dihydrofolate reductase inhibitors
Aminopterin
Aminopterin was the first antifolate used in humans, and heralded the advent of antimetabolite cancer
chemotherapy. In 1945, chemists at Lederle were searching for the factor in liver that prevented a
nutritional deficiency anemia in rats, brought on by feeding the animals chow that had been pre-treated
with activated charcoal (Rosenberg 2012). After laborious purification of the biologically active factor, it
could not be determined whether the active principal was folic acid, or one of its derivatives, including
4-aminofolic acid or, aminopterin. The compounds were fed to anemic rats, alone and in combination
and the folic acid cured the anemia, whereas aminopterin made the anemia worse (Rosenberg 2012).
Importantly, aminopterin interfered with the anemia-curative effect of folic acid. The term antimetabolite or, anti-folate was thus coined. Sidney Farber initially used folic acid to treat his pediatric
leukemic patients for their advanced anemia, but noted that these patients quickly deteriorated. He
then used the antifolate compound from Lederle, aminopterin, and remarkably this compound caused
dramatic remissions in some of his ALL pediatric patients (Farber et al. 1948).
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Methotrexate
Aminopterin and its derivatives were later used to treat mice with transplantable L1210 leukemias
(GOLDIN et al. 1953a; GOLDIN et al. 1953b; Moran, Werkheiser, Zakrzewski 1976). An aminopterin
derivative, 4-amino-10-methyl substituted pteroyl glutamic acid (amethopterin or MTX) was found to
have more activity at less toxic doses. MTX inhibits DHFR as a tight-binding or stoichiometric inhibitor
(Bertino et al. 1963; Huennekens 1994; OSBORN, FREEMAN, HUENNEKENS 1958; Werkheiser, Grindey,
Moran 1973). Binding to DHFR is stoichiometric when there is a low ratio of inhibitor to enzyme (BrokSimoni et al. 1975). This tight binding was found to be reversible and to occur at a Ki of 0.004 nM,
making MTX extremely efficient at competing with the DHFR substrate, DHF (Stone and Morrison 1986).
Nevertheless, the binding of MTX to DHFR upregulates DHFR expression, by a mechanism involving gene
amplification and translational autoregulation (Alt, Kellems, Schimke 1976; BERTINO 1963; Hillcoat,
Swett, Bertino 1967; Kellems, Alt, Schimke 1976). In 1976, Moran showed that that the cellular folate
derivatives in logarithmically growing L1210 cells consisted entirely of polyglutamyl derivatives or folaterestricted cells, implying that polyglutamyl folates were the active forms of folate cofactors (Moran,
Werkheiser, Zakrzewski 1976). Several groups then showed that the same enzyme (later determined to
be FPGS) that catalyzed the addition of these glutamates, also polyglutamated MTX, aminopterin and a
host of related antifolates. MTX is a relatively poor substrate for human FPGS with a Km of 40() µM
(Sanghani and Moran 2000), but its potency against other folate-dependent enzymes increases with
glutamate chain length.
Early clinical trials showed that MTX was effective against choriocarcinoma (HERTZ, LI, SPENCER 1956).
MTX was also used in combination with three other drugs (vincristine, prednisone, and 6mercaptopurine) and this was found to produce durable remissions in ~ 100% of pediatric patients with
ALL. However, ~85% relapsed due to central nervous system leukemia, until MTX was given
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intrathecally. MTX has since been used in combination therapy to treat lymphoma, gastric, bladder and
neck cancer, and as induction and maintenance therapy in ALL.
Thymidylate synthetase inhibition
Raltitrexed
In an attempt to improve the effectiveness, spectrum of activity, and acquired resistance to MTX, a host
of novel antifolates were developed. In order to create drugs with specificity to enzymes other than
DHFR, the 2,4-diamino pharmacophore was avoided. The compound, 5,8-dideazafolic acid was found to
be a weak inhibitor of TS (Alison et al. 1985). With this molecule serving as the lead compound, the drug,
CB3717 (2-amino-4-hydroxyquinazoline) was developed. CB3717 is a potent TS inhibitor with a Ki of 3
nM (Jones et al. 1981). In clinical trials, this drug caused an unpredictable life-threatening toxicity, due
to crystallization in the renal tubules of patients (Calvert et al. 1987). Nevertheless, this compound
sparked interest in the development of additional TS inhibitors. Using structure activity studies and the
FPGS activity of candidate compounds (Moran, Colman, Rosowsky 1987), the compound CB3920
(ZD1964 or RTX) was selected as a promising TS inhibitor. The specificity for TS was demonstrated by
end-product reversal studies (Jackman et al. 1991). CB3920 had superb activity against TS and robust
polyglutamation by FPGS, with polyglutamation increasing its potency towards TS. RTX enters the cell via
the RFC and has a Km of 1.3 µM for FPGS (Jackman et al. 1991). RTX binds TS with a Ki of 60 nM, but like
other molecules in this class, increased polyglutamation increases the potency to the target enzyme.
The tetraglutamate form has a Ki of 1 nM (Hughes and Calvert 1999). The Ki the pentaglutamate was
100 fold lower than the parent monoglutamate.
The inhibition of TS by RTX leads to thymineless cell death (Tillman, Petak, Houghton 1999). Responses
to RTX included breast, ovarian, pancreatic, gastric, and colorectal cancers. Its effectiveness in colorectal
cancer was compared to the gold standard treatment of the time, 5-FU plus leucovorin, but no
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differences in efficacy were found and there was greater toxicity with RTX (Walling 2006). RTX was
clinically active against 5-FU-refractory colon cancer, and was approved for clinical use in Britian, Europe
and Asia under the trade-name, tomudex and then Ralitrexid. It is still widely used today, especially in
elderly patients who cannot tolerate 5-FU/leucovorin for their colon cancers.
By the late 1980s to early 1990s, most common mechanism of resistance to DHFR inhibitors and the
folate-based TS inhibitors was found to be mutations in FPGS (Zhao et al. 2000). Nevertheless,
antifolates inhibitory to any of the other folate enzymes were highlighted as being potentially useful in
the treatment of human carcinomas.
Purine synthesis inhibition
Lometrexol
In the mid-1980s, a collaboration between E.C. Taylor at Princeton and his former PhD student, Peter
Beardsley (who was, at that time, an Assistant Professor at Harvard’s Dana-Farber Cancer Center) led to
the discovery of LTX (6R-5,10-dideazatatrahydrofolate or DDATHF) (Taylor et al. 1989). Eight years of
difficult synthetic chemistry followed and subsequent tests in L. casei TS showed that it was completely
inactive at TS any concentration. DDATHF was then sent to R.G. Moran for analysis of FPGS activity, who
found that it was an excellent substrate for FPGS, and that this activity would translate to strong
antiproliferative activity (Taylor et al. 1989). Moran et al. found that DDATHF did not inhibit TS or DHFR
in vitro, but that it was the strongest inhibitor of de novo purine synthesis yet seen (Moran et al. 1989).
It was also a potent inhibitor of leukemic cell growth and WiDr colon carcinoma growth (Moran et al.
1989; Smith, Lehman, Moran 1993). LTX enters the cell via the RFC and is a potent and tight-binding
inhibitor of the de novo purine synthesis enzyme, GART (Kan and Moran 1995; Kan and Moran 1997;
Sanghani and Moran 1997). GART is a trifunctional protein, containing three enzymatic activities on a
single polypeptide chain that catalyzes the formation of purines using a reaction that converts 10173

formyl-THF to THF. LTX action as an anticancer drug is thought to be related to its depletion of
intracellular purine pools.
LTX was the first GART inhibitor to be investigated clinically when E.C. Taylor sold the rights to DDATHF
to Eli Lilly and it advanced into clinical trials (1987). It was found to have broad antitumor spectrum in
four Phase I trials. Unexpected and severe delayed cumulative toxicity, later thought to be due to host
folate status (Tse and Moran 1998; Tse et al. 1998), prompted extensive characterization of the
efficiency, metabolism, pharmacokinetics and metabolism of GART inhibitors. After delayed reporting of
the toxicity results by the Lilly Clinic in Indianapolis, LTX was considered a failed antifolate.
Subsequently, John Roberts at VCU did a very careful Phase I study in patients treated with low dose
folic acid, and he found the drug to be easily tolerated by humans (Roberts et al. 2000). Folic acid
supplementation was thus necessary to prevent myelosuppression and mucositis. By this time though,
the patent had almost expired and a second-generation compound was brought forward, LY309887. This
compound did well in clinical trials, and two additional analogs were brought to forward by Agouron
Pharmaceuticals, namely AG2034 and AG2037. All four sets of clinical trials had occasional, remarkable
responses in patients, clearing their tumors and extending life expectancy, but unfortunately, all
patients eventually relapsed.
Combined TS and purine synthesis inhibition
Pemetrexed
The toxicity observed for LTX, lead to the search for an antimetabolite with a better biochemical,
pharmacological and toxicological profile (Mendelsohn et al. 1996a; Mendelsohn et al. 1996b).
Importantly, one compound did away with the intrinsic problems caused by a center of asymmetry at
carbon 6, by the introduction of a double bond into the structure. This compound, LY231514 was
exceedingly potent and broadly active in several dozen rodent tumors and human xenografts (Taylor et
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al. 1992). Although Eli Lilly wanted to introduce LY231514 as a TS inhibitor, it was also found to be
inhibitory to DHFR at single digit nM levels, GART at ten to 50 times higher concentrations, and to
AICART only at exceedingly high concentrations. Polyglutamated LY231514 also inhibited GART with a
potency of 65 nM, 50-fold less potent than LTX. LY231514 exhibited weaker affinity for the FRs, although
the selectivity for the FRβ isoform was twice that of LTX (Mendelsohn et al. 1996a; Mendelsohn et al.
1996b). LY231514 became known as MTA for Multiply-Targeted Antifolate, and later as pemetrexed or
PTX.
In the course of Phase I clinical trials in Northern Germany and Northern England, it became clear that
PTX had exceptional activity against the asbestos-related lung cancer, mesothelioma. Approval was fasttracked by the American FDA for this disease. With clinical use in thoracic oncology units in the United
States and England, it was found that PTX had occasional use in NSCLC and had activity in this disease.
Two large-scale clinical Phase III trials compared PTX against Taxol plus cisplatin and it transpired that
PTX was the superior drug. Subsequent clinical trials showed that this notable effect was only in a
subgroup of histologically non-squamous NSCLCs, and it is used today as first-line therapy in
combination with cisplatin in these diseases.
Exceptionally, PTX was approved as a maintenance agent in NSCLCs. The Moran laboratory then went
back to try solve the twin riddles of the second mechanism of action of PTX, and its activity in lung
cancers. Whole cell reversal experiments showed that the second action of PTX was, surprisingly,
inhibition of AICART (Racanelli et al. 2009). This was then confirmed by the observation that the
substrate of the AICART reaction built up in PTX-treated tumor cells (Racanelli et al. 2009). This
metabolite, ZMP, is normally found below 1 µM in cell water, but it built up to 1-2 mM in leukemic cells,
and 4-15 µM in carcinoma cells. Two students in the Moran laboratory, Alex Racanelli and Scott
Rothbart sought the potential for inhibition of other targets by these huge concentrations of nucleotide.

175

Ultimately, they did not find inhibited targets, but rather they found that the high levels of ZMP served
to robustly activate the AMPK (Racanelli et al. 2009; Rothbart, Racanelli, Moran 2010).

4.1.5 Summary
Over 60 years of study has firmly established the role of antifolates in cancer chemotherapy. Activity of
these drugs is not the carried out by a single target: MTX inhibits DHFR, RTX inhibits TS, and LTX inhibits
GART. PTX has broad activity and circumvents some forms of resistance (Fig. 4.2). It has now been
approved for first line therapy in non-squamous-cell lung cancer, and first-line treatment of malignant
pleural mesothelioma, thus substantially adding to the importance of antifolates in clinical oncology. It
was appreciated that PTX targets more than one site, but the success of PTX in NSCLCs may involve its
unusual AMPK-mediated control of mTORC1, the growth promoting complex that sits downstream of
several oncogenes. The future of antifolates will hinge on the development of strategies to individualize
treatment. The identification of pharmacogenetic markers, such as tumoral expression of TS, will be
paramount to this strategy. This study investigates the effects of the other classical antifolates on AMPK
activation.
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4.2

Results

MTX, RTX, LTX, and PTX promote AMPK activation to varying degrees over 48 h
Antifolate drugs have cell cytotoxic effects due to their ability to inhibit the folate dependent enzymes
that catalyze crucial biosynthetic reactions. PTX (+TdR) has been shown by our lab to activate AMPK by
increasing the levels of ZMP, the substrate of PTX’s target enzyme in de novo purine synthesis, AICART
(Rothbart, Racanelli, Moran 2010). As a result, mTORC1 activity is decreased and p53 is stabilized by
unknown mechanisms (Agarwal et al. 2015). This study aimed to determine whether the effect of PTX
(+TdR) could be generalized to PTX treatment alone, as well as to the other classical antifolates, MTX,
RTX, and LTX.
To determine whether these agents could modulate AMPK activation, HCT116 colon carcinoma cells
were treated with 1 µM of each antifolate for 24 hours. PTX (+TdR) was included as a positive control
since this combination circumvents the effects of PTX on TS, and is thought to represent pure AMPK
activation. AMPK activation was determined by measuring AMPK Thr172 phosphorylation by
immunoblotting. As seen previously, PTX (+TdR) increases P-AMPK Thr172 over the TdR-treated control
lane (Fig. 4.3, lane 2 and 3). Interestingly, all four of the tested antifolates also increased P-AMPK Thr172
levels over the no drug control, with LTX, RTX, and PTX inducing higher levels of phosphorylation (Fig.
4.3 lanes 1, 4-8).
The level of activation by MTX was surprising low, so a time course of AMPK activation by the antifolates
was performed to evaluate whether we were missing peak AMPK activation by this drug. Cells were
treated as before for 6, 12, 24, and 48 hours before harvesting and immunoblotting. HCT116 cells
showed varying degrees of increased P-AMPK Thr172 across the time course for each drug (Fig. 4.4A).
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Figure 4.3: AMPK is activated by all four antifolates, MTX, RTX, LTX, and PTX over the no drug control.
HCT116 cells were treated with 1µM of each antifolate drug for 24h. PTX (+TdR) was included as a
positive control. Proteins were detected by immunoblotting.
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Figure 4.4: AMPK is activated to varying degrees over 48 h by the four antifolates. (A) HCT116, (B)
H358, and (C) NIH3T3 cells were treated with 1µM of the indicated antifolate for times on 6, 12, 24, and
48 h. Cells were harvested and the lysates immunoblotted for evidence of AMPK activation.
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Figure 4.5: AMPK activation over 48 h. The time course of AMPK activation was quantified for four
individual experiments by Licor densitometry. P-AMPK signal is normalized to the β-actin signal for that
experiment. n=4 biological repeats.
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MTX showed full AMPK activation at 48 hours, which explains the lower levels seen in figure 4.3. RTX
and PTX induced the most robust phosphorylation at 24 hours.
LTX showed low levels of activation in this experiment across the time points, in contrast to prior
experiments. To assess whether this activation of AMPK was cell line specific, the time course
experiment was repeated in H358 non-small cell lung cancer cells, and in “normal” mouse NIH3T3
fibroblasts. Once again, activation of AMPK was noted with all antifolate treatments, including with LTX
in H358 cells (Fig. 4.4B and C).
Time course experiments were repeated three more times in HCT116 cells. The immunoblot results
were quantified by Licor densitometry, and then graphed as signal normalized to β-actin, over time (Fig.
4.5). No drug treatment remains stable over the 48 hours (Fig. 4.5, dark blue circles). Overall, the peak of
AMPK activation occurs for all the antifolates at 24 hours. Averaging out four experiments shows that
AMPK activation at 24 hours can be ordered as such: RTX>PTX>MTX=LTX.
The small molecule, A-769662 binds directly to the carbohydrate-binding module of the AMPK β-subunit
and in doing so, allosterically activates the kinase (Sanders et al. 2007; Scott et al. 2014). To compare
indirect AMPK activation to direct activation by A-769662, HCT116 cells were treated with 100 µM of A769662 for 1, 2, 4, 8, 16, and 24 hours. DMSO was the vehicle treatment. Since upstream signaling and
Thr172 phosphorylation are not required for AMPK activity when A-769662 is bound (Scott et al. 2014),
we were not surprised to see no increases in phospho-AMPK Thr172, except at one hour (Fig. 4.6). This
one-hour time point is perplexing, and may represent upstream kinase activation as an acute response
to the drug. We then looked downstream for mTORC1 inhibition by AMPK. A-769662 treatment
decreases phospho-S6K1 Thr389 levels at 2 and 4 hours and at 24 hours (Fig. 4.6). A similar increase in
phospho-S6K1 was in our lab at seven hours post-treatment with PTX (+TdR) (Rothbart, Racanelli, Moran
2010).
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Figure 4.6: AMPK activation by the direct activator. HCT116 cells were treated with 100 µM of the βsubunit binding drug, A-769662 for 1, 2, 4, 8, 16, 24 h. Cell lysates were resolved by SDS-PAGE, and
indicated proteins were detected by immunoblotting.
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This may represent two separate phenomena, or the involvement of different upstream kinases.
Interestingly, insulin and epithelial growth factor (EGF) induce ROS production as a byproduct of
respiration, activating p38-MAPK, thereby activating mTORC1 (Cully et al. 2010). This is increase in
phospho-S6K1 is a phenomena that remains unexplained in our lab.

AMPK activation by these antifolates decreases mTORC1 signaling
It is believed that mTORC1 exerts a large portion of its effects on protein translation by phosphorylating
and downregulating 4EBP1 activity at the 5’ mRNA cap (Hsieh et al. 2012). To confirm that AMPK
activation by MTX, RTX, LTX, and PTX was in fact leading mTORC1 inhibition, we probed HCT116 cell
lysates for the levels of 4EBP1. Multiple bands represent different phospho-species of 4EBP1 (Fig. 4.7A).
Antifolate treatment decreased the number of phospho-bands send by immunoblot, with the most
bands seen with no drug treatment and at 6 hours post-treatment, and this was diminished to one band
by 48 hours (Fig. 4.7A). This indicates that 24 and 48 hours after antifolate treatment there is a block in
mTORC1 kinase activity towards 4EBP1.
4EBP1 can also be studied by looking for binding to m7GTP-sepharose beads that mimic the 5’ guanosine
mRNA cap (Holz et al. 2005). 4EBP1 normally binds eIF4E on this cap and prevents assembly of the
preinitiation complex (Holz et al. 2005). Phosphorylation of 4EBP1 by mTORC1 causes it to move off the
cap followed by proteasomal degradation, thus allowing initiation of translation (Holz et al. 2005). To
test mTORC1 activity by this approach, cells were treated with the antifolate drugs for 24 hours before
precipitation of m7GTP-beads, and immunoblotting for 4EBP1 and eIF4E. As a negative control, cells
were treated with insulin for 15 minutes before harvesting. Compared to no drug and insulin treated
cells, all four antifolates result in higher levels of 4EBP1 bound to the guanosine cap, despite similar
levels of eIF4E loading (Fig. 4.7B). The antifolates thus downregulate mTORC1 signaling, and result in
greater amounts of inhibitory 4EBP1 bound to the 5’ mRNA cap.
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Figure 4.7: mTORC1 signaling is blunted by all four antifolates. (A) Immunoblotting for total 4EBP1
7

protein over a 48 h time course of 1 µM antifolate treatment. (B) 4EBP1 and eIF4E bound to m GTPsepharose beads were pulled down 24 h after treatment of cells with each of the antifolates. ND = no
drug control. INS = insulin stimulated control (1 µM for 15 minutes).
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The antifolates have different effects on p53 activation
PTX (+TdR) activates AMPK and also stabilizes p53 (Agarwal et al. 2015). However, this stabilization did
not result in activation of transcription of p53 targets (Agarwal et al. 2015). The effect of PTX treatment
in the absence of TdR was assessed to determine if this effect was carried through to the single agent.
Cells were treated with 250 µM AICAR as a positive control for p53 activation. AICAR caused the
expected p53 accumulation and increase in p53 targets, p21 and hDM2 (Fig. 4.8A, lane 1 and 2). In
contrast, PTX (+TdR) caused an expected accumulation in p53 but did not increase the levels of p21 and
hDM2 (Fig. 4.7A, lanes 4 and 5). This was also seen for treatment with PTX alone (Fig4.8A, lane 3). The
effect of the other antifolates on p53 was then determined by immunoblotting the time course lysates
for p53 and its downstream targets. MTX, RTX, and PTX show accumulation and phosphorylation of p53,
corresponding to the increases in DNA damaged-induced phospho-γH2.AX (Fig. 4.8B). This suggests
DNA-damage mediated activation of an upstream kinase, such as ATM or ATR. The p53-targets, p21 and
hDM2 are completely absent after PTX treatment. This was also seen for LTX treatment, although p53
accumulation was slight in this experiment. MTX and RTX treatment cause a more canonical activation
of p53, accompanied by increases in phosphorylation, and levels of p21 and hDM2 (Fig. 4.8B). PTX and
LTX thus cause the accumulation of a transcriptionally inactive species of p53, while MTX and RTX
activate p53, causing increased production of the cell cycle arrest protein, p21, and the p53-regulatory
protein, hDM2.
Overall, these preliminary experiments suggest that the four classes of antifolates are able to cause
activation of AMPK, and a consequent decrease in mTORC1 kinase. Concomitantly, p53 is stabilized but
only MTX and RTX activate p53 signaling.
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Figure 4.8: p53 is stabilized and accumulates with all four antifolates, but p53 driven transcription is
blocked by LTX and PTX. (A) HCT116 cells were treated with 250 µM AICAR, 1 µM PTX, or 1 µM PTX
(+TdR) for 24 h prior to immunoblotting for p53 and its transcriptional targets, hDMA2 and p21. (B)
HCT116 cells were treated with 1 µM of each drug for a time course spanning 48 h, prior to
immunoblotting for p53.
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4.3: Discussion
The development of anticancer agents has had a discouragingly high rate of failure, and the therapeutic
effectiveness is variable and sometimes unpredictable (Martz et al. 2014). The last decade has seen the
development of anticancer drugs that focus on the targeting of specific molecules and signaling
pathways, thus moving away from cytotoxic chemotherapy. Nevertheless, over the past 60 years, the
cytotoxic agents that target folate metabolism have endured among the most-successful drugs used in
the treatment of cancer. These drugs remain integral components of therapeutic regimes, and continue
to be approved new indications. Understanding the underlying molecular mechanisms of antifolate
action could lead to the development of new agents, and identify important synergistic interactions.
This chapter therefore presented preliminary data exploring the effect of MTX, RTX, PTX, and LTX on
AMPK, mTORC1, and p53 signaling.

Known effects downstream of antifolate targets
MTX, RTX, and PTX induce a state of thymidylate deficiency by causing imbalances in the nucleotide
pool, which impairs DNA replication and repair. MTX does this chiefly by inhibiting DHFR, thereby
diminishing the reduced folates necessary for all folate dependent reactions. This leads to the
suppression of thymidylate and purine synthesis, as well as DNA replication and repair. RTX potently and
specifically inhibits TS, causing DNA damage by depleting dTTP, increasing dUTP, and increasing the
misincorporation of uracil into DNA. The base-excision repair enzyme, uracil-DNA glycosylase (UDG)
effectively removes these uracil bases from DNA, but if dTTP levels remain low, a futile cycle of base
excision and uracil-DNA repair leads to significant DNA damage and cell death. Therefore, the levels of
the enzyme, dUTPase will affect this outcome, since it causes the depletion of dUTP, limiting the
concentrations of this nucleotide in the cell. PTX also primarily inhibits TS, and therefore will also
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increase the extent of apyrimidinic sites in DNA PTX also inhibits AICART in de novo purine synthesis,
leading to the accumulation of ZMP and activation of AMPK. LTX inhibits GART, the folate-dependent
enzyme upstream of AICART in de novo purine synthesis. Both PTX and LTX lead to perturbations in
purine synthesis, decreasing AMP and GMP pools in the cell.

Antifolate effects on AMPK
MTX, RTX, and PTX increase the phosphorylation of AMPK at Thr172 (Fig. 3.4 and 4.4). This is not
unexpected since these drugs will diminish purine levels and/or thymidylate levels. The decrease in AMP
would lead to decreases in ATP, thus activating AMPK. Importantly, the inhibition of TS has been shown
to increase DNA damage or stalled replication forks, both of which are known to activate AMPK via ATM
kinase. MTX has been shown to increase the levels of phospho-AMPK by at least two other groups
(Pirkmajer et al. 2015; Thornton et al. 2015). Both groups speculated that increased ZMP levels were
involved in the activation of AMPK. The former study, however, only saw activation of AMPK by MTX
after cotreatment with AICAR. MTX was thus described as being able to decrease the threshold for
AMPK activation by AICAR-induced increases in ZMP (Pirkmajer et al. 2015).
LTX was seen to activate AMPK in some experiments, but the effect appears to be minor or less
reproducible (Fig. 4.3 versus 4.4). This is somewhat surprising since LTX inhibits the first folatedependent enzyme in de novo purine synthesis. Perhaps AMPK is not activated because there is no
increase in ZMP levels, and ATP pools may remain stable. The DNA-damage signal is also not as strong as
with the other antifolates (Fig. 4.7B), suggesting that ATM activation of AMPK is also not occurring.

Antifolate effects on mTORC1
All the drugs resulted in an unphosphorylated species of the mTORC1 target, 4EBP1 by 24 and 48 hours
post-treatment (Fig. 4.6A). All four drugs also increased the binding of 4EBP1 to m7GTP-sepharose
beads, implying that mTORC1-dependent depletion of 5’ mRNA cap-bound 4EBP1 is not occurring (Fig.
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4.6B). This corresponds to AMPK activation, except for LTX where 4EBP1 accumulates in the absence of
robust AMPK activation. This suggests an AMPK-independent mechanism of mTORC1 inhibition for LTX.

Antifolate effects on p53
MTX, PTX, and RTX all stabilize p53 and increase the levels of phospho-p53 ser15 (Fig. 4.7B). This
corresponds to data from our lab showing an increase in phospho-ser15 after treatment with PTX alone
(Agarwal et al. 2015). Consistently, DNA-damage signals are increased with all the drugs except LTX, as
seen by the increases in phospho-γH2A.X, a common marker for the initiation of DNA repair
mechanisms. Interestingly MTX and RTX are the only antifolates that caused p53-dependent
transcription, seen by the increased levels of hDM2 and p21 (Fig. 4.7B). As observed previously by our
lab, PTX treatment did not increase the levels of p53 targets despite accumulation of p53, matching the
effect seen with PTX (+TdR) (Fig. 4.7A; (Agarwal et al. 2015)).
LTX has also been reported by our lab to stabilize p53 without activation of its transcriptional activity
(Bronder and Moran 2003). Only mild p53 accumulation was seen in these experiments with LTX, and
there is no production of p21 or hDM2. This effect on p53 transcriptional activity was shown by our lab
to be related to the inhibition of p53 by Chk1 (Agarwal et al. 2015). The inhibition of Chk1 has been
shown to relieve a block on p21 transcription in hydroxyurea-treated cells and was traced to a Chk1induced inhibition of the elongation of p21 transcripts (Gottifredi et al. 2001). To date, three drugs have
been reported to cause the accumulation of a transcriptionally inactive p53: PTX (Agarwal, 2015b),
lometrexol (Bronder and Moran 2003), and hydroxyurea (Beckerman et al. 2009; Gottifredi et al. 2001);
and all three cause a substantial prolongation of transit through S-phase.
In summary, mTORC1 signaling is inhibited by all four classical antifolates, and all except LTX activate
AMPK. AMPK activation is likely due to DNA damage signals resulting from the depletion of thymidylate
by RTX, PTX, and MTX, as seen by the corresponding increase in phospho-γH2A.X. The activation of
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AMPK by PTX is also due in part to increases in ZMP levels by inhibition of AICART. P53 also accumulates
with all four drugs, but only RTX and MTX activate p53-dependent transcription. This deficiency in p53activation by PTX was shown to be Chk1 dependent, since inhibition of Chk1 increased the levels of p21
(Agarwal et al. 2015). This may also be the case for LTX, although further experiments are necessary to
validate this.
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5

Synopsis and perspectives

The tumor suppressor TP53 is the most frequently altered gene in human cancers. In fact, it is nearly
impossible for a normal cell to become a cancer cell without inactivating the p53 network (Solomon,
Madar, Rotter 2011). This network dictates the cell’s decision to initiate DNA repair, growth arrest,
senescence, or apoptosis in response to a range of cell stressors. The growth-promoting complex,
mTORC1 plays a significant part of the oncogenic profile that results from altered p53 function. mTORC1
also sits downstream of other crucial tumor suppressors and oncogenes, including PTEN, LKB1, and Akt.
This complex has therefore garnered much interest for the development of targeted cancer therapies.
The work presented here delved into the mechanism of mTORC1 activation with p53 loss, mTORC1
inhibition by PTX-induced AMPK activation, and asked whether PTX’s effects could be generalized to the
other classical antifolates used in cancer therapy. The major findings and implications of these studies
are outlined below, and in table 5.1, 5.2, and 5.3.
 mTORC1 activity is substantially upregulated by the loss or mutation of p53. This activation was
downstream of AMPK and involved endogenous levels of p53. This observation stood apart from
previous reports that mTORC1 activity was decreased by DNA-damage stabilized p53 (Feng et al.
2005). The increased mTORC1 activity was linked to the decrease in p53-driven transcription of the
negative regulator, TSC2.
 TSC2 is lost from lysosomal membranes. The activation of mTORC1 in cells with sufficient amino acids
occurs on the membranes of lysosomes (Sancak et al. 2010). Activation of this complex in response to
growth factor signaling entails the phosphorylation of TSC2 by Akt, and the subsequent translocation
of TSC2 away from the lysosome (Cai et al. 2006; Menon et al. 2014). In our work, p53 loss resulted in
a loss of TSC2 from lysosomes (Table 5.1). This possibly meant that the GAP control of Rheb-GTP on
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lysosomes was lost, and mTORC1 activation could occur unrestrained. An understanding of the status
of Rheb-GTP binding at these membranes in p53 null cells would be necessary to support this claim.
 Rheb increases at lysosomal membranes. The loss of p53 was accompanied by a marked increase in
Rheb on lysosomes (Table 5.1). This increase in Rheb was correlated to the loss of TSC2. The evidence
for this came from observations that Rheb was enriched in lysosome-containing compartments of
TSC2 null MEFs, and overexpression of TSC2 in p53 null cells could induce the loss of Rheb from
LAMP1. This remains an exciting observation, and one that requires further investigation. The loss of
Rheb from lysosomal membranes has only been reported in the presence of farnesyl transferase
inhibitors (Menon et al. 2014), but it is known that Ras-like GTPases undergo repeated cycles of
attachment and removal from endomembranes (Schmick, Kraemer, Bastiaens 2015). It would
significant to explain the mechanism of TSC2-induced Rheb turnover at membranes. Future work
would involve the use TSC2 phosphorylation site mutants, as well as TSC2 GAP mutants, to assess the
role of phospho-TSC2 or TSC2 GAP activity on lysosomal Rheb levels.
 Control of mTORC1 signaling is restored by exogenous expression of TSC2 or of Sestrin2. Both TSC2
and Sestrin2 are p53-transcritpion targets. Overexpression of either was sufficient to bring the levels
of phospho-S6K1 back down to baseline. TSC2 apparently accomplished this by decreasing lysosomal
Rheb (Table 5.1). Conversely, overexpression of Sestrin2 decreased the levels of mTOR at lysosomes.
This was in line with recent publications showing that in response to stress, Sestrin2 levels increase,
which inhibits the loading of Rag GTPase with GTP, preventing the recruitment of mTOR to the
lysosome (Chantranupong et al. 2014; Kim et al. 2015; Parmigiani et al. 2014). The levels of mTOR in
p53 wild type and nulls cells, however, was unchanged suggesting that the loss of Sestrin2 that
accompanies the loss of p53 is not sufficient to increase lysosomal mTOR (Table 5.1).
 The antifolate, pemetrexed activates AMPK but does not activate TSC2. Our lab was the first to show
that PTX enhances the phosphorylation of AMPK. AMPK controls mTORC1 activity by activating TSC2,
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and by inhibiting Raptor. Recently we showed that PTX is not able to activate TSC2. This was due to
the accumulation of a nonfunctional species of p53 with PTX treatment. TSC2, as a transcriptional
target of p53, was diminished by PTX. Nevertheless, the robust phosphorylation of Raptor by PTX was
necessary and sufficient, on its own, to suppress mTORC1 signaling (Table 5.2). This brings the
importance of this AMPK-driven phosphorylation event into focus. It was known that TSC2 null cells
remained responsive to energy stress (Gwinn et al. 2008). Furthermore, AMPK phosphorylation of
Raptor was necessary for cell-cycle arrest in the face of energy stress (Gwinn et al. 2008). How this
phosphorylation of Raptor decreases mTORC1 signaling and induces cell-cycle arrest is still unknown.
 Pemetrexed treatment results in the loss of TSC2 from lysosomes, but Rheb is also decreased at
lysosomes. In line with the p53-linked loss of TSC2 from cells treated with PTX, the levels of lysosomal
TSC2 decreased. In contrast, AMPK-activation by AICAR resulted in TSC2 phosphorylation, and
increased levels of TSC2 at lysosomes. Surprisingly, both PTX and AICAR reliably decreased lysosomal
Rheb (Table 5.2). This suggests a TSC2-independent mechanism of Rheb loss from endomembranes.
Future studies would use phosphorylation site mutants of both TSC2 and Raptor to assess the
importance of these proteins to lysosomal Rheb presence. Perhaps the robust phosphorylation of
Raptor by PTX is also involved in the shift of Rheb away from lysosomes. PTX treatment of TSC2-/MEFs would also be necessary.
 AICAR causes the loss of mTOR from lysosomes. AICAR treatment caused a significant decrease in
lysosomal mTOR. This was reminiscent of the results seen with overexpression of Sestrin2 in p53 null
cells. In addition, there was no change in lysosomal mTOR with PTX treatment (Table 5.2). Again, this
corresponds to the p53-linked reduction in Sestrin2 with PTX. AICAR was known to activate the p53reponse pathway and to cause a corresponding increase in Sestrin2 levels. Future work would look
into the connection between activation of Sestrin2 in AICAR treated cells and mTOR loss from
lysosomes.
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 AMPK activation by PTX or AICAR does not increase the lysosomal levels of AMPK. Recent studies
have shown that the upstream AMPK kinase, LKB1 is retained at the lysosome via a Ragulator-AXIN
tether (Zhang et al. 2013). In response to low-energy signals LKB1 recruits AMPK to the lysosomal
membrane and promotes its activation (Zhang et al. 2014). In contrast, we saw that AMPK levels were
reduced at the lysosome in AICAR- or PTX-treated carcinoma cells. Instead, the levels of AMPK in the
nucleus were increased, significantly so after PTX treatment (Table 5.2). This is similar to the activation
of AMPK in myocytes by leptin, exercise, and AICAR, which shows translocation to the nucleus.
Activated AMPKα2 is known to translocate to the nucleus where it modulates transcription factor
activity, while AMPKα1 is restricted to the cytosol (Salt et al. 1998). Future work will thus require qRTPCR quantitation of the AMPK isoforms before and after AMPK activation in these cells. Since the
antibody to detect AMPK in this study recognizes all β1- and β2-containing complexes, isoform specific
antibodies would be useful to tease out the localization of different species of AMPK in PTX-treated
cells.
 mTORC1 is inhibited by all the classes of classical antifolates. This work introduced preliminary data
that surveyed the effect of the other antifolates on AMPK activation and mTORC1 inhibition. RTX,
MTX, and PTX alone all increased AMPK phosphorylation, while LTX caused no or minor activation.
Nevertheless, 4EBP1 was stabilized on mRNA cap-like beads after treatment with all the antifolates,
suggesting mTORC1 signaling was suppressed. Interestingly, p53 accumulates after treatment with all
the antifolate drugs, but only MTX and RTX activated the transcriptional function of p53 (Table 5.3).
This agrees with two previous studies from this lab (Agarwal et al. 2015; Bronder and Moran 2003).
The mechanism of AMPK activation by each antifolate still needs to be determined. This will likely
involve looking for signs of activation upstream of AMPK, including DNA-damage, increased ROS, and
ATP depletion. Overall, this work is important because these drugs are firmly established in cancer
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therapy regimes. Identifying downstream mediators in the cancers that respond to these drugs would
shed light on key therapeutic targets.
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